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CHAPTER I 
 
 
INTRODUCTION 
 
 
 Alzheimer’s disease (AD) is the most prevalent form of dementia worldwide.  
Currently, it is estimated that nearly 40 million people suffer from this devastating form of 
dementia, and it is estimated that, if the current forms of treatment and diagnosis persist, 
this number will jump to 120 million as soon as 2050 (1).  New treatment and diagnostic 
methods are still being developed, as we are only beginning to understand the 
mechanisms that drive this disease.  The following work will attempt to put forth novel 
information showing both how structural biological information and cholesterol/protein 
interactions may play key roles in the etiology and pathology of AD. 
 
Historical Perspective 
 It was in 1907 when Dr. Alois Alzheimer published the results of his findings 
following the autopsy of his patient, Auguste Deter.  Prior to his publication, Dr. 
Alzheimer spent 4 years with Ms. Deter, during which her case appeared so unusual that 
it could not be classified as any recognizable illness.  Alzheimer reported Ms. Deter as 
“unable to understand any situation” and “her memory is seriously impaired, if objects 
are shown to her, she names them correctly, but almost immediately afterwards she has 
forgotten everything” (2).  As Ms. Deter’s illness progressed, it was noted that her 
complex symptoms sometimes appeared stronger, and on other days weaker, but they 
never reached a critical level.  Before performing the autopsy, Alzheimer could only find 
a slight hardening of the radial arteries as a means for diagnosis. 
 Post-mortem analysis of brain tissue showed an evenly atrophic brain, with the 
larger vascular tissues showing increased arteriosclerosis.  Alzheimer also noticed two 
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key phenotypical changes present in Ms. Deter’s brain tissue.  The first was described 
as “Inside of a cell which appears to be quite normal, one or several fibrils can be 
distinguished by their unique thickness and capacity for impregnation.”  Alzheimer 
noticed that these “fibrils” were found next to apoptotic neurons.  The second component 
noticed was described as “minute miliary foci which as caused by the deposition of a 
special substance in the cortex.”  In addition to these clear changes in the brain tissue, 
Alzheimer further commented that “Approximately ¼ to 1/3 of all neurons in the cortex 
show these changes.  Many neurons, especially those in the upper layer, have 
completely disappeared” (2).   
While he did not know it, Alzheimer had described the key defining pathological 
features of AD.  The “fibrils” he discovered were aggregations of the 
hyperphosphorylated microtubule stabilizing protein tau; which are now commonly 
referred to as neurofibrillary tangles.  The “miliary foci” were aggregations of the Aβ 
peptide; commonly referred to as Aβ or amyloid plaques.  As of the present date, the 
clinical definition of AD is a form of dementia characterized by the presence of 
proteinaceous deposits in the cerebral vessels and in the parenchyma of the affected 
brain region.  Regions implicated in AD include the prefrontal and entorhinal cortex and 
the hippocampus, regions of the brain associated with memory formation, cognitive 
function, expression of emotions, and other higher level brain functions (1).  One 
anecdote of particular interest to Dr. Alzheimer’s findings was not only did he describe 
the initial pathology of AD, but his patient also developed the disease at the early age of 
51, making this also the first documented case of early onset AD; also known as familial 
Alzheimer’s disease (FAD) (3), since it is caused by specific, inherited mutations. 
 The “deposition of a special substance” described by Alzheimer was eventually 
isolated 77 years later by Dr. George Glenner and Caine Wong at UCSD in 1984.  While 
it was known these depositions were amyloid like in nature (aggregates of a β-sheet 
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stacked protein), the identity of the initiating protein was unknown.   By using polarization 
microscopy, Glenner and Wong were able to isolate these amyloid aggregates from the 
meningeal vessels of post-mortem AD patient brains.  Following the isolation and 
subsequent purification by HPLC, Glenner and Wong identified a peptide of 4,200 
daltons (4.2 kDa) and termed it the Aβ, or amyloid β polypeptide.  Interestingly, Glenner 
and Wong also identified an additional peak at lower abundance during the HPLC study 
of 4 kDa.  This was the first evidence that the Aβ polypeptide is not only the cleavage 
product of a larger protein, but that different Aβ lengths could have different aggregation 
properties (4).  Three years later, the lab of Benno Müller-Hill determined that the Aβ 
peptide was in fact a cleavage product of a larger protein, by showing that the Aβ 
peptide came from the Amyloid Precursor Protein (APP), a transmembrane protein of 
neuronal origin approximately 695 amino acids in length (5). 
  
The Amyloid Hypothesis 
 The evidence provided by Alios Alzheimer and others indicated that the Aβ 
peptide, and more specifically the ability of this protein to oligomerize and aggregate, 
was important to the progression of AD.  It was apparent that dysregulation in the 
function of Aβ, and most likely APP, could strongly promote a cascade of cellular 
changes that drove the development of AD.  This became known as the “amyloid 
hypothesis” (6).  The amyloid hypothesis was initially put forth in 1991 by John Hardy 
and David Allsop, when they discovered that the gene encoding APP was found on 
chromosome 21; the same chromosome that causes Down syndrome (7).  It was later 
found by Nistor and colleagues that patients with Down syndrome exhibit AD like 
symptoms by age 40, implicating APP as a potential link between the two diseases (8).  
Hardy and Allsop hypothesized that altered regulation in the metabolism of APP led to 
the overproduction of Aβ during AD.  The amyloid hypothesis has since evolved from the 
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initial findings of Hardy and Allsop, and now it includes many different risk factors, such 
as genetic and environmental influences, that can cause the dysregulation of APP 
metabolism and not only promote Aβ generation, but also enhance the deleterious 
effects of its oligomerization and aggregation.  Figure 1.1 highlights the cascade of 
events involved in the amyloid hypothesis.   
  
 
Figure 1.1.  The amyloid hypothesis is a series of events that leads to the 
overproduction of the Aβ peptide, which causes neuronal cell death, and 
ultimately leads to dementia.  APP metabolism in the cell can be altered by a 
number of factors (highlighted red).  This work will focus on cholesterol 
homeostasis.  This altered metabolism leads to an increase in Aβ production 
(highlighted in cyan).  Studies below will show mechanisms that potentially lead 
to this increase in Aβ levels.  Overproduction of the Aβ peptide is followed by Aβ 
oligomerization and neuronal cell death (highlighted in green).  Neuronal cell 
death is a potential mechanism that feeds back into this loop by releasing 
additional Aβ back into the brain (highlighted with the orange arrow).  All these 
factors lead to the phenotype of dementia seen in patients with AD. 
 
The goal of this thesis is to gain a better understanding of how structural and 
functional features of proteins within the amyloid hypothesis, specifically APP and its 
proteolytic components, may contribute to increased Aβ production, and ultimately, AD.   
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The Biological Role of APP 
 In order to gain a better understanding of how APP can contribute to the 
overproduction of Aβ during AD, it is essential to know the biological role APP plays in 
maintaining cell viability, especially in neuronal cells, as any alteration in this function 
may contribute to AD pathogenesis.  Efforts to define the ultimate function of APP in 
neurons have proven difficult, however, as the sequence, knockout trials, and other 
experiments have suggested multiple roles the protein may fill.   
 The amyloid precursor protein (APP) is a single-pass transmembrane protein that 
is expressed throughout the body (9).  There are various isoforms found, with the major 
form in the brain being 695 amino acids in length (5).  Of these amino acids, only 
approximately 70 residues make up the transmembrane helix and C-terminal 
intracellular domain, leaving an extremely large, multi-domain extracellular N-terminus 
that includes heparin, F-Spondin, and collagen binding regions (10).  These 
characteristics led initial studies to speculate that APP may function as a putative 
receptor or adhesion molecule at the membrane surface.  The large, multi-domain 
extracellular region had many structural similarities to known receptors, such as Notch 
and EGFR (11, 12), as well as select Integrin dimers (13).   
Congruent with functioning either as a receptor or as an adhesion protein are the 
multiple GxxxG motifs within the transmembrane helix of APP (14-16).  These are known 
motifs within helical transmembrane proteins that allow for avid homo- and 
heterodimerization, based on the high level of close packing and van der Waals 
interactions provided by the small glycine residues (17-19).  It is through this mechanism 
which EGFR functions, where upon binding an extracellular ligand, EGFR 
transmembrane dimerization occurs, initiating a signaling cascade within the cell (20-22).  
Additionally, it is known that these GxxxG interactions occur in different Integrin systems, 
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allowing for activation/deactivation of the Integrin complex (23-25).  Though empirical 
evidence suggests APP may function as a membrane receptor or adhesion protein, 
researchers have been hard pressed to identify the absolute biological function of full 
length APP.  In addition to this fact, recent evidence has suggested that the GxxxG 
motifs of APP may not only function as a dimerization domain, but also as a cholesterol 
binding region, suggesting alternate biological functions modulated by the same 
transmembrane region (26-28).  Recent work from Pierrot et al collaborates the 
importance of the cholesterol interaction, as they showed that increases in cholesterol 
content increase APP expression(29).  Taken in conjunction with the finding that the 
transmembrane region of APP can bind cholesterol, it highlights the hypothesis that APP 
may function as a cholesterol sensor within the cell membrane (30). 
 
Competing Cleavage Pathways of APP 
While the exact function of APP is still being explored, it is widely accepted that 
APP is able to be cleaved by multiple enzymes in two distinct mechanisms, known as 
the Non-Amyloidogenic and Amyloidogenic pathways, as certain cleavage products of 
the amyloidogenic pathway lead to AD onset (10, 15, 31-34).  The non-amyloidogenic 
pathway, which is the more common of the two cleavage cascades, is initiated by 
cleavage, or “shedding” by the transmembrane enzyme α-secretase, a member of the 
metalloprotease family (35, 36).  Cleavage by α-secretase occurs at residue L688 (using 
the APP770 numbering nomenclature), releasing a large, soluble ectodomain (sAPPα) 
and forming the transmembrane fragment C83 (83 amino acids in length).  Cleavage of 
APP by α-Secretase occurs at the plasma membrane surface (1).  Following cleavage 
by α-Secretase, C83 is subject to subsequent cleavage within the membrane by an 
enzyme complex called γ-Secretase (31).  γ-Secretase consists of four transmembrane 
proteins; presenilin-1 or -2 (PS-1/PS-2), anterior pharynx defective (APH-1), presenilin 
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enhancer-2 (PSEN-2), and nicastrin (37-39), with the active site occurring between two 
aspartyl residues within presenilin.  Cleavage of C83 occurs within the cell membrane, 
splitting the transmembrane helix into two components, a signaling peptide called P3 
and the APP intracellular domain (AICD) (31).  The details of γ-Secretase cleavage will 
be discussed in further detail later on.   
The residues cleaved by α-secretase cleavage are proximal to the cell 
membrane surface (28), and it has been shown that when moved to a rigid membrane 
environment (Liquid ordered domains), α-secretase cleavage can be inhibited (40).  This 
is of particular importance as it is postulated that endogenous α-secretase cleavage 
occurs in fluid membrane domains on the cell membrane surface that are devoid of 
cholesterol and sphingomyelin and it has been shown that elevated levels of cholesterol 
may actively inhibit α-secretase cleavage of APP (41-43).  When overexpressed in cells, 
mice, or injected into adult animals, sAPPα has been shown to enhance cognitive ability 
by promoting neuron growth, neuron survival, and neuron motility and improving 
synaptic density (44, 45).  Interestingly, these were the same results reported during full 
length APP overexpression studies (46), and when the subsequent RNAi studies were 
performed, these results were ameliorated (47), suggesting that α-Secretase cleavage of 
APP plays a role in neuron outgrowth and possibly in neuron protection. 
The amyloidogenic pathway is initiated by the enzyme β-Secretase (BACE1), a 
transmembrane protein that is part of the aspartyl protease family (48).  β-Secretase 
cleavage occurs only sixteen residues N-terminal to the α-Secretase cleavage location 
at residue D672.  β-Secretase cleavage sheds a large, soluble ectodomain (sAPPβ) and 
generates a transmembrane peptide called C99 (99 amino acids in length).  Cleavage by 
β-Secretase occurs in early and late endosomes, which have a lower pH to facilitate the 
aspartyl cleavage mechanism.  In order for β-Secretase cleavage to occur, APP and β-
Secretase must be transported into endocytic vesicles, either by endocytosis from the 
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plasma membrane or by movement from the trans golgi network into endosomal 
compartments (49).  Similar to C83, C99 is subject to cleavage by the enzyme complex 
γ-secretase.  The AICD polypeptide is again generated, but instead of the signaling P3 
peptide, cleavage of C99 by γ-secretase generates the Aβ peptide (31, 35, 50), which 
can accumulate overtime and lead to the onset of AD.  While ultimately the over 
generation, oligomerization, and aggregation of the Aβ peptide is what leads to AD, by 
gaining a deeper understanding of the amyloidogenic pathway we will ultimately discover 
what  drives the overproduction of the Aβ peptide in AD. 
At first glance it may seem that the amyloidogenic pathway serves no purpose 
other than to promote AD progression, as this cleavage pathway endogenously occurs 
at a much lower frequency than the non-amyloidogenic pathway, but the cleavage 
products of the amyloidogenic pathway serve a unique biological function as well.  
Nikolaev et al showed that sAPPβ serves as a ligand for Death Receptor 6 (DR6).  Upon 
binding DR6, sAPPβ activates caspase 6 and caspase 3, causing axonal and neuronal 
cell body apoptotic degradation (51).  sAPPβ production was stimulated by growth factor 
deprivation, suggesting that β-Secretase cleavage could be a natural response to 
changes in growth factor levels within the brain.  It is also interesting to note that β-
Secretase cleavage may not promote AD by only producing the Aβ peptide, but by also 
promoting neuron death by the overproduction of sAPPβ. 
In order to gain a better understanding of the driving force behind overstimulation 
of the amyloidogenic pathway in AD, we must first understand what factors promote one 
pathway over the other.    Figure 1.2 summarizes the steps in the non-amyloidogenic 
and amyloidogenic cleavage pathways.   
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Figure 1.2.  The cascade of cleavage events involved in the non-amyloidogenic 
and amyloidogenic processing of APP.  The non-amyloidogenic cleavage pathway 
is initiated by cleavage of APP by the enzyme α-Secretase.  This cleavage sheds a 
large, soluble domain and generates the transmembrane fragment C83 (83 amino 
acids in length).  C83 is then cleaved within the membrane by the enzyme complex 
γ-Secretase, releasing the p3 peptide and the APP intracellular domain (AICD).  
Amyloidogenic processing of APP is initiated by the enzyme β-Secretase.  This 
generates the membrane protein C99 (99 amino acids in length).  C99 is subject to 
cleavage by γ-Secretase, generating the same AICD, but instead of the benign p3 
peptide, the neurotoxic Aβ peptide is generated.  It is this peptide that can go on 
to oligomerize and lead to cell death as well as aggregate and form the hallmark 
Aβ plaques found in AD. 
 
As stated above, changes in growth factor levels may be one factor.  In addition, it has 
been shown that oxidative damage can play a role in stimulating the amyloidogenic 
pathway (52-55).  While there are numerous genetic and environmental factors that have 
been shown to enhance the amyloidogenic cleavage of APP, the overarching goal of this 
work will be to focus on two key components that could promote amyloidogenesis; the 
structure of C99 (the amyloidogenic product of APP cleavage by β-Secretase and the 
direct precursor to the Aβ peptide) and the ability of C99 to specifically bind cholesterol.  
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By investigating the structure of C99, we will gain an understanding of how Aβ is 
generated by γ-Secretase cleavage.  By investigating the ability of C99 to bind 
cholesterol, information will be gained as to how cholesterol levels in the cell membrane, 
and more specifically, how microenvironments enriched in cholesterol known as “lipid 
rafts” (Liquid ordered [Lo] domains), may impact the balance between the non-
amyloidogenic and amyloidogenic cleavage pathways.    
 
 
Modulation of γ-Secretase Cleavage by Pharmaceutical Compounds1 
 Among the therapeutic targets for AD, the amyloidogenic pathway has long been 
a principle focus (6).  Familial early onset AD (FAD) is associated with autosomal 
dominant mutations in APP and in the catalytic subunits (PS-1/PS-2) of the 
intramembrane protease that processes it, γ-Secretase (3).  According to the amyloid 
hypothesis, oligomeric forms of Aβ are the principle agents underlying disease 
pathogenesis.  The Aβ polypeptide is generated by proteolysis of APP.  Cleavage of 
APP by β-Secretase yields C99, which is then heterogeneously processed by γ-
Secretase to generate Aβ species with a variety of lengths, the principle species being 
Aβ40, as it is 40 residues in length (57).  While Aβ40 is the predominant length of the 
peptide formed, pro-AD risk factors are those that stimulate the production of a more 
toxic Aβ species, known as Aβ42.  Genetic mutations (to APP or PS), alterations in 
cholesterol metabolism, and oxidative damage are some of the key players known to 
increase the Aβ42/Aβ40 ratio, and are thus termed pro-AD risk factors (41, 58-62).  
Because Aβ is thought to be central in the pathogenesis of AD, inhibiting its production is 
                                                            
1 (Portions of this section were adapted from the published work Nonspecificity of binding of γ-Secretase Modulators to 
the Amyloid Precursor Protein by Beel et al in Biochemistry56. Beel, A. J., Barrett, P., Schnier, P. D., Hitchcock, 
S. A., Bagal, D., Sanders, C. R., and Jordan, J. B. (2009) Nonspecificity of Binding of γ-Secretase Modulators to the 
Amyloid Precursor Protein, Biochemistry 48, 11837-11839.) 
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a potential therapeutic strategy.  Although significant progress has been made in the 
identification and development of potent γ-Secretase inhibitors, their clinical application 
has been limited by significant toxicities resulting from the interference with processing 
of other γ-Secretase substrates, particularly Notch (63).  Indeed, γ-Secretase is a highly 
promiscuous protease with more than 60 identified substrates (31). 
 The discovery that a subset of nonsteroidal anti-inflammatory drugs (NSAIDs) 
could selectively reduce Aβ42 production without abrogating Notch cleavage suggested 
an alternative therapeutic approach for AD (64).  The Aβ42 lowering activity of these γ-
Secretase modulators (GSMs) was recapitulated in cell-free assays of γ-Secretase 
activity.  Several groups have produced data suggesting that GSMs interact allosterically 
with presenilin, thereby modifying the enzyme’s conformation (65-67).  Additionally, 
recent work shows that GSMs directly interact with presenilin, giving even more 
evidence for the mechanism of GSM action (68, 69).  Moreover, GSMs were observed to 
influence the cleavage of an unrelated substrate by signal peptide peptidase, an enzyme 
homologous to the presenilin subunit of γ-Secretase, suggesting that the modulators 
interact with the enzyme rather than the substrate (70).  Corroborating the premise that 
GSMs are enzyme-targeting was the finding that certain NSAID GSMs can also 
influence the precise γ-Secretase cleavage of Notch (71).  Okochi et al have shown that 
Notch cleavage is modulated, but not inhibited, by NSAID GSMs, providing a plausible 
explanation for the lack of adverse Notch-related toxicities of such compounds (71). 
 
Nonspecificity of Binding of γ-Secretase Modulators to the Amyloid Precursor Protein 
 Previous work from the Golde and Multhaup laboratories postulate that GSMs 
specifically target APP, its C-terminal derivatives, and the Aβ peptide, providing an 
alternative explanation for the apparent specificity that GSMs exert on cleavage of C99 
(72-74).  Work from the Golde lab demonstrated that application of biotinylated 
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photoactivatable affinity probe derivaties of certain GSMs, namely, fenofibrate (an Aβ42 
increasing GSM) and tarenflurbil (an Aβ42 lowering agent), to CHAPSO detergent 
extracts from human neuroglioma H4 cells failed to label any core γ-Secretase subunits 
but instead produced covalent conjugates with C83, the product of α-Secretase cleavage 
of APP.  While labeling of C99 did not appear to take place in those same extracts, 
purified recombinant C99 in CHAPSO containing solutions could be modified by 
derivatized fenofibrate and tarenflurbil, an interaction subject to complete abrogation by 
a number of other GSMs.  Photoaffinity labeling of purified C99 was localized to residues 
G700-L705, the first GxxxG motif found within the transmembrane helix (72). 
 Additional studies from the Multhaup lab suggested that GSMs not only bind with 
high affinity to C99, but also bind the Aβ polypeptide (73, 74).  Using surface plasma 
resonance (SPR) studies, molecular dynamics, and TOXCAT analyses, these studies 
suggested that GSMs once again interacted with the GxxxG motifs found within the 
transmembrane helix of C99, and that the addition of GSMs could actively break C99 
dimers in a concentration dependent manner, leading to the hypothesis that the 
mechanism of GSM ability to lower Aβ production was to modulate APP dimerization.  
Taken together these studies suggest a novel mechanism for how the interaction 
between APP and various GSMs may modulate Aβ levels, both in cellular and purified 
systems.  
Based on the data presented in these papers, we thought to further the 
understanding of how the GSM molecules were interacting with C99 in a more specific 
manner.  To investigate the putative binding of GSMs to APP and its derivatives, we 
monitored the spectroscopic response of purified and monodisperse uniformly 15N (U-
15N) C99 to addition of GSMs in a membrane-like environment.  Human C99 was 
expressed, labeled, and purified into LMPG micelles.  Titrations of U-15N C99 in LMPG 
micelles with the GSMs tarenflurbil, indomethacin, fenofibrate, and sulindac sulfide 
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revealed no evidence of specific binding, even at compound concentrations in the 
millimolar range.  Figure 1.3 shows a representative titration experiment with the GSM 
tarenflurbil.   
 
Figure 1.3. Titration of [U-15N]C99 with tarenflurbil as monitored using 600 MHz 
1H-15N TROSY NMR. Samples contained 1 mM [U-15N]C99 in 200 mM LMPG 
micelles at pH 6.5 and 45ºC and the indicated molar ratios of tarenflurbil to C99. 
The modest changes observed indicate only nonspecific interactions. 
 
 
While the titration of tarenflurbil induces modest chemical shift perturbations in the 1H-
15N TROSY-HSQC spectra of C99, the concentration dependence of the changes 
observed is not consistent with avid and specific binding of the protein by the GSMs.  
Moreover, the C99 NMR resonances that undergo GSM-induced shifts tend to differ 
from GSM to GSM, as might be expected for nonspecific interactions.  In no case were 
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the peaks from residues in the putative GSM binding site (G700-L705) seen to be 
among those that shifted the most in response to addition of GSMs.  In addition, 
experiments of a reciprocal nature were performed in which titrations of U-15N C99 in 
LMPG micelles with tarenflurbil were monitored using the 19F NMR signal from this GSM.  
Figure 1.4  reveals that the 19F signal from tarenflurbil neither shifts nor is significantly 
broadened relative to free ligand over a range of GSM/C99 molar ratios from 0.1 to 1 (at 
ca. 250μM C99), indicating a lack of significant binding.   
 
 
 
 
 
 
 15 
 
 
Figure 1.4.  19F NMR-monitored titration of (A) 250uM U-15N-C99 and (B) 200uM U-
15N-KCNE1 (negative control) in 10% LMPG with tarenflurbil at pH 6.5 and 45 
degrees C. Red curves represent the addition of 25uM, 50uM, and 250uM 
tarenflurbil to protein-containing solutions. Black – control series with no protein. 
Notice that the modest linebroadening in samples with protein present are similar 
for both C99 and KCNE1 samples. KCNE1 is a 129 residue single span membrane 
protein that modulates certain voltage-gated potassium channels. It is here used 
as negative control protein to which GSMs are not expected to bind. 
 
These results indicate that nonaggregated C99 in LMPG micelles exhibits no specific 
avidity for GSMs and related compounds.  These results were recapitulated for C99 in 
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CHAPSO micelles, indicating that the detergent used was not causing the disparities 
between our work and the Golde and Multhaup studies. 
While these results were encouraging for understanding the mechanism of GSM 
action, we were determined to find the reason for which others found that GSMs 
interacted with the APP protein and its derivatives.  Chapter III will discuss recent work 
in greater depth to highlight the mechanism driving the nonspecific interaction between 
APP and the GSM molecules. 
 
The Role of Cholesterol in Amyloidogenesis 
 For over 20 years there has been increasing evidence that suggests the lipid 
molecule cholesterol is intimately related to the etiology of AD (41, 42, 75-80).  While the 
direct mechanism behind cholesterols impact on the development of AD is unclear, 
research groups have found that both increased and decreased levels of cholesterol 
may promote AD progression; it is clear that the molecule, and its homeostasis within 
the brain, play an important role in disease pathogenesis.  Numerous studies suggest 
that increased levels of cholesterol can simultaneously promote β-Secretase cleavage of 
APP while actively inhibiting α-Secretase cleavage (40, 42, 78, 81, 82).  Concurrent with 
these findings, the enzyme β-Secretase is often associated with regions of the plasma 
membrane enriched in cholesterol, often referred to as “lipid rafts” (33), demonstrating a 
direct link of between cholesterol and promotion of the amyloidogenic pathway.  Lastly, 
early AD studies showed that when mice or rabbits were fed high cholesterol diets, they 
exhibited an increase in Aβ production (83-85).  This is in accord with the finding that 
patients with hypercholesterolemia have an increased prevalence of AD (86).  While we 
now predict that plasma cholesterol levels do not impact brain cholesterol levels, the link 
is still intriguing.  In contrast to these findings it has been shown that decreased levels of 
cholesterol may promote the amyloidogenic pathway, by forcing APP and β-Secretase to 
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interact under cellular conditions where they normally would not (87).  This and later 
sections will serve to show how the cholesterol molecule may be implicated in promoting 
Aβ production as and present a concept of how both increased and decreased 
cholesterol levels may both promote AD. 
 
Cholesterol Metabolism in the Brain 
 In order to gain a better understanding of how cholesterol plays a key role in the 
etiology of AD, one must first understand how cholesterol homeostasis is regulated in 
the brain and how alterations in this homeostasis could lead to the development of AD.  
The regulation of cholesterol levels within the brain are highly complex, as the blood 
brain barrier prevents cholesterol within the circulation from entering the brain, leading to 
the brain having to generate all of its cholesterol de novo (88).  This was proved by two 
separate studies by Bloch et al and Waelsch et al where cholesterol doped with D2O was 
fed to adult rats and both groups saw that the brain and spinal cord were completely 
devoid of deuterated cholesterol, leading to the conclusion that there was little, if any, 
exchange of plasma and brain cholesterol (89, 90).  As a consequence, it was found that 
cholesterol in the brain has an extremely long half-life, with the bulk of cholesterol 
remaining for approximately 5 years (91).   
Cholesterol synthesis is a complicated, multi-step process, with the limiting 
reaction being catalyzed by the enzyme 3-hydroxy-3-methylglutaryl-coenzyme-A 
reductase (HMGCoA reductase) in the endoplasmic reticulum (ER) (92).  This enzyme is 
regulated by a potent negative feedback loop that affects activity, stability, and gene 
regulation (93).  Many potential anti-AD therapeutics are inhibitors of HMGCoA 
reductase, and epidemiological studies have demonstrated that select inhibitors known 
as statins have the ability to decrease AD risk (94).  However, the exact mechanism of 
the effect of statins on AD is still unclear, as these compounds cannot cross the blood 
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brain barrier, and thus cannot directly lower brain cholesterol levels, and due to the fact 
that the brain regulates its own cholesterol synthesis, decreased plasma cholesterol is 
also an unlikely mechanism for the success of statins (60).  The current thinking is that 
statins, while not directly lowering cholesterol levels within the brain, are able to promote 
enhanced brain oxygenation and clearance of the accumulating Aβ peptide, but this 
hypothesis is still being tested (94). 
 While cholesterol production in the brain on the whole is thought to be fairly 
consistent over time, the production of cholesterol by different neural cell types varies 
greatly with time.  During early development, all cells within the brain generate 
cholesterol at a high rate, to stimulate neuron development and plasma membrane 
production.  However, with time, mature neurons lose the capability to produce 
cholesterol (95).  It is thought this occurs because neurons need to focus cellular energy 
on transmitting signals within the brain, and the metabolic cost of producing cholesterol 
is too great.  While neurons may not generate cholesterol, the demand for cholesterol in 
these cells is extremely high, as there is constant turnover of the plasma membrane 
during neurotransmitter release and uptake.  To circumvent this problem, cells within the 
brain known as astrocytes produce 2-3 times the normal level of cholesterol of other 
brain cells (88).  Cholesterol generated in these cells is then transported to neurons by 
the ApoE family of proteins.  There are four isoforms of ApoE found within the brain, and 
all function by forming lipoprotein complexes to shuttle cholesterol from astrocytes to 
neurons.  One particular ApoE form, ApoE4, is a pro-AD risk factor.  The exact 
mechanism of how this protein increases Aβ levels is still not well understood, but it is 
known that ApoE4 can not only modify cholesterol homeostasis, but also may play a role 
in facilitating clearance of Aβ, thus dysregulation of either or both of these functions may 
contribute to AD (96, 97).  Interestingly, ApoE2 is thought to be a therapeutic agent 
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against AD, making regulation of the production of these two proteins of high importance 
(98). 
 ApoE family members are not the only proteins that have been implicated as Pro-
AD risk factors involved in cholesterol regulation.  In fact, APP has been shown to play 
an important role in cholesterol homeostasis within the brain.  Recent work from Pierrot 
et al has shown that APP expression is upregulated in response to increased levels of 
cholesterol in neurons (29).  The study ultimately demonstrated that the function of 
increased APP levels was to decrease the overall levels of cholesterol within the cells.  It 
has also been shown that the Aβ peptide has the ability to inhibit HMGCoA reductase, 
thus abrogating the synthesis of cholesterol (87).  In addition, Aβ has been shown to 
impair SREBP2 processing, a key step in a cells ability to monitor membrane cholesterol 
levels (29).  This has led to the hypothesis that APP may serve as a putative cholesterol 
sensor within the membrane, and that the amyloidogenic pathway, under normal 
circumstances, facilitates this process.  Overall, it has been shown that APP plays a 
central role in the monitoring of cholesterol turnover, and that this function is essential for 
proper neuronal function in the brain.     
Two other proteins demonstrating altered expression levels and possible genetic 
contributions to AD pathogenesis are cholesterol 24-hydroxylase (CYP46) (99) and 
selective AD indicator-1 (Seladin-1) (100), as they have been implicated in both 
cholesterol turnover and synthesis in the brain.  CYP46 is the enzyme that converts 
cholesterol to 24-hydroxycholesterol.  This is of particular importance as this is the only 
cholesterol analogue that is able to cross the blood brain barrier and leave the brain, 
thus stimulating cholesterol synthesis and turnover.  A study by Lund et al showed an 
increased amount of CYP46 in the brains of aged humans and mice compared to youths 
(99).  Work from the Ledesma lab has implicated the age dependent increase of CYP46 
with a decrease of membrane cholesterol levels in hippocampal neurons, both in vitro 
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and in vivo (95).  While the initial results from this study suggested that the loss of 
cholesterol was neuroprotective, this work will argue that over time this decrease in 
cholesterol may serve to initiate the amyloidogenic pathway.  In addition to potentially 
playing an important role for modulating Aβ levels, this increase in 24-hydroxycholesterol 
in aged patients may serve as a potential biomarker for assessing risk of developing AD.        
 Another potential protein that plays a key role in cholesterol homeostasis in the 
brain is Seladin-1.  Seladin-1 is the last protein in the cascade of events that generate 
cholesterol, and functions to convert the cholesterol analogue desmosterol to native 
cholesterol (101).  Seladin-1 has been shown to be down regulated in the brains of AD 
patients (102), with the resulting phenotype being an overproduction of desmosterol and 
a decrease in cholesterol levels.  These results are replicated in Seladin-1 deficient mice 
(103).  As with the overexpression of CYP46, the down regulation of Seladin-1 is 
consistent with decreased levels of cholesterol within the brain of AD patients.  As aging 
proceeds in non-AD individuals, there is a moderate loss of cholesterol within the brain 
of approximately 20%.  While this decrease is termed normal, and in fact, a slight 
decrease in cholesterol has been shown to be neuroprotective, a 30% loss of cholesterol 
in the brain has been shown to be a pro-AD risk factor (95).  This work will go on to 
argue that the alterations found within the CYP46 and Seladin-1 expression levels will 
contribute to a model of AD progression, which will ultimately combine both the loss and 
gain of cholesterol levels seen in different AD studies. 
 
Cholesterol Rich Membrane Domains and Their Role in AD 
 The plasma membrane of cells is a complex and crowded environment, 
consisting of an intricate, but precise, mixture of lipids and proteins.  While at first glance 
this environment may seem quite chaotic and random, cells have developed 
mechanisms of sorting and organizing this mosaic environment.  One such method is 
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the formation of regions of the membrane known as cholesterol rich domains, regions 
often referred to as lipid rafts or liquid ordered (Lo) domains, that have distinct 
biophysical and biochemical properties that separate them from the bulk, or liquid 
disordered (Ld), membrane environment (104, 105).  These cholesterol rich membrane 
domains form when cholesterol molecules in the membrane congregate with specific 
lipids, namely a lipid known as sphingomyelin (106).  Sphingomyelin (SM) has a unique 
acyl chain structure when compared with other phospholipids of the plasma membrane, 
allowing it to pack much tighter together when stabilized by cholesterol.  This packing is 
enabled by the structure of the (SM) acyl chain, which contains a single unsaturated 
carbon double bond at the 2-3 position, as compared to most phospholipids, which 
contain an unsaturated carbon double bond (and sometimes more) at the 9-10 position.  
The double bond position in SM permits an acyl chain structure that is almost linear, 
allowing close packing of lipids in the presence of cholesterol and creating an ordered 
lipid environment.  The double bond found in phospholipids at the 9-10 position creates 
a kink in the acyl chain, inhibiting close packing and creating a more fluid membrane 
environment.   
 Formation of cholesterol rich domains is highly sensitive to the concentration of 
the lipids present, and domain formation will not occur in model membranes unless the 
cholesterol concentration is approximately 15 mol% with a SM concentration of about 25 
mol% (107).  These values are for model membranes in isolation, and the conditions for 
which cholesterol rich domain formation occur in cellular membranes is still highly 
debated, with the current estimate that cellular membranes are comprised of 30% lipids 
and 70% proteins, by dry weight (88).  However, it is known that in the plasma 
membrane of neurons, the cholesterol concentration is approximately 10-20%, with 
myelinated regions containing up to 25-30% (88, 108).  These levels are well within the 
range needed to generate cholesterol rich domain formation, and it is even hypothesized 
 22 
 
that these domains can form as early as the trans-golgi network (TGN) (109).  As 
cholesterol levels steadily increase from the ER through the TGN to the plasma 
membrane (75), even slight alterations in cholesterol levels in these different organelles 
may impact Aβ production.  The idea that different organelles may impact the cleavage 
of APP was first introduced in the study by Hartmann et al, where it was shown that 
Aβ40 is preferentially generated in the TGN, while Aβ42 mainly originates from the ER 
(110).  While these findings are potentially important for understanding the regulation of 
Aβ production, the mechanism of action is still not understood.  Recent findings from our 
lab will show how the interaction between APP and cholesterol and the properties of 
cholesterol rich domains may stimulate Aβ40 or Aβ42 production.    
While the overall concentration of cholesterol within the plasma membrane has 
an estimated range, the concentration between the inner (cytofacial) and outer 
(exofacial) layers (leaflets) of the cell membrane are quite different and are highly 
dependent on the age of the neuron (111).  This concept was first put forth by Friedhelm 
Schroeder, who argued that as one ages, the localization of cholesterol moves from the 
cytofacial to the exofacial leaftlet (112).  Using the synaptic plasma membrane of young 
(3-4 months) c57bl/6j mice, it was shown that the exofacial leafleat was comprised 
mostly of phosphatidlycholine (POPC) and SM, while the cytofacial leaflet consisted 
mainly of phosphatidylethanolamine (POPE), phosphatidylserine (POPS), and 
posphatidylinositol (POPI).  85% of the total membrane cholesterol was found in the 
cytofacial leaflet (113).  This asymmetrical distribution of lipids and cholesterol led to the 
exofacial leaflet being much more fluid in nature compared to the cytofacial leaflet; with 
an effect equivalent to approximately a 6º change in temperature on bulk membrane 
fluidity (111).  If extrapolated to humans, this would leave only 15% of the total 
membrane cholesterol in the exofacial leaflet in young adults, the same leaflet where 
APP would potentially bind cholesterol.   
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When the same mice were studied at 14 months of age, it was noted that the 
exofacial leaflet contained 24% of the total membrane cholesterol.  When the 
presynaptic membranes were examined after 25 months, 32% of the total cholesterol 
resided in the exofacial leaflet, suggesting that as neurons age, there is a shift of 
cholesterol from the cytofacial to the exofacial membrane leaflet (114).  This increase in 
cholesterol in the exofacial leaflet may serve to increase the total number of cholesterol 
rich domains in the exofacial leaflet, since this is the only leaflet in which SM residues.  
This is consistent with the findings that cholesterol rich domains preferentially form only 
in the exofacial membrane leaflet (115).  An increase in cholesterol rich domains, as well 
as total cholesterol, could potentially increase the amyloidogenic processing of APP and 
lead to an increase in Aβ production.  One finding of particular interest is that mice 
deficient in ApoE proteins showed an even greater increase in exofacial cholesterol (2 
fold) with age, suggesting that changes in ApoE function may exacerbate cholesterol 
rich domain formation in the exofacial leaflet (111). 
As mentioned above, the formation of cholesterol rich domains (lipid rafts) is 
thought to be intimately connected with amyloidogenic processing of APP by β-
Secretase (33, 34, 60, 81, 111, 116-118).  In addition to the evidence that increased 
cholesterol increases Aβ production (85, 119), there is considerable evidence showing 
that Aβ production is dependent on cholesterol rich domain formation.  Targeting of APP 
to cholesterol rich domains was noticed when studying Niemann Pick type C disease, 
which causes the accumulation of free cholesterol in late endosomal compartments with 
increased Aβ production (120).  Work from the Herman group showed that increases in 
membrane cholesterol stimulate β-Secretase cleavage of APP and that β-Secretase co-
localizes with cholesterol in detergent resistant membranes (which correlate to 
cholesterol rich domains) (85).  Work from Kai Simons lab has shown APP and β-
Secretase co-localization in detergent resistant membranes from purified neurons (33), 
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indicating both components can reside in the same membrane domains.  Studies from 
intact cells validated this study by using fluorescence resonance energy transfer (FRET) 
studies to show close proximity of APP and β-Secretase both at the cell surface and in 
early endosomes (121).   
Interestingly, when a cholesterol rich domain targeting sequence is added to β-
Secretase (34) or when APP and β-Secretase are cross-linked by antibodies in 
cholesterol rich domains (122), the rate of Aβ production is greatly enhanced.  Further 
work from the Simons lab showed that Aβ generation is dependent upon cholesterol rich 
domain formation, and that when these domains are prevented from forming by 
decreasing cholesterol levels or by the chemical methyl β-cyclodextrin, the subsequent 
Aβ levels are decreased.  When β-Secretase is prevented from entering cholesterol rich 
domains, Aβ production is completely inhibited.  A key component to this process noted 
by the Simons group was that in order for β-Secretase cleavage to occur, not only did 
both APP and β-Secretase need to co-localize in cholesterol rich domains, but 
endocytosis was needed (33).  Blocking clathrin-mediated endocytosis greatly 
decreased the amount of Aβ produced, indicating the bulk of β-Secretase cleavage 
occurs after both APP and β-Secretase are engulfed into the cell in the same endocytic 
vesicle.  It is thought that during this process, APP and β-Secretase do not need to be 
localized to the same cholesterol rich domain, but that the act of endocytosis, which is 
cholesterol rich domain mediated, brings enzyme and substrate into closer proximity for 
cleavage to occur (123).  This is due to the fact that there are approximately only 30 or 
so protein molecules per cholesterol rich domain, so a mechanism would be needed to 
increase the local protein concentration for efficient amyloidogenic cleavage (124).  
Blocking endocytosis had no impact on α-Secretase cleavage, further implicating 
cholesterol rich domains in promoting the amyloidogenic pathway (116).  All of these 
findings are consistent with the literature that states α-Secretase cleavage occurs in the 
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ER and at the plasma membrane and β-Secretase cleavage occurs in endocytic 
vesicles, indicating that incorporation into cholesterol rich domains may promote Aβ 
production by segregation into different cell organelles (75). 
In addition to regulating endocytosis and subcellular localization, the biophysical 
properties of cholesterol rich domains may also play an important role in promoting non-
amyloidogenic or amyloidogenic processing of APP.  Work from Kojro et al has shown 
that increased membrane fluidity (low cholesterol levels) in neuron membranes 
stimulated the non-amyloidogenic pathway by increasing α-Secretase cleavage activity 
and APP content in the cell membrane, where it will preferentially undergo α-Secretase 
cleavage (42).  The converse effect of decreasing α-Secretase cleavage of APP when 
localized in cholesterol rich domains has also been seen.  A study by Marenchino et al 
showed that when placed in model membranes that have the same biophysical 
properties of cholesterol rich domains (based on the order of the lipids used), the α-
Secretase cleavage site of APP was embedded into the membrane, and became less 
accessible to the enzyme (40).  When combined with the ability of C99 to bind 
cholesterol (26), and the evidence that APP resides in cholesterol rich domains when 
cleaved in the amyloidogenic pathway(33, 43), the hypothesis was generated that 
cholesterol binding by APP may actively inhibit α-Secretase cleavage by occluding the 
α-Secretase cleavage site. 
While important for production of Aβ peptides, cholesterol rich domains are also 
thought to play an important role in promoting cell death during AD (117).  Seminal work 
from Dennis Selkoe showed that oligomeric forms of Aβ, specifically spherical trimer-
hexamers to 24mer aggregates, and not monomers or higher order fibrils, were the 
neurotoxic species in AD (125).  This does not exclude large order aggregates and fibrils 
of the Aβ from being neurotoxic, as these forms can be cytotoxic indirectly by activating 
an inflammatory response with activation of glial cells, resulting in the production of cell 
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damaging cytokines (87), however this is not initiated until cell death from Aβ oligomers 
has occurred.  It is now thought that the oligomerization of Aβ is initiated by Aβ binding 
to the cell membrane (126), specifically in cholesterol rich domains (127).  Work from the 
Youkin lab showed that Aβ co-purified in detergent resistant membrane fractions from 
cultured neurons, rodent brains, and the brains of human patients with AD, linking 
cholesterol rich domains with Aβ oligomerization (127).  Importantly, Aβ has been shown 
to accumulate in presynaptic terminals in AD cortex where it co-localizes with the 
cholesterol rich domain markers, such as cholesterol and the lipid ganglioside GM1 
(128).  Like sphingomyelin, gangliosides are a family of lipids that are often associated 
with cholesterol rich domains (129).  Mounting evidence suggests that gangliosides 
within cholesterol rich domains appear to be the main driving force behind the 
oligomerization of Aβ on neuronal membranes.  The development of AD within certain 
brain regions has been found to correlate with increased ganglioside levels (130).  In 
addition, exogenously applied Aβ was shown to bind to neuronal membranes and to 
redistribute into cholesterol rich domains where it co-localized with ganglioside GM1 in a 
time-dependent manner (131, 132).  These results suggest that not only cholesterol rich 
domains as a whole, but also specific lipid components, may be responsible for initiating 
the cascade of events that promotes Aβ oligomerization, opening potential new avenues 
for therapeutic intervention in AD. 
Furthermore, recent evidence suggests that the interplay between Aβ and 
cholesterol rich domains may not be limited to promoting Aβ oligomerization.  Multiple 
studies have shown that the Aβ oligomers that form in cholesterol rich domains can go 
on to bind a variety of membrane proteins, alter their membrane localization, and 
ultimately promote neuronal cell death.  One such membrane protein is the N-methyl-D-
aspartate receptor (NMDARs), a major class of glutamate receptors in the brain found at 
the postsynaptic membrane of excitatory synapses (133).  NMDARs function by 
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permitting the rapid influx of Ca2+, which triggers long-term potentiation (LTP) in the 
brain, which is important for maintaining synapses (134).  NMDARs function by localizing 
to cholesterol rich domains, a lateral membrane translocation mediated both by 
phosphorylation of NMDARs and the interaction with the cholesterol rich associated 
proteins flotillin-1 and -2 (135-137).  Interestingly, APP has been shown to also 
associate with flotillin-2, adding another piece of evidence linking APP processing and 
Aβ generation to cholesterol rich domains (49).  By examining hippocampal slices, it was 
found that NMDARs and Aβ co-localize (138).  Further evidence showed that Aβ 
oligomers were able to co-immunoprecipitate with NMDAR subunits (139).  Aβ oligomers 
were found to decrease NMDAR-dependent influx of Ca2+ into dendritic spines by 
preventing NMDARs from localizing to cholesterol rich membrane domains, (140) using 
a mechanism that also involved the phosphorylation of tau, another dysregulated protein 
important in the pathogenesis of AD (141).  This decrease in Ca2+ resulted in the loss of 
LTP, leading to the loss of synapses between neurons and neuronal impairment (142). 
Another membrane protein that exhibits altered function in the presence of Aβ 
oligomers is the metabotropic glutamate receptor 5 (mGluR5), a protein that plays an 
important role in Ca2+ mobilization and the modulation of LTP in hippocampal neurons 
(143, 144).  Unlike the NMDARs, which function as ion channels, mGluRs are G-protein 
coupled receptors (145).  Work from the lab of Antoine Triller showed that mGluR5 was 
a putative Aβ oligomer receptor by showing co-localization of fluorescently labeled Aβ 
with the receptor in hippocampal neurons (139).  The work went on to show that the Aβ 
oligomers formed complexes with mGluR5 receptor, which altered the lateral distribution 
of the receptor into dendritic spines followed by Ca2+ dysregulation.  It was also noted 
that Aβ oligomers induced a time-dependent increase in cholesterol rich domain 
associated mGluR5 as noticed as a decrease in receptor mobility and aggregation.  This 
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aggregation led to a constitutively active receptor as the protein was permanently 
residing within a pathological signaling platform (139). 
The interaction between Aβ, membrane receptors, and cholesterol rich domains 
is not limited to only NMDARs and mGluRs; these are the most studied receptors to 
date.  Increasing evidence suggests that cholesterol rich domains serve as signaling 
platforms for proper neuronal function (117), and the sequestration or occlusion of 
receptors from these domains by Aβ oligomers leads to aberrant cellular signaling, and 
ultimately neuronal death.  While more research is needed to substantiate these ideas, 
this is promising research identifying how the Aβ peptide actually initiates cell death 
during AD. 
 
 
Experimental Overview2 
Protein structure determination is a vital component for understanding of how 
proteins function, and an invaluable technique for developing the production of effective 
therapeutics (147).  While there are multiple methods of protein structure determination, 
including X-ray crystallography and cryo-electron microscopy; nuclear magnetic 
resonance (NMR) spectroscopy has seen numerous recent advancements that enhance 
its ability to determine high resolution protein structures, specifically of membrane 
proteins like C99 (146, 148).  As NMR-based structure determination is becoming more 
routine and compatible with larger protein systems, because in addition to to static 
protein structures it can also provide dynamic information about a proteins motion, 
something many other structure determination methods cannot do.  This section of the 
                                                            
2 (Portions of this section were adapted from the published work “The Quiet Renaissance of 
Protein NMR by Barrett et al, published in Biochemistry146. Barrett, P. J., Chen, J., Cho, M.-
K., Kim, J.-H., Lu, Z., Mathew, S., Peng, D., Song, Y., Van Horn, W. D., and Zhuang, T. (2013) 
The quiet renaissance of protein nuclear magnetic resonance, ibid. 52, 1303-1320.) 
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introduction will deal with the practical considerations and experiments used for 
determining the three dimensional structure of C99 (26). 
 
Nuclear Magnetic Resonance Spectroscopy 
 NMR spectroscopy is a strikingly diverse technique, enabling researchers to 
obtain detailed information regarding protein structure, dynamics, and the surrounding 
chemical environment.  There are two main types of NMR spectroscopy used for 
investigating the properties of biological compounds, solution state and solid state NMR.  
As the names suggest, solution state NMR studies proteins suspended in aqueous 
solutions while solid state NMR utilizes molecules in a crystalline (solid) state.  For 
purposes of clarity, the NMR methods discussed in this section will relate exclusively to 
solution state NMR, as that was the method used to study C99.  Scientists Isidor Rabi, 
Felix Bloch, and Mills Purcell noticed that certain atomic nuclei, such as hydrogen (1H) 
and phosphorous (31P) had the ability to absorb radio frequency (RF) energy when 
placed in an aligned magnetic field (149, 150).  When this absorption occurred, it was 
termed that the nucleus was in resonance.  Subsequent work showed that different 
atomic nuclei resonate at different rates when placed in different magnetic fields, leading 
to unique chemical signals, known as chemical shifts (151).  While it is true that NMR 
spectroscopy can be utilized for studying a wide array of biological molecules such as 
proteins, nucleic acids, sugars, and more, the focus of this work is on the use of NMR 
spectroscopy to study the structure and function of proteins, so for simplicity the 
following paragraphs will highlight applications for proteins only.  Figure 1.5 shows a flow 
chart for how a basic NMR experiment works. 
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Figure 1.5.  A schematic flow chart of the process for how an NMR experiment 
works.  Prior to being placed in the NMR spectrometer (magnet), the magnetic 
spins of the system are randomly oriented.  Following placement in the 
spectrometer, the spins align parallel or anti-parallel to the direction of the static 
magnetic field.  The orientation of these spins can be summed and due to the ½ 
spin number of the NMR active nuclei, the overall spin orientation can be 
represented as a single vector (bulk magnetization).  RF energy can be absorbed 
by the spins, which can change the orientation of the bulk magnetization from the 
Z plane into the X/Y plane.  Due to angular momentum, this vector will precess 
within the X/Y plane.  As the absorbed energy is released to the system, the bulk 
magnetization will relax back to the Z plane.  This energy is recorded as a free 
induction decay, which can undergo a Fourier transformation to generate the NMR 
spectrum. 
 
 
While a number of recent advances are based on using NMR methods of 
formidable complexity, simple 1-D solution NMR methods can be used to address highly 
significant biological questions.  A variation of this approach involves fluorine NMR.  19F 
is a spin-½ nucleus with an NMR sensitivity that approaches that of protons, making it 
easy to obtain satisfactory signal-to-noise at short acquisition times even for dilute 
samples of large proteins and complexes.  Moreover, 19F NMR chemical shifts are highly 
sensitive to local environment, such that 19F NMR generally yields well-resolved 1-D 
NMR spectra, (152, 153) making 19F is an excellent reporter probe in binding studies or 
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in studies of protein folding or conformational changes.  19F probes can be attached to 
proteins by chemical modification of cysteine thiol sites (154) or via incorporation of 
labeled amino acids. (153, 155, 156)   
1D NMR is an extremely powerful technique, as a single experiment can give 
massive amounts of information regarding the properties of a protein, but NMR 
spectroscopy has the ability to link multiple NMR active nuclei, such as coupling all 15N 
and 1H spins together, by manipulating the pulses used during the experiment.  This is 
known as a 2D experiment, since instead of analyzing only one dimension (one nuclei), 
we are now looking at two.  2D NMR spectroscopy was developed to enhance spectral 
resolution, thereby reducing the level of NMR peak overlap seen in 1D experiments.  It 
should be noted that 2D NMR is not the limit, and the use of higher ordered 
multidimensional NMR is common practice when investigating the structure and function 
of proteins.  While there are many different types of 2D NMR experiments, this  work will 
focus exclusively on the heteronuclear single quantum coherence (HSQC) experiment 
(157) as it is the main experiment used in the various NMR studies described herein. 
 The HSQC experiment is a common 2D NMR experiment used to investigate 
structural changes and binding events in proteins. In this spectrum, the horizontal axis 
represents the proton (1H) chemical shift and the vertical axis represents the chemical 
shift of a hetero nucleus, such as 15N or 13C.  The NMR spectrum for an HSQC 
experiment shows the chemical shift for each correlated proton-heteroatom bond as a 
single peak in the 2D plane, similar in style to a contour map.  When performing an 15N 
HSQC for a protein, each peak represents one amino acid, based on the N-H bond 
found within the protein backbone.  The chemical shift (location) of each peak is 
dependent on the chemical environment of each nuclear spin.  Even without knowing 
which peak corresponds to which amino acid, one can determine if a protein is folded as 
well as get a prediction of the secondary and tertiary structure of the protein based on 
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the dispersion of the chemical shifts.  Using higher dimensional NMR techniques (such 
as 3D NMR which correlate 1H, 15N, and 13C nuclear spins), it is possible to assign which 
amino acid in the protein corresponds to which peak in the NMR spectrum.  Using this 
information, it is possible to determine which residues interact with ligands or other 
proteins as they are added to the chemical environment, as only peaks that experience a 
change in their chemical environment (involved in the binding event or undergo some 
structural change) will show a perturbation in the chemical shift.   
While the 15N HSQC is a useful experiment, it is limited by the size of the protein 
it can study.  Relaxation properties of proteins give rise to the NMR signal, and when 
proteins become large the nuclear spins relax at a faster rate, due to the fact that the 
elevated mass causes the protein system to tumble in solution at a much slower rate.  
This increased relaxation rate leads to broadening of the NMR signal, such to a point 
that no signal can be detected.  The size limit for standard HSQC experiments is ~ 
35kDa.  Advancements in experimental design led to the development of transverse 
optimized spectroscopy (TROSY) (158), which allows for the basic heteronuclear 
correlation technique to be extended to larger proteins up to ~100 kDa in size.  In an 
HSQC spectrum in which decoupling has not been applied, peaks appear as multiplets 
due to J-coupling.  Crucially the different multiplet components have different widths.  
This is due to constructive or destructive interaction between different relaxation 
mechanisms.  Typically relaxation for large proteins at high magnetic field strengths the 
transverse (T2) is dominated by the dipole-dipole (DD) mechanism and the chemical shift 
anisotropy (CSA) mechanism.  As the relaxation mechanisms are generally correlated 
but contribute to the overall relaxation rate of a given component with different signs, the 
multiplet components relax with very different overall rates.  The TROSY experiment is 
designed to select the one component for which the relaxation is slowest, leading to a 
single, sharp peak in the spectrum. This significantly increases both spectral resolution 
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and sensitivity, both of which are at a premium when studying large and complex 
biomolecules, relative to a corresponding HSQC spectrum(158). 
This approach significantly extends the molecular mass range of molecules that 
can be studied by NMR, but it generally requires high magnetic fields to achieve the 
necessary balance between the CSA and DD relaxation mechanisms; CSAs scale with 
field strength, while dipole-dipole couplings are field-independent. Since this technique 
only serves to select a component of the HSQC experiment, the resulting NMR spectrum 
still shows a series of peaks, each representing one amino acid within the protein (for 
the 1H, 15N TROSY-HSQC experiment).  Figure 1.6 shows a representative TROSY-
HSQC for C99. 
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Figure 1.6.  A representative 2D 1H,15N HSQC-TROSY NMR spectrum of C99 in 
LMPG detergent micelles.  The horizontal dimension represents the proton 
dimension and the vertical dimension represents the nitrogen dimension.  Each 
peak represents a single amino acid from the protein, with the location  (chemical 
shift) of the peak being dependent upon the chemical environment surrounding 
the amino acid.     
 
C99 Preparation and Experimental Considerations 
 As stated above, in order to perform these higher dimensional NMR experiments, 
the protein being studied must have NMR active nuclei, such as 13C or 15N, incorporated 
into the amino acids.  While there are a variety of methods for incorporating 15N into 
proteins, such as cell free expression (159) and injecting living cells with 15N labeled 
compounds (160, 161), the method utilized for the studies of C99 was to overexpress 
the protein in E. Coli while supplementing the bacterial medium with 15N labeled 
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ammonium chloride (162-164) in a growth medium devoid of all other nitrogen sources.  
The human C99 gene was cloned into a pET-21a vector, with an added methionine 
encoded at the N-terminus and an added spacer/His-purification tag 
(QGRILQISITLAAALEHHHHHH) at the C-terminus. This vector was then used to 
transform the BL21(DE3) strain of Escherichia coli (28).  C99 overexpression was driven 
by inducing the cells with isopropyl thiogalactoside (IPTG).  Following overexpression of 
C99, the E. Coli cells were lysed and the protein was purified via immobilized metal 
affinity chromatography with nickel resin.  The resulting purified protein was enriched 
with 15N for NMR studies.  Further details on C99 preparation and purification are found 
in the methods section of Chapter II. 
 In addition to incorporating NMR active nuclei into the protein for NMR studies, 
another consideration for preparing C99 was the ability to effectively mimic the 
hydrophobic environment of the cell membrane.  Since C99 is a transmembrane protein, 
in order for the protein to be properly folded and functional, the hydrophobic environment 
of the lipid bilayer must be replicated.  Due to the size limitations of NMR, it is impractical 
to study membrane proteins using native lipids, as the system is too large to study.  
Multiple membrane mimetics have been utilized, but for the studies on C99 two distinct 
mimetics were used, detergent micelles (165-167) and lipid bicelles (167-169). 
  Detergent micelles form when surfactants (detergents) are placed in an aqueous 
solution above a critical concentration (critical micelle concentration, CMC) when 
detergent aggregation can occur.  Micelles form due to the chemical structure of the 
detergent molecules used to form them.  Detergents are similar in structure to lipids, as 
each contains a polar head group and a hydrophobic tail, but opposed to lipids, 
detergent molecules normally have an acyl chain forming the hydrophobic tail, not two.  
When a concentration above the CMC is reached, it is energetically favorable for the 
hydrophobic tails of the detergent molecules to cluster together and exclude any 
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surrounding water, driving the formation of a spheroid shape.  It is in this hydrophobic 
environment that the transmembrane region of C99 is inserted.  For the studies of C99 in 
detergent micelles, the detergent lyso-myristoylphosphatidylglycerol (LMPG) was used.  
LMPG contains a single, saturated acyl chain of 14 carbons linked to a glycerol head 
group, resulting in a net negative charge. 
 Lipid bicelles are the practical middle ground for solution NMR between 
detergent micelles and native lipid bilayers, in the fact that they contain lipid molecules 
with two acyl chains, but are small enough in size to be studied by solution NMR.  
Bicelles are formed by mixing two amphipathic compounds, one a lipid with two acyl 
chains in the hydrophobic tail and the other an amphipathic molecule, such as a 
detergent.  During mixing, the lipid components come together to form a lipid bilayer, 
which is then capped on either end by the amphipathic molecules to prevent any 
hydration of the hydrophobic environment.  As with detergent micelles, the 
transmembrane protein being studied inserts into the hydrophobic environment of the 
bicelle, only in this mimetic the hydrophobic region more closely replicates the lipid 
bilayer found within the cell membrane.  In addition to being a better membrane mimetic, 
bicelles allow the incorporation of other hydrophobic molecules, such as cholesterol, so 
binding studies with these compounds can be performed and monitored by NMR 
studies.  Figure 1.7 shows a cartoon representation comparing detergent micelle and 
lipid bicelle structures. 
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Figure 1.7.  A comparison between micellar and bicellar structures.  A 
representative membrane protein is shown by the black cylinder.  Detergent 
micelles are represented on the left by the red molecules.  A detergent micelle can 
be thought of as a hydrophobic inner tube around the membrane spanning region 
of a protein.  A bicelle is shown on the right by the blue and green molecules.  The 
blue molecules represent lipids with two acyl chains.  The green molecules 
represent detergent molecules that cap the ends of the bicelle.  A bicelle can be 
thought of as having the shape of a hockey puck, with the lipid bilayer forming the 
middle of the puck. 
 
NMR Experiments for 3D Structure Determination 
 The process for structure determination by NMR requires two key components; 
the first being known as obtaining “assignments”, where each NMR resonance is 
assigned to a specific amino acid.  The second component is obtaining an abundance of 
NMR structural restraints, such as long and short range distances between atoms and 
the orientation of specific atomic bonds within the protein (170, 171).  While there are a 
variety of methods used to facilitate the acquisition of structural restraints, this section 
will focus solely on the experiments used for determination of the 3D backbone structure 
of C99 at a modest resolution.  When working with membrane proteins it is often difficult 
to obtain high resolution structures, as the larger size of the protein/membrane complex 
limits the NMR signal.  Following the procurement of numerous experimentally obtained 
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structural restraints, these parameters are converted using computational methods 
(172).  
 Prior to obtaining structural restraints for 3D structure determination, the NMR 
assignment process must be completed.  This preliminary work was performed and 
published from the Sanders lab prior to the 3D structure determination (28).  The 
assignment process utilizes a variety of triple resonance (3D) NMR experiments, which 
connect the atoms of the protein amino acid chain by using the NMR active nuclei 15N, 
13C, and 1H (162, 173-175).  By manipulating the nuclear spins, specific atoms within the 
amino acid chain can be correlated to each other through bonds.  For example, there are 
two key 3D NMR experiments that allow one to “walk” along the protein backbone, 
connecting consecutive amino acids by transferring the magnetization between them 
through bonds, essentially tracing the linkage between the amino acids.  These two 
experiments are called HNCA and HN(CO)CA (Figure 1.8).   
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Figure 1.8.  Cartoon representation of backbone assignment experiments HNCA 
and HN(CO)CA.  In these two NMR experiments, magnetization is transferred 
between 1H, 15N, and 13C atoms within the protein backbone.  When performing an 
HNCA (left) experiment, magnetization is transferred to the 13Ca atom in both the 
initiating (i) residues as well as the previous residue (i-1).  The bottom panel 
represents an NMR spectrum, showing the two different resonances for residues i 
and i-1.  When performing an HN(CO)CA (right), magnetization is transferred only 
through the carbonyl carbon (CO) to residues i-1.  This is shown in the bottom 
panel as only 1 NMR resonance.  By combining the data obtained in both 
experiments, it is possible to “link” all the residues together through the 
backbone atoms. 
 
In the HNCA experiment, the resulting NMR spectrum shows two peaks, one from the 
alpha carbon from residue i and the other from the alpha carbon in residue i-1.  These 
 40 
 
two carbon atoms are linked through bonds two the same amide proton via the identical 
nitrogen atom.  The resulting NMR spectrum from the HN(CO)CA experiment shows 
only the NMR resonance from the i-1 alpha carbon, as the magnetization from this 
experiment must be transferred through the carbonyl bond (CO) to the previous amino 
acid (176).  By connecting a string of amino acids via this method, it is possible to assign 
which residue belongs to which resonance, by comparing the sequence of the string to 
the amino acid sequence of the protein.  While these two experiments are an effective 
way of determining the assignments of NMR resonances, a variety of different NMR 
pulse programs have been developed to enhance the process and ensure a complete 
assignment process.    
 Due to the challenges presented by membrane proteins, structural analysis is 
based only on backbone resonances.  Following completion of the backbone resonance 
assignment, the first set of structural restraints is also collected.  By examining the 
chemical shift of the 13C resonances, restraints on the secondary structure and torsion 
angles of the protein backbone can be estimated.  Secondary structures are analyzed by 
performing chemical shift indexing (CSI) analysis (177, 178).  During CSI analysis, the 
chemical shift values of all carbon resonances are compared to known values for 
structures with random coils.  Based on the resulting patterns, it can be determined if the 
protein has any alpha helical or beta sheet secondary structural elements.  In addition to 
information about secondary structure, the carbon chemical shift values can also be 
calculated to torsion angles, in this case using the computer software TALOS+ (179).   
 In addition to the structural information from chemical shifts, additional structural 
restraints are acquired in the form of long and short range internuclear distances 
between atoms and the orientation of bond vectors.  Traditionally speaking, structure 
determination of soluble proteins is done almost exclusively using an NMR phenomenon 
called nuclear Overhauser enhancement (NOE) (180-183).  When studying membrane 
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proteins such as C99, it is difficult to assign all of the proton resonances due to the high 
level of spectral overlap, but more importantly due to the fact that the large 
protein/micelle complex tumbles too slowly, leading to rapid relaxation and broadening of 
NMR signals.  Due to these complications, it is not uncommon that when working with 
membrane proteins the NOE experiment is used to not collect the bulk of the distance 
restraints between atoms, but instead to collect distances between the amide protons 
within the protein backbone, facilitating the process of secondary structure determination 
as well hydrogen bonding networks.  It is not impossible to collect distance restraints 
using the NOE experiment for membrane proteins, and with recent advancements in 
labeling techniques and NMR pulse programs (184-187) this is becoming more frequent, 
but for the studies done on C99, only amide proton-proton distances were obtained. 
To circumvent the problem of a lack of distance restraints from limited NOE data, 
long range distance restraints between atoms were obtained using a phenomenon 
known as paramagnetic relaxation enhancement (PRE) (188).  Early in the development 
of NMR, the physics of nuclear relaxation enhancement arising from the presence of 
proximal paramagnetic species was explored (189).  NMR signals are broadened to a 
degree that is proportional to 1/r6, where r is the distance between the paramagnet and 
the NMR nucleus.  This broadening stems from the PRE phenomenon.  In biological 
NMR, paramagnets can be added to samples as free probes (such as Mn(II) and Gd(III) 
and their chelates) or can be attached to proteins either through metal ion coordination 
or by modifying free cysteines with thiol-reactive nitroxide spin labeled compounds such 
as MTSL ((S-(2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl 
methanethiosulfonate) (188, 190-195).  PRE of NMR sites can be quantified using 
methods as simple as recording 1- or 2-D NMR spectra of matched samples, one 
containing a paramagnet and the other in which the paramagnet is absent or quenched 
to a diamagnetic form.  The PRE effect can be detected over a broad range from 
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approximately 0 to 25 Å for a proton experiencing relaxation enhancement from a 
nitroxide spin label. The distance can be extended to approximately 35 Å if a more 
dominant paramagnetic species is used (e.g. Mn2+) (196).  
The most common PRE measurements today involve use of 2-D 1H,15N-HSQC or 
TROSY to measure the distances between a nitroxide spin label fixed at a specific 
protein site and the backbone amide protons of the same protein, an experiment that 
can generate dozens of distances from a single pair of NMR spectra. The derived 
distances can be used as a source of restraints for structure determination (188, 197).  
Such measurements have proven especially important for structural studies of 
challenging molecules where only the backbone chemical shift assignments are 
available, as is commonly the case for integral membrane proteins (26, 171, 192, 197-
199).  Most recently, the use of the PRE effect has been extended to aid in the NMR 
assignment process (200, 201), increase the sensitivity of NMR experiments (202), 
serve as a route to map intermolecular binding surfaces of macromolecular complexes 
(203, 204), elucidate the active/binding sites of proteins (192), map the topology of 
membrane proteins (28), and probe dynamic and sparsely populated states of 
macromolecules (193, 205, 206). 
While the advent of PRE experiments for determining long range distance 
restraints during structure determination has greatly advanced our abilities to determine 
structures of membrane proteins, the lack of close range (2-5Å) distances can lead to 
the loss of finer details during structure calculations, such as bent or kinked helical 
segments.  To complement the distances obtained from PRE and NOE experiments in 
order to determine a more accurate structure, residual dipolar couplings (RDCs) can be 
collected (207-209).  RDCs are the measurement of magnetic interactions between two 
spins that are coupled (bonded) together when the molecule being studied is placed in a 
partially aligned media.  RDCs are a vector quantity and have an angular dependence to 
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the external magnetic field.  Under standard solution NMR conditions, proteins tumble 
isotropically, thus averaging out any RDC vector quantities between atoms.  However, 
when placed in a partially aligned media, these vector quantities are no longer averaged 
out, and can thus be calculated by comparing the NMR spectrum of the isotropic sample 
to the anisotropic sample.  The magnitude of the RDC is proportional to the angle 
between the coupled spins and the external magnetic field.  By determining the RDC 
between two atoms, it is possible to back calculate the angle of that vector relative to the 
molecular frame. 
The standard way of implementing RDC experiments by NMR is to use a 2D 15N-
1H HSQC experiment and collect two NMR spectra, one of an isotropic sample and one 
of a matched anisotropic sample.  Anisotropy can be introduced into the media by a 
variety of methods; the most common of which are using large magnetically susceptible 
bicelles that align in the external magnetic field, bacterial phage molecules, or by 
soaking a low percentage polyacrylamide gel with the protein solution and then 
stretching the gel, causing the polyacrylamide matrix to collapse and limit the protein 
motion (208).  RDC experiments for C99 were performed using the stretched 
polyacyrmalide gel method.  After the magnitude of the couplings are determined by 
measuring the separation in frequency between peaks from both NMR spectra, the 
values can be incorporated into structure calculations to provide orientation information 
regarding the two spins coupled together.  In addition to 15N-1H backbone RDC 
experiments, it is possible to measure RDCs between other atoms, such as 13C and 1H.  
Additional levels of RDC experiments continue to increase the precision and accuracy of 
structures determined by NMR spectroscopy (210). 
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Validation of NMR Structures Using Electron Paramagnetic Resonance Spectroscopy 
 Structure determination by NMR spectroscopy gives researchers invaluable 
information regarding not only the overall architecture of a protein, but also how 
dynamics may influence protein function.  However, when studying membrane proteins, 
it is difficult to ascertain whether certain properties of the protein are native to the 
structure, or are an artifact of the model membrane used.  To solve this issue, many 
NMR studies supplement the information gained with electron paramagnetic resonance 
(EPR) spectroscopy experiments.  EPR spectroscopy is a method similar to NMR 
spectroscopy, but allows proteins to be studied in lipid vesicles, which are a much closer 
membrane mimetic to the plasma membrane of cells.  Like NMR, EPR monitors the 
transition of magnetic spins, but instead of monitoring nuclear spins, EPR monitors the 
transitions of unpaired electrons.  Additionally, instead of being placed in a static 
magnetic field and having RF energy pulsed into the system, as with NMR, EPR utilizes 
an older magnetic resonance approach in which the input of energy is scanned across a 
range of frequencies with the implantation of an oscillating magnetic field (211).  As with 
the use of PRE measurements in NMR, the unpaired electron for EPR experiments is 
incorporated into the protein using the molecule MTSL.  When the frequency reaches a 
resonance value, energy is absorbed by the unpaired electron, resulting in an energy 
state transition.  This transition is recorded, is Fourier Transformed, and the derivative of 
this signal is taken giving rise to the traditional EPR spectrum seen.  CW EPR can be 
used to monitor the local dynamics and motion of the incorporated MTSL spin label.  If 
incorporated into a region with dampened dynamics and motion, such as a region of the 
protein that is well structured or located within the plasma membrane, the resulting EPR 
spectrum will be broad.  When incorporated into a region that is dynamic in nature, such 
as an unstructured loop that is solvent exposed, the EPR spectrum will appear sharp 
(Figure 1.9) (212).   
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Figure 1.9.  Representative EPR spectra indicating how EPR lineshape changes 
between fast and slow motion.  As motioned is dampened, the EPR trace becomes 
broader (as shown in the bottom right panel). 
 
In addition to monitoring protein movement and dynamics, single MTSL labeled 
proteins can undergo an EPR experiment known as power saturation (213-215).  Power 
saturation studies utilize the phenomenon that paramagnetic molecules, such as oxygen 
and nickel, can influence the relaxation rate of the unpaired electron center, thus 
changing the EPR signal recorded.  When studying membrane proteins, power 
saturation studies are important for determining the membrane penetration of individual 
residues, once modified with MTSL.  This is due to the fact that nickel EDDA (NiEDDA) 
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is hydrophilic and will not penetrate the membrane and oxygen (O2) is hydrophobic and 
will preferentially partition into the lipid bilayer (213).  Close proximity to either compound 
will result in a drastic change in the EPR signal based on the enhanced rate of spin 
relaxation.  This change is then monitored over a range of microwave frequencies.  By 
taking the ratio of accessibility between NiEDDA and O2 when compared to a non-
paramagnetic standard (nitrogen), the penetration into the membrane of each residue 
can be obtained. 
In addition to gaining information of protein mobility and membrane topology, 
when two MTSL spin label sites are incorporated into a protein, the double electron 
electron resonance (DEER) EPR method can determine discrete distances between the 
two spin label sites (216-218).  DEER, also known as PELDOR or Pulsed ELDOR, uses 
two separate microwave frequencies to examine the coupling between two electron 
spins in order to make a distance measurement, typically between two nitroxide spin 
labels.  In the experiment, a Hahn Echo sequence is used to produce an echo for the 
spins in resonance with the probe microwave frequency.  At a time τ2 after the first echo, 
a second π pulse is applied to form a refocused echo.  At a separate microwave 
frequency, the pump frequency, a π pulse is applied to invert the population of a 
separate set of spins.  This π pulse is then incremented in time and the intensity of the 
refocused echo is monitored.  The set of spins affected by the probe frequency 
experiences a different magnetic environment before and after the pump π pulse.  The 
change in the magnetic environment affects the ability of the magnetization to be called 
back with the second probe π pulse.  The net effect is a modulation in the intensity of the 
refocused echo with a periodicity that is a function of the strength of the coupling and 
therefore, the distance, between the two electron spins (219).     
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Initial Structural Studies of C99 
 As stated above, the backbone resonance assignment for C99 was previously 
accomplished and published by the Sanders lab (28).  In addition to assigning each 
residue to an NMR resonance, the completion of the backbone assignment also allows 
for initial secondary structure analysis of the protein using chemical shift indexing (CSI) 
analysis (177, 178, 220).  CSI analysis of C99 indicated that in addition to a helical 
transmembrane helix, the protein contained two other regions that had helical secondary 
structure; a 6 residue helical turn from residues V688-V694 (termed the N-helix due to its 
location N-terminal to the transmembrane helix) and the extreme C-terminus of the 
protein (C-helix) (26, 28).  In addition to the backbone resonance assignment and 
secondary structure analysis, this previous work also established the membrane 
topology of C99 in lyso-myristoylphosphatidylglycerol (LMPG) detergent micelles.  The 
membrane topology studies determined which regions of C99 were embedded in the 
hydrophobic environment of the detergent micelle and which regions were exposed to 
the solvent.  These studies were performed by adding paramagnetic probes to the 
protein NMR sample and monitoring changes within the NMR TROSY-HSQC spectrum.  
Paramagnetic probes function by enhancing the relaxation rate of proximal NMR nuclei 
(188).  This enhancement in relaxation is manifested as broadening of the NMR signal 
for those nuclei, and in extreme cases, the complete disappearance of the resonance 
from the NMR spectrum.  By using the paramagnetic probes 16-doxylstearic acid (16-
DSA) (inside the micelle) and Gd(III)-diethylenetriaminepentaacetic acid (Gd-DTPA) 
(outside the micelle), Beel et al were able to determine which regions of C99 were within 
the detergent micelle and uncover the first experimantlly determined glimpses into the 
protein topology.  They discovered that in addition to the transmembrane helix, the two 
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other helical regions of the protein (N-helix and C-helix), were also both embedded in the 
membrane (Figure 1.10) (28). 
 
   
 
Figure 1.10.  A 2D topology plot of C99 in a cartoon lipid bilayer.  C99 possesses 
three regions that are α-helical.  Residues 688-694 (circled in green), residues 700-
723 (circled in red), and residues 762-770 (circled in cyan). 
 
The discovery of these additional membrane bound regions of C99 shed some 
initial light on how the structure of the protein may play a role in regulating its function.  It 
was noted that both membrane embedded helices contained two consecutive 
phenylalanine residues, leading to the speculation that these residues may help to 
anchor the helical structure into the membrane.  This hypothesis was corroborated by 
work from the lab of Tobias Ulmer when his lab determined the 3D structure of the 
αIIbβ3 integrin and showed a similar phenomenon (221).  Linking the N-helix to the 
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transmembrane helix is a short, five residue loop (N-loop), and when examined in the 2D 
topology plot, the overall structure from the N-helix through the transmembrane domain 
provides what appears to be a ligand binding pocket for a lipid or other hydrophobic 
molecule.  In fact, initial work from Beel et al showed that this region of C99 was able to 
specifically bind the soluble cholesterol analogue β-Cholbimalt, suggesting the first 
biochemical evidence that C99 could potentially bind native cholesterol (28, 30). 
 While the exact function of APP is still being elucidated, it is known that APP is 
able to undergo rapid turnover from the plasma membrane to endocytic vesicles through 
clathrin mediated endocytosis (1, 9, 33, 49, 77).  Contained within the C-helix of APP is 
a known trafficking amino acid sequence, NPxY, which allows for the binding of a variety 
of adaptor proteins to promote APP internalization (222, 223).  A potential new 
hypothesis to study would be that the membrane proximity of the C-helix allows for 
preferential interactions with different adaptor proteins under different cellular conditions, 
either promoting or inhibiting APP internalization.  If found to be true, this may be a way 
of preventing the overproduction of Aβ peptides, as their generation occurs only after 
endocytosis of APP and β-Secretase (81, 224).  While the initial work performed by Beel 
et al set a great foundation for how the structure of C99 regulates AD, determination of a 
3D structure of the protein was the next step into gaining a better understanding of how 
the structure of this protein regulated its function. 
 
Giant Unilamellar Vesicles to Study Cholesterol Rich Domains 
 As previously noted, there is an ever present link between APP, cholesterol rich 
domains, and AD.  However, the exact understanding of how all these components lead 
to increased Aβ production and neuronal death is still unclear.  Recent evidence from 
our lab indicates that the β-Secretase cleavage product of APP, C99, can specifically 
bind cholesterol in the bicelle model membrane system (26).  This result gives strong 
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biochemical evidence that C99, and potentially APP, can bind cholesterol under 
conditions found within the plasma membrane of cells.  Our findings led to the 
hypothesis that cholesterol binding by APP promotes the amyloidogenic cleavage 
pathway in AD by increasing the partitioning of APP to cholesterol rich domains. 
 To study the impact cholesterol binding has on C99 membrane partitioning, we 
developed a method to monitor this membrane partitioning by confocal fluorescence 
microscopy using the model membrane system known as giant unilamellar vesicles 
(GUVs) (225-227).  GUVs are a powerful technique for investigating cholesterol rich 
domain formation and membrane protein partitioning, as the exact lipid content can be 
manipulated very easily, but more importantly, the formation process creates GUVs that 
can be imaged by microscopy, as they range from 10-100μM in diameter.  This allows 
for the incorporation of fluorescent lipid probes or fluorescently labeled protein molecules 
to actively image cholesterol rich domains and changes in protein membrane 
localization.  The process of cholesterol rich domain formation in GUVs has been 
rigorously studied for a variety of lipid mixtures (228-233).  These experiments have 
determined phase diagrams of ternary mixtures of lipids, all of which include an 
unsaturated lipid (i.e. POPC), a saturated lipid (i.e. SM), and cholesterol.  Within this 
phase diagram are regions where co-existing liquid disordered (Ld) and liquid ordered 
(Lo) cholesterol rich domain formation occurs.  It is within these regions that our studies 
were performed to monitor C99 membrane partitioning (Figure 1.11). 
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Figure 1.11.  The phase diagram for the ternary lipid mixture of 
POPC/SM/Cholesterol.  The region highlighted in dark grey represents the regime 
used for future experimental studies, that contains both liquid disordered (Ld) and 
cholesterol rich (Lo) domains.  X represents the mol fraction of each lipid.  This 
figure was modified with permission from (233). 
 
 The details of GUV experiments will be covered in more depth in later chapters, 
but as an introduction GUVs are formed by exposing a multi-layer lipid film to a process 
known as electroformation (234).  The lipid film is created by taking a mixture of lipids in 
chloroform and dehydrating them on an indium tin oxide (ITO) glass microscope slide.  
By mixing lipids in chloroform, one can manipulate the percentage of lipids to generate 
cholesterol rich domains with different properties, such as size and dynamics.  
Electroformation is a process that involves connecting the ITO slides to a wave 
generator, which outputs an applied voltage of 1-2 volts using a sinusoidal wave with a 
frequency of approximately 10 Hz.  A combination of electrostatic, mechanical, 
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hydrophobic, and van der Waals interactions force the multi-layered lipid film to separate 
into the surrounding aqueous buffer where GUVs spontaneously form (234-236). 
 
Summary 
 The purpose of the following chapters is to help elucidate how the structure and 
function of C99 contribute to increased Aβ production during AD.  Three stories will be 
told in all.  The first will highlight how 3D structure determination of membrane proteins 
can show how protein structure and dynamics impact protein function.  It will be shown 
that C99 possess a flexible transmembrane helix, and that this flexibility may serve to 
regulate γ-Secretase cleavage.  The second component will highlight how GSM 
compounds modulate γ-Secretase activity through a mechanism independent of 
interactions with APP.  In addition, this section will also show results of how previous 
studies interpreted that GSMs specifically interact with APP and the Aβ peptide.  The 
last story will highlight how cholesterol binding influences C99 membrane partitioning in 
GUVs, and how this partitioning can be controlled by the presence of different sterols.  
These findings will further support that cholesterol rich domains play an important role in 
Aβ production, and that manipulating APP’s preference for these domains may be a 
potential therapeutic not yet studied to ameliorate the effects of AD. 
 
 
 
 
 
 
 
 
 53 
 
CHAPTER II 
 
THREE-DIMENSIONAL STRUCTURE OF C993,4 
 
Introduction 
 Alzheimer’s disease (AD) is a severe form of dementia that current affects nearly 
40 million people worldwide, a number that is estimated to increase by the year 2050 to 
roughly 120 million (1).  The production and subsequent aggregation of amyloid-β (Aβ) 
peptides are widely thought to play a central role in most forms of AD (1, 238); 
accordingly, factors that increase Aβ production and oligomerization or that reduce its 
elimination increase the risk of AD.   
 Amyloidogenic cleavage of full-length amyloid precursor protein (APP) by β-
Secretase generates the transmembrane protein C99 (APP672-770, also known as β-CTF, 
figure 2.1).   
 
 
 
                                                            
3 This section is adopted from the published manuscript by Barrett et al in Science26. Barrett, P. J., Song, Y., Van 
Horn, W. D., Hustedt, E. J., Schafer, J. M., Hadziselimovic, A., Beel, A. J., and Sanders, C. R. (2012) The amyloid 
precursor protein has a flexible transmembrane domain and binds cholesterol, Science 336, 1168-1171. 
4 This section was adopted from the published manuscript by Pester et al in JACS 237. Pester, O., Barrett, 
P. J., Hornburg, D., Hornburg, P., Pröbstle, R., Widmaier, S., Kutzner, C., Dürrbaum, M., Kapurniotu, A., and Sanders, C. 
R. (2013) The Backbone Dynamics of the Amyloid Precursor Protein Transmembrane Helix Provides a Rationale for the 
Sequential Cleavage Mechanism of γ-Secretase, Journal of the American Chemical Society 135, 1317-1329.) 
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Figure 2.1.  Primary sequence and domain organization for C99 as determined in 
this work, with transmembrane glycines highlighted (red).  The uppermost 
numbering scheme, based on full length APP, is used in this work.  The middle 
numbering system is based on the numbering of the most common splice variant 
of APP found in neurons.  The bottom numbering system is based on that of the 
amyloid-β peptide.  Most structural studies in this work included an added 
purification tag at the C-terminus with the sequence –
QGRILQISITLAAALEHHHHHH.  It is well known that tags at the C-terminus of C99 
do not interfere with its processing by γ-Secretase. 
 
The transmembrane domain (TMD) of C99 is then processively but imprecisely cleaved 
by γ-Secretase to release the Aβ polypeptides (239, 240).  Cleavage by γ-Secretase is 
believed to be initiated at either the ε48 (linking T719 and L720) or ε49 (L720/V721) sites 
and continues by release of tri- and tetrapeptides after proteolysis at alternate ζ- (ζ45 = 
I716/V717; ζ45 = V717/I718), and γ-sites (γ37 = G708/G709; γ38 = G709/V710, γ40 = 
V711/I712, γ42 = A713/T714), resulting in two distinct product lines.  Successive 
cleavage leads to release of the most abundant Aβ40 and the minor Aβ42 and Aβ38 
peptides.  Structural information on C99 may provide insight into amyloidogenesis; 
however, previous structural studies have employed only low resolution methods or have 
focused on TMD-only containing fragments (16, 28, 241-243).  It is imperative that a 
structure be determined for the intact full length C99 protein in order to elucidate the 
diverse biological roles of APP.  In addition, information gained from the 3D structure of 
C99 will permit for a better understanding of how cleavage by γ-Secretase occurs within 
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the membrane, and show possible mechanisms for regulating the Aβ42-Aβ40 ratio.  
Lastly, there are inherited mutations in APP that can results in AD onset early in life, 
called Familial Alzheimer’s disease (FAD).  The structure and stability of wild-type C99 
can then be compared to known FAD mutants, which may illuminate possible 
mechanisms for FAD pathogenesis. 
 Extensive work by Beel et al in 2008 determined the secondary structure of C99 
utilizing chemical shift indexing (CSI) analysis from backbone 13C NMR resonances.  In 
addition, this study also revealed a novel membrane topology of C99 utilizing 
paramagnetic probes during NMR experiments (28).  These studies determined that in 
addition to a helical TMD, C99 possesses two additional segments that have α-helical 
secondary structure; a region spanning residues 689-694, called the N-helix, and the 
extreme C-terminus of the protein (residues 762-770), named the C-helix.  Using the 
paramagnetic probe studies it was found that both of these regions are embedded in the 
micelle.  By determining the 3D structure of C99, we will not only validate the findings of 
Beel et al in a 3D model, but also lay the groundwork for future studies that will impact 
how AD is understood and treated.   
 
Materials and Methods 
 
NMR Sample Preparation and Resonance Assignments for C99 in LMPG Micelles 
As described previously (28), the cDNA for full length human C99 was cloned 
into a modified pET21a plasmid. To facilitate spin labeling or alanine scanning of C99, a 
series of single-cysteine and site-directed alanine mutant forms of C99 were generated 
using QuickChange site-directed mutagenesis (Stratagene).  The protein was then 
expressed in E. coli with either an added N-terminal His6-Gly- tag or a C-terminal tag 
that includes a His6 sequence (28). The protein was then purified in into lyso-
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myristoylphosphatidylglycerol (LMPG) micelles (28). LMPG is a phospholipid-like 
detergent.  Relative to other micelles and also to isotropic bicelles, LMPG micelles were 
found to yield NMR spectra of superior quality for this protein (28). NMR samples of C99 
contained 0.25 mM protein and 10% LMPG in 100 mM imidazole, 2 mM EDTA, and 10% 
D2O, pH 6.5.  NMR data was collected at 45°C on either a Varian Inova 900 MHz 
spectrometer with a cryoprobe, a Bruker Avance 800 MHz spectrometer with a 
cryoprobe, or a Bruker Avance 600 MHz spectrometer with a conventional probe.  
Backbone resonance assignments were previously reported (28) and were deposited in 
the BioMagResBank (www.bmrb.wisc.edu) with accession number 15775.  
 
Use of NMR Chemical Shifts as Restraints and Measurement of NOE Restraints for C99 
in LMPG Micelles 
Backbone 
13
Cα, 13Cβ, 13CO, 15N chemical shifts were used to estimate backbone 
dihedral angles using the program TALOS+ (179). Only restraints that were classified by 
this program as being in the highest confidence category were used in structural 
calculations. Chemical shift index (CSI) analysis (220) was also implemented to assess 
secondary structure for hydrogen bond restraints. 
1
H-
1
H NOEs were obtained using the 
3D (
1
H,
1
H,
15
N)-TROSY-NOESY experiment (120 ms NOE mixing time) on uniformly-
13
C/
15
N double-labeled C99 in LMPG micelles at 900 MHz(28). 65 amide-amide NOEs 
were used in structural calculations. Measurements of side chain-side chain NOEs were 
not feasible because of the difficulty of assigning side chain resonances in a large 
protein-detergent complex that has been shown to exhibit generally unfavorable 
transverse relaxation rates(28). NH-NH NOEs were assigned by correlating diagonal 
amide parent resonances with coupled amide resonances via the TROSY spectrum. 
Spectra were analyzed using NMRView (244) and assigned using Sparky (245). 
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Measurement of Residual Dipolar Couplings for C99 in LMPG Micelles   
Stretched neutral polyacrylamide gels (7.0% acrylamide concentration, 0.5% 
AMPS, and acrylamide/bisacrylamide molar ratio of 50:1) were prepared according to 
Chen et al (210). Cylindrical polyacrylamide gels were cast with a 7.0 mm diameter in 
100 mM imidazole, pH 6.5 buffer in the absence of detergent and then cut to 1.5 cm in 
length.  This was followed by soaking gels in three successive changes of 100 mM 
imidazole buffer (pH 6.5).  1 mL of a U-
2
H/
15
N-C99 in an LMPG micelle solution (see 
above NMR sample conditions) was then soaked into the wet gel for at least 48 hours. 
The gel was subsequently stretched (using a device from New Era Enterprises, 
Vineland, NJ) into an open-ended NMR tube with a 4.2 mm inner diameter. The 
stretched gel was 2.2 cm in length.  The concentration of C99 in the 500 μl gel was 
determined to be 0.45 mM by measuring the C99 concentration in the solution remaining 
outside of the gel after soaking.  
1
H-
15
N residual dipolar couplings (RDCs) were 
measured using a uniformly
2
H,
15
N-labeled sample at 800 MHz by acquiring a pair of 2D 
1
H-
15
N TROSY spectra in an interleaved manner, one in which the ideal TROSY 
components were selected and one in which the semi-TROSY (TROSY in the 
15
N 
dimension, anti-TROSY in the 
1
H dimension) peaks were selected. The J+D couplings 
were then measured in the 
1
H dimension.  The difference in the observed couplings 
between aligned and isotropic samples correspond to the 
1
H-
15
N dipolar couplings(7, 8). 
An example of the RDC data is shown in figure 2.2. 
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Figure 2.2.  Measurement of HN RDCs for C99.  The top panel shows the 1H, 15N-
TROSY NMR spectra of C99 in LMPG micelles in a stretched polyacrylamide gel 
and in a free (isotropic) solution.  The spectrum for the aligned sample 
(polyacrylamide) was collected at 800 MHz using U-2H, 15N C99 in a stretched 7% 
acrylamide, 0.5% AMPS gel, under otherwise standard sample conditions (10% 
LMPG micelles, pH 6.4, 318K).  The red and black spectra denote semi-TROSY and 
TROSY resonances respectively.  The bottom panel shows superimposed TROSY 
(black) and semi-TROSY (red) peaks for residue V707, found in the TMD. 
 
Preparation of Spin-Labeled C99 for NMR Paramagnetic Relaxation Enhancement 
(PRE) Measurements   
Wild type C99 has no Cys residues.  Select residues were mutated to cysteine 
using the Quik-Change protocol (Stratagene Company, La Jolla, CA, USA) utilizing 
wholeplasmid PCR. From the C99 plasmid, a total of four single-Cys mutants were 
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prepared: Val695Cys, Gly700Cys, Leu705Cys, and Leu723Cys.  These mutations were 
selected to be located on relatively immobile sites: V695C is located in the N-terminal 
helix, G700C and L723C mark the termini of the transmembrane helix, and L705C is 
located towards the middle of the transmembrane helix. Prior to PRE measurements, 
1
H-
15
N TROSY experiments were performed to validate that these mutations did not perturb 
the native structure of C99.  Single-Cys mutant forms of C99 were overexpressed and 
purified as described for wild type(28). After purification, each cysteine mutant was 
concentrated to 0.5mM and the pH was lowered to 6.5.   Samples were then reduced 
with 2.5mM DTT, with gentle agitation at room temperature for 24 hours to ensure 
complete conversion to Cys-SH.  To verify this, samples were analyzed by SDS-PAGE. 
Mutants were then Cys-modified by the thiol-reactive nitroxide free radical probe, 1-oxyl-
2,2,5,5-tetramethylpyrroline-3-methyl-methanethiosulfonate (MTSL, Toronto Research 
Chemicals, Toronto, Canada). MTSL was added to 10 mM from a 250 mM solution in 
dimethylsulfoxide into a 0.5 mM C99 solution (buffer: 100 mM imidazole, 2 mM EDTA, 
2.5 mM DTT, 0.05% LMPG, pH 6.5), which was then gently agitated at room 
temperature for 30 minutes, followed by incubation at 37ºC for 3 hours.  Samples were 
then buffer-exchanged into a 50mM phosphate, 0.05% LMPG, pH 7.8.  Following buffer 
exchange, samples were bound to Ni(II)-chelate chromatography resin in a column, 
which was then washed with 100 mL of 50mM phosphate, 0.05% LMPG, pH 7.8 to 
remove excess MTSL.  The spin-labeled C99 was eluted using elution buffer (250mM 
imidazole, 0.05% LMPG, pH 7.8).  Samples were then processed (as above) to achieve 
standard NMR conditions (100mM imidazole, 10% LMPG, 10% D2O, 2mM EDTA, pH 
6.5).  Prior to NMR PRE experiments, the % of nitroxide spin-labeling for each C99 
sample was quantitated by double-integrating EPR resonances from each labeled 
sample relative to the signal from a 100 μM TEMPOL standard.  In all cases, the 
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efficiency of spin-labeling was >90%.  
NMR Paramagnetic Relaxation Enhancement-Based Distance Measurements for C99   
Paramagnetic relaxation enhancement (PRE) experiments were used to 
measure long range distance restraints.  For each spin-labeled single-cysteine mutant, a 
pair of 2D 
1
H-
15
N TROSY spectra were acquired for spin-labeled C99: one for the spin-
labeled protein in the paramagnetic form, and one after adding ascorbic acid (to 7.5 mM) 
to the sample in order to reduce the nitroxide, yielding the diamagnetic species.  The 
spectra for each pair of paramagnetic and diamagnetic samples were processed and 
then zero-filled in both t1 and t2 dimensions.  The spectra were then analyzed to 
measure PRE-based differences in peak intensities using the programs nmrPipe (246), 
nmrView (244), and Sparky (245). Intensity ratios of peaks from the oxidized and 
reduced spectra were converted into paramagnetic relaxation rate enhancements 
(PREs, R2sp) by estimating the additional transverse relaxation needed to reduce peak 
intensity relative to diamagnetic conditions by the observed intensity ratio using the 
following equation (188):  
(1) Iox / Ired = R2 exp(-R2sp τ) / (R2 + R2sp)   
The intrinsic R2 were estimated from the 
1
H line widths from diamagnetic samples.  Tau 
(τ) was the duration of the INEPT delay in the TROSY pulse sequence (13.3 msec).  
The R2sp values were then calculated from the above equation using Microsoft Excel 
and converted into distances using the following equation:  
(2) r = [K/R2sp (4τc + 3τc / (1 + ωh
2τc
2
)) ] 
1/6 
  
where r is the distance between the electron and nuclear spins (in angstroms), τc is the 
correlation time for the electron-nuclear interaction, ωh is the Larmor frequency of the 
nuclear spin (600.13 X 10
6
 sec
-1
 X 2π) and K is 1.23 x 10-32 cm6/s2   (188). The rotational 
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correlation times (τc) were calculated based on previously reported backbone amide 
15
N 
T1 and T2 relaxation values for C99(28). An example of the PRE data collected is shown 
in figure 2.3. 
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Figure 2.3.  Representative 15N TROSY PRE data used to derive long range 
distance restraints used in structure determination of C99.  PRE data from spin-
labeled V695C C99 are shown as the overlay of two NMR spectra.  The red 
spectrum represents the paramagnetic state of the MTSL probe (active) and the 
black spectrum represents the diamagnetic state after the MTSL probe has been 
reduced.  These data were recorded for a 250μM U-15N C99 sample at 800 MHz, 
318K, pH 6.5 in the presence of 1mM EDTA, 100mM imidazole, 10% LMPG 
micelles, and 10% D2O. 
 
Structural Calculations for C99 in LMPG Micelles   
Initially, structural calculations were carried out for full length C99 (all 99 
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residues).  However, it became apparent from these calculations that the N-terminus 
prior to residue 687 is disordered, as is the C-loop extending from residues 724 to 759. 
While the C-helix (residues 760 to 770) is a well-ordered α-helix and is located at the 
membrane (i.e. micelle) interface, it is not restrained in terms of placement with respect 
to the TMD. Given the above considerations, we completed the final structural 
calculations using only the relatively ordered N-helix, N-loop, and transmembrane 
domains plus a few residues on either side (683 to 728).  It is the outcome of these final 
calculations that are represented by PDB deposition 2LP1. Unambiguously assigned 
1
H(N)-
1
H(N) NOEs were employed as structural restraints, as were backbone dihedral 
angles (φ, ϕ) generated using TALOS+.  Hydrogen bond restraints for the N-terminal 
helix and transmembrane helix were applied based on the results of CSI analysis and 
H/D exchange rates (237).  PRE distance restraints were classified in different 
categories as described (188). Resonances with paramagnetic/diamagnetic intensity 
ratios less than 0.15 were classified as “close” and therefore restrained to being between 
2 and 19Å from a given MTSL modified cysteine residue.  Resonances with intensity 
ratios between 0.15 and 0.85 were converted to distances as described above (and 
(188)), with uncertainties of ±4Å.  Peaks unaffected by the paramagnetic probe (intensity 
ratio >0.85) were restrained to being between 21 and 74Å. These distance restraints 
were implemented as pseudo-NOEs from the nitroxidecontaining pyrroline ring to the 
backbone amide hydrogen utilizing MTSL-labeled pseudo-atoms, known as CYSP 
residues (172).  RDC data was only incorporated for the N-terminal helix and 
transmembrane helix.  Data-restrained structural calculations were carried out using a 
slightly modified version of the XPLOR-NIH v2.24 ‘anneal.py’ structure calculation script 
(172). Calculations started with an extended C99 template with randomized backbone 
torsion angles followed by 1000 cycles of Powell energy minimization.  Simulated 
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annealing was performed using 15,000 steps at 3500 K with gradual cooling to 100K.  
During the cooling stage the van der Waals interactions were increased by varying the 
force constant of the atom-atom repulsive term from 0.5 to 4 kcal·mol
-1
·Å
-4 
with an initial 
effective atom radius of 0.5Å.  Hydrogen bond restraints were enforced with flat-well 
harmonic potentials, with the force constant being fixed at 25 kcal·mol
-1
·Å
-4
. Force 
constants for NOE, PRE, and RDC restraints were ramped from 1, 1, and 0.01 to 30, 30, 
and 1 kcal·mol
-1
·Å
-4
, respectively. Dihedral terms were ramped from 5 to 500 kcal·mol
-
1
·Å
-4
. Default anneal.py values and parameters were used for all other restraints and 
steps.  During the structure calculations, the van der Waals interaction involving CYSP 
residues were turned to zero to avoid steric clashes between the side chains of these 
residues that were not present under experimental conditions (where, at most, only a 
single CYSP site would be present. After the high temperature simulated annealing was 
complete, a round of torsion angle minimization and full atom minimization was carried 
out using 500 steps of Powell energy minimization.  CYSP residues were mutated back 
to wild type residues using a Pymol based script and subjected to three rounds of Powell 
energy minimization, consisting of 100, 60, and 200 steps to optimize side chain 
packing.  Of the 100 output structures, the 30 lowest energy structures were used to 
generate an ensemble.  When aligned to the average structure, the N-terminal helix 
(residues 688-695) displayed an RMSD of 0.731Å.  The transmembrane domain 
(residues 699-723) exhibited an RMSD of 0.508Å when compared to the average TMD 
structure. The RMSD for both domains (residues 688-723) when compared to the 
average structure was 1.023Å.  A summary of the structure calculations and the related 
statistics for the results are presented in Table 1.  The protein databank code is 2LP1. 
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Table 1.  Structural statistics for the ensemble of the 30 lowest energy structures 
for C99.  
 
Amide H/D Exchange Rate Measurements  
C99 with a C-terminal tag containing His6 was recombinantly expressed in 
uniformly 15N-labeled form and purified in to lyso-myristoylphosphatidylglycerol micelles 
as described previously (247), followed by adjustment of the pH to 6.5. 15N1H-15N 
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TROSY-HSQC experiments were serially recorded using a 900MHz Bruker 
spectrometer on a C99 sample after mixing with a 10X volume excess of 100% D2O.  A 
500μL U-15N-C99 NMR sample was mixed with 5 mL of 100% D2O in 100 mM Imidazole, 
pH 6.5.  The sample was then concentrated back to 500 μL using a 30 kDa cutoff filter.  
Final C99 samples contained 0.2 mM U-15N-C99 in 10% LMPG (w/v), 100mM Imidazole, 
pH 6.5 in ca. 100% D2O.  TROSY experiments were performed at times points starting 
at 0 h, 2 h, 8 h, 16 h, and 24 h after mixing with the D2O.  The 0 hour time point was 
recorded on the C99 NMR sample prior to the 10x excess of D2O.  Identical NMR 
experiments were performed at each time point, with 128 scans and 256 incremented 
being performed. To quantify the exchange data, peak intensity was monitored at each 
time point and compared to the reference sample prior to D2O addition (time = 0).  
Amide protons of residues exposed to the solvent or not in a H-bonding network will 
disappear from the TROSY spectrum once the proton is exchanged for a deuteron.  For 
each experiment, the total acquisition time was approximately 6 h, such that the 
temporal resolution of observed H/D exchange process is low.  For this reason, we 
limited our analysis to comparison of the exchange states represented by the TROSY 
spectra collected over the 2-8 h and 16-22 h time ranges (figure 2.4). By 2-8 h in 100% 
D2O all observable peaks in dynamic loop regions had effectively disappeared from the 
TROSY-HSQC spectrum. All regions of predicted helical secondary structure (residues 
688-694, and 699-723) did not exchange with the D2O until at least 16 h, many showing 
little exchange at all.  The only segments for which H/D exchange rates were consistent 
with stable secondary structure are those previously determined to be helical (247). 
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Figure 2.4.  Use of NMR to monitor exchange of C99 backbone amide protons for 
deuterons as a function of time.  This figure depicts the overlay of five 900 MHz 1H, 
15N-TROSY NMR spectra of C99, collected at different points of time following 
dilution of C99 into D2O.  The black spectrum shows the reference spectrum 
collected in an H2O solution.  Red, green, purple, and cyan spectra reveal the state 
of changes after 2, 8, 16, and 24 hr, respectively.  All NMR resonances that could 
be accurately assigned are labeled.  It should be noted that because each 
spectrum required 6 hr of acquisition time, the actual time reflected by the data is 
a window spanning the designated time plus 6 hr, with the observed spectra being 
weighted toward the early part of the 6 hr window because of the way the 2-D NMR 
data are collected (most of the signal is detected in the early increments of the 2D 
experiment). 
 
Reconstitution of Spin-Labeled C99 into POPC/POPG Vesicles for EPR Studies   
Reconstitution of C99 into lipid vesicles was initiated by purifying the protein as 
described above, with the only difference being that the final elution buffer consisted of 
0.2% SDS in lieu of 0.05% LMPG.  Purified single-cysteine mutants forms of C99 were 
then conjugated to MTSL using the same spin-labeling protocol as described above for 
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PRE measurements.  Spin-labeled C99 in SDS was concentrated using centrifugal 
ultrafiltration to a final concentration of 1mM.  The concentrated C99 solution was then 
mixed with a stock SDS/lipid mixture of 400mM SDS/75mM POPC/25mM POPG 
(400mM SDS:100mM lipid), resulting in a clear solution.  The final C99:lipid molar ratio 
was set to 1:400. The SDS/lipid solution was prepared by multiple cycles of 
freeze/thawing to ensure complete conversion to mixed micelles.  The C99/SDS/lipid 
mixture was then subjected to extensive dialysis to remove all SDS present, during 
which process C99/POPC/POPG vesicles spontaneously formed.  The 4L dialysis buffer 
(50mM imidazole and 2.25mM EDTA at pH 6.5) was changed three times daily.  The 
completion of SDS removal was determined when the C99/lipid solution became cloudy 
and the surface tension of the dialysate indicated complete removal of detergent.  The 
C99/lipid vesicles solution was then extruded using a 50 nm filter to generate unilamellar 
vesicles. 
  
Continuous Wave (CW) EPR Measurements   
X-band CW-EPR spectra were collected at 9.8 GHz on a Bruker EMX 
spectrometer with a TM110 cavity (Bruker Biospin, Billerica, MA) using 5 mW microwave 
power and 1 G field modulation at 100 kHz. Samples were prepared were prepared as 
described in the above sections.  For each, 20 microliters were transferred to a 50 
microliter glass capillary (Kimble Glass, Inc., Vineland, NJ).  EPR data was collected at 
298K. 
 
Power Saturation EPR Measurement of Membrane Depth for Spin-Labeled Sites of C99  
Spin labeled C99 was reconstituted into POPC/POPG liposomes as described 
above with a protein/lipid molar ratio of 1:400.  The accessibilities of the spin label to 
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oxygen (lipophilic) and NiEDDA (hydrophilic) were determined using power saturation 
methodology.  5 microliters of each sample were taken up into a gas-permeable plastic 
capillary (TPX) and mounted into an ER4123D resonator (BrukerBiospin, Billerica, MA).  
To establish oxygen-free conditions (for both the control and for the samples containing 
5 mM NiEDDA), samples were equilibrated with flow of nitrogen gas for 15 min prior to 
and during the measurement.  For samples in which oxygen was allowed to be present 
to serve as a lipophilic probe the use of nitrogen gas was replaced by atmospheric air 
(20% oxygen). A 25 G scan of the central resonance line for each mutant was carried 
out using a 1 G modulation amplitude of 100 kHz frequency.  A total of 24 scans were 
separately recorded at microwave powers ranging from 1 mW to 200 mW with 
increments of 1 dB attenuation. The central line height (A) was then plotted against the 
square root of the incident microwave power (P) and fitted into the following equation 
with I, P1/2, and ε as adjustable parameters (214).  
(3)  ܣ ൌ ܫ ቀܲభమቁ ቎
ቆଵାሺଶ
భ
ഄିଵቇ∗௉
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Membrane depth (Φ) was expressed numerically as a dimensionless value 
according to the following equation (214).  
(4)  ߔ ൌ ln	ሾ
௉భ
మ
ሺைమሻି௉భమ
ሺேమሻ
௉భ
మ
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మ
ሺேమሻሿ 
An example of the data from these power saturation EPR experiments is shown in figure 
2.5. 
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Figure 2.5.  Representative power saturation accessibility data for C99 in 
bilayered POPC/POPG vesicles.  The panel on the left shows power saturation 
accessibility measurements for spin-labeled V695C C99 in POPC/POPG 
proteoliposomes, representing a spin labeled site (695) that is located in the N-
Helix.  The panel on the right shows power saturation accessibility 
measurements for spin-labeled L720 C99 in POPC/POPG vesicles, 
representing a site that is located inside the bilayer.  Samples consisted of 
approximately 100μM C99, and were ~90% MTSL-labeled.  C99 was 
reconstituted into POPC/POPG vesicles with a protein/lipid molar ratio of 
1:400.  The accessibilities of the spin label to oxygen and NiEDDA were 
determined using a power saturation methodology (see methods).  Membrane 
accessibilities determined from this data for the many other sites probed are 
presented in figure 2.10A. 
 
Four-Pulse DEER Measurements and Data Analysis to Determine Distances 
Between Spin-Labels in C99  
Double spin-labeled C99 was either reconstituted into LMPG micelles or into 
bilayered POPC/POPG vesicles as described above with a spin label concentration 
range of 200 to 300 μM (2X the C99 concentration).  30% (w/w) glycerol was added 
to the sample to serve as a cryoprotective agent. The sample was loaded into 2.4 
mm inner diameter quartz capillaries (Wilmad LabGlass, Buena, NJ).  After the 
resonator was cooled to 80K, the capillary was mounted into a plastic rod. The rod 
was then inserted into the resonator quickly to avoid a temperature increase. 
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Experiments were continued after waiting for the temperature to stabilize at 80K. 
Four-pulse DEER experiments were performed at X-band (9.5 GHz) on a Bruker 
EleXsys E580 spectrometer equipped with a Bruker split ring resonator (ER 4118X-
MD5).  A standard four-pulse sequence (219) was employed with a 32 ns π pulse 
and a 16 ns π/2 pulse. All measurements were performed at 80 K using an Oxford 
CF935 cryostat with an Oxford ITC4 temperature controller.  
All DEER data were analyzed using in-house software that simultaneously fits 
the background signal as a function of both the effective spin concentration and the 
radius of the molecule while determining the specific interactions of interest using 
distance distribution defined as a sum of Gaussians. The advantage of this approach 
is that it takes into account the excluded volume of the molecule, typically giving a 
better fit to the data than those obtained using a priori background correction. DEER 
data and results are illustrated for the case of doubly (sites 700 and 723) spin-
labeled C99 in LMPG micelles in figure 2.6.  
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Figure 2.6.  DEER data for C99 in LMPG micelles.  C99 was MTSL spin-labeled at 
both residues G700C and L723C, the two ends of the transmembrane domain.  The 
sample contained 200μM C99, 250μM imidazole, 10% (w/w) LMPG, 30% (w/w) 
glycerol at a pH of 6.5.  The DEER experiment was conducted on a Bruker E-580 
spectrometer equipped with an X-band MD5 resonator at 80K.  The dipolar 
evaluation of the DEER signal after the baseline correction is presented in the top 
panel.  The average distance and distribution are presented in the bottom panel. 
 
Results 
3D Structure Determination of C99 
 The backbone structure of C99 in lyso-myristoylphosphatidylglycerol (LMGP) 
detergent micelles was determined by nuclear magnetic resonance (NMR) restraints that 
included residual dipolar couplings (RDCs) and distances derived from paramagnetic 
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relaxation enhancement (PRE) experiments (Figure 2.7).  To prevent dimerization (14-
16, 28), we used an 800:1 LMPG:C99 ratio.  C99 is composed of three helical domains.  
A short extracellular “N-helix” (residues 689-694) is connected by an interfacial “N-loop” 
(695-699) to the helical TMD (700-723).  The N-helix is embedded in the membrane 
surface and dynamically samples a range of orientations around the TMD helix axis (Fig 
2.7b).  A third helix at the C-terminus (residues 762-770) is surface-associated but 
structurally uncoupled from the TMD by the intervening 38-residues “C-loop” (734-761). 
 The NMR structure reveals that the TM helix of C99 is highly curved, with the 
apex of curvature being located near glycine residues 708 and 709, close to the center 
of the micelle (Fig 2.7).   
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Figure 2.7.  Structure of C99 in LMPG micelles.  (A) Representative structure from 
a preliminary structural ensemble that illustrates the disorder of the N-terminus 
and C-loop and the interfacial location of the C-helix.  The 35Å sphere inscribed 
on the structures of these figures represents an LMPG detergent micelle.  (B) The 
30 lowest energy structures in which the disordered N-terminus (residues 672-
685) and cytosolic domain (726-770) are omitted.  (C) Representative structure 
from (B) with atoms for glycine residues 700, 704, 708, and 709 highlighted (red) in 
van der Waals mode (left panel) and as a surface representation (right). 
 
Pulsed EPR double electron-electron resonance (DEER) experiments confirmed 
that the TMD curvature in LMPG micelles had an average end to end distance of 34.2 ± 
0.5Å.  With the use of EPR, we found that mutations of G708/G709 to L708/L709 only 
modestly straightens the helix (average distance now 35.3 ± 0.5Å), suggesting that the 
curvature of the TMD derives only partially from the glycine pair (figure 2.10C).  In 
addition to containing two glycine residues at the apex of curvature, the TMD also 
contains 14 β-branched amino acids (leucine, isoleucine, valine), over 50% of the total 
TMD amino acid composition (figure 2.8).   
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Figure 2.8.  Structure of C99 TMD highlighting β-branched amino acids.  Three 
views of the TMD of C99 are shown with all amino acids represented as spheres.  
All β-branched amino acids are highlighted in blue, and glycines 708 and 709, 
which are responsible for the flexibility of the TMD are shown in red.  All other 
amino acids are shown in grey. 
 
It is know that a high abundance of β-branched amino acids can distort the ideal packing 
of methyl groups, limiting the conformational space residues can adopt and resulting in 
distorted helical structures (248).  We speculate that is the combination of two, dynamic 
glycine residues at the middle of the TMD and the abundance of β-branched amino 
acids that generate the curved TMD structure of C99.  The ranges of distances sampled 
around the mean by the G708L and G708L/G709L mutations are dramatically reduced 
compared to those of the wild type (figure 2.10C).  This suggests that G708 confers 
flexibility to the TMD. 
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Amide H/D Exchange Supports a Flexible TMD  
 Confirming the flexible nature of the TMD was a collaborative effort with the lab 
of Dieter Langosch, which utilized both NMR spectroscopy and molecular dynamics to 
monitor and model the dynamic nature of the TMD of C99/APP.  The rationale of the 
study was to determine the backbone dynamics of the APP TMD helix by recording 
amide exchange kinetics, which is a powerful way to analyze the conformational 
equilibria along a protein sequence.  The exchange kinetics of amides that are 
potentially involved in intramolecular H-bonding reports local and transient unfolding of 
secondary structure (249-252). 
 C99 was recombinantly expressed in uniformly 15N-labeled form and purified into 
LMPG micelles.  LMPG is a close analogue of natural phospholipids and is generally 
regarded as a mild detergent.  C99 dimerizes with only very modest affinity in LMPG 
micelles(28, 253) and H-/D-exchange (HDX) studies were carried out using a high 
(1000:1) LMPG:C99 mol ratio which only the monomeric form of the protein was present 
(26).  An aliquot of concentrated U-15N-C99 stock solution was diluted into D2O and 
1H,15N-TROSY spectra were recorded at time intervals, allowing monitoring of the 
disappearance of the backbone amide 1H,15N cross peaks due to replacement of the 
amide protons with deuterons (figure 2.4).  Because each TROSY spectrum required 6 
hours of acquisition time, exact quantification of amide exchange rates from these data 
is not possible.  However, comparison from the 2 hr and 16 hr time points provides a 
very clear assessment of the relative rates of amide exchange in C99 in LMPG micelles 
(figure 2.9). 
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Figure 2.9.  Time-dependent replacement of amide protons with deuterons upon 
dilution of C99 into D2O solution.  The intensity ratio is for the peak intensity 
observed after exchange with D2O for 2 (red bars) or 16 (blue bars) hr relative to a 
nonexchanged “time=0” reference sample.  Negative bars indicate that the peaks 
had disappeared completely, while the absence of either a positive or negative bar 
indicates that data was not measure for that site because of difficulties due to 
peak overlap or assignment.  The known topology of C99 is shown below each 
graph, with helical regions indicated by large, colored rectangles and dynamic 
loops by gray, small rectangles.  The numbering given in the upper line refers to 
full-length APP numbering while the lower line gives Aβ numbering.  Data was 
collected for 0.2mM U-15N C99 in 10% LMPG micelles at pH 6.5 and 45ºC. 
  
C99 contains three domains in which DHX rates are relatively rapid, reaching 
completion at 16 hr.  These are (i) the N-terminus, (ii) the N-loop, and (iii) the C-loop.  
Within these segments are sites that are completely exchanged even at 2 hr, and other 
sites with significant retention of protons are seen at 2 hr.  These results are consistent 
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with the previous NMR studies of micellar C99 and of the isolated intracellular domain in 
solution have suggested that these segments do not adopt stable secondary or tertiary 
structure, although some local transient structure is evident (28, 254, 255).  Further, 
based on significant protection from exchange even after 16 hr at 318K, the exchange 
data are consistent with the presence of both a surface-associated α-helix just prior to 
the TMD (N-helix) and one formed by the residues of the C-terminus (C-helix) (26). 
 The exchange data for the TMD is complex.  While exchange is at no position 
complete at 16 hr, the N-terminal portion of the TMD (G700-V711, N-TM) shows much 
lower protection (most evident for the 16 hr data of figure 2.9) than the I712 to I718 
segment of the C-terminal portion of the TMD (C-TM) that includes the γ- and ζ-cleavage 
sites.  Some evidence for “fraying” of the C-TM is evident in the transition from I718 (at 
which protection is high even after 16 hr) to the end of this domain at L723.  These 
results indicate significantly greater helix backbone dynamics at, and/or greater access 
of water to, sites located in N-TM as compared to C-TM, except near the frayed C-
terminus of the TMD. 
 
Validation of C99 Structure in Lipid Vesicles 
 To validate the membrane topology and TMD curvature determined in the C99 
structural studies, various EPR methods were utilized to examine these structural 
features in a lipid bilayer.  Power saturation EPR measurements for spin labeled C99 
(figure 2.10A and figure 2.5) confirmed that the span of the TMD is the same in both 
micelles and lipid vesicles and that the N- and C-helices are surface associated, 
indicating the membrane topology of C99 previously determined (28) and calculated 
during the structural studies were not artifacts of the micellar environment. Pulsed 
EPR DEER experiments confirmed that the TMD curvature also occurs in lipid bilayers 
(Figure 2.10C and figure 2.6).  The measured end-to-end average distance in micelles 
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(34.2 ± 0.5Å) is consistent with the NMR structure and nearly identical to the distance 
measured in lipid vesicles (33.5 ± 1.0Å)  
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Figure 2.10.  EPR studies of C99 in 1:4 1-palmitoyl-2-oleoly-phosphatidylglcerol:1-
palmitoyl-2-oleoyl-phosphatidylcholine (POPG/POPC) lipid vesicles.  (A) Bilayer 
depth parameters measured for spin-labeled sites on C99 as determined form 
power saturation EPR measurements.  Positive values indicate burial in the 
membrane, whereas negative values indicate exposure to water.  Through the 
samples used for NMR structure determination contained a C-terminal purification 
tag (see caption to figure 2.1), the samples used for measurements involving the 
C-terminal site (752-770) did not contain this tag, such that these measurements 
verify that the membrane association of the C-terminus is not the result of the 
presence of a non-native tag sequence.  (B)  X-band DEER time evolutions 
measured at 80K for C99 that was spin-labeled at the ends of its TMD (sites 700 
and 723).  Results are shown for C99 with its wild-type sequence, except for the 
two spin-labeled sites, and for C99 that was additionally subjected to Gly-to-Leu 
mutations at G708 and G709.  (C)  Distance distributions between the spin labels 
measured from the DEER data from (B).  The SD associated with each average 
distance relates to the uncertainty of the average, not the population distribution 
around the average. 
 
 
Discussion 
 The flexibly curved nature of the TMD may be well suited for its interactions with 
γ-Secretase.  Medium-resolution electron microscopy structures of the full assembled 
and activated γ-Secretase (256, 257) suggest a sluice-like active site that might best 
accommodate a substrate with a curved TMD (figure 2.11). 
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Figure 2.11.  Transmembrane domain of C99 (blue) docked into the active site of γ-
Secretase (from the 12Å cryo-EM structure of Osenkowski et al (256)).  (A) 
Cutaway view showing C99 at the putative active site.  (B) Same view as in (A) but 
γ-Secretase is shown in full surface mode. 
 
Analogous active sites have been observed for other intramembrane proteases (258, 
259).  TMD flexibility may also promote the processive cleavage of C99 by γ-Secretase, 
with flexibility colluding with random thermal motion to allow the TMD to slide through the 
active-site channel.  Curvature may also play a role in exposing scissile bonds for 
proteolytic access. 
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 The surface associated N-helix and N-loop immediately following the cleavage 
site (K687) for non-amyloidogenic α-Secretase processing contain a number of familial 
AD mutation sites (260) and, in conjunction with the extracellular end of the TMD, 
appear to play crucial roles in determining the ratio of short versus the more toxic long 
forms of the Aβ peptides released by γ-Secretase (14, 15).  A space-filling surface 
representation (figure 2.7C) suggests that these segments may also partially occlude 
approach by another TMD to the glycine zipper GxxxGxxxG (X, any amino acid) 
sequence located on the extracellular end of the TMD, which helps to explain the 
weakness of C99 self-association. 
 The organization of the N-loop and N-helix with respect to the membrane surface 
and the TMD is consistent with the possibility of a lipid binding site centered around the 
N-helix/N-loop/TMD structural element, as suggested by previous studies (28, 243).  
Titrations of C99 with cholesterol were carried out using bicelles as the model 
membranes and will be discussed in further detail in chapter IV. 
 In conclusion, determination of the structure of C99 provides insight into 
amyloidogenesis.  The flexibly curved TMD of C99 offers insight into how it is recognized 
and proteolyzed by γ-Secretase.  The structure of C99 can potentially assist in the 
design and optimization of C99-selective AD therapeutics that act by altering its 
interactions with γ-Secretase. 
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CHAPTER III 
 
NSAID-BASED γ –SECRETASE MODULATORS DO NOT BIND TO THE AMYLOID- β 
POLYPEPTIDE5 
 
Introduction 
Alzheimer’s disease (AD) is one of the most common neurodegenerative 
disorders, affecting more than 26 million people worldwide  - a number that is expected 
to more than quadruple by the year 2050 (262).  AD is characterized by cognitive decline 
induced by a loss of neurons and synapses in the cerebral cortex (263). This 
degeneration of neural activity is associated with the existence of extracellular amyloid 
plaques and intracellular neurofibrillary tangles, both of which characterize the pathology 
of the disease (264).  The neural plaques are comprised of insoluble deposits of 
amyloid-β (Aβ) peptides, which result from sequential proteolytic cleavage reactions of 
the amyloid precursor protein (APP) involving β- and γ-secretase.  The APP substrate is 
first cleaved by β-secretase (BACE-1) to release its large ectodomain from a 99 residue 
transmembrane bound C-terminal fragment (C99, also referred to as APP-β-CTF). C99 
then serves as a substrate for γ-secretase, cleavage by which results in release of the 
APP intracellular domain (AICD) and the amyloid-β polypeptide.  The Aβ produced is not 
completely homogeneous, but varies in length from 37 to 49 amino acids, with Aβ42 and 
Aβ40 being the most prominent products.  Aβ42 is believed to be the most neurotoxic of 
the amyloid-β polypeptides due to its particularly high propensity to form toxic 
                                                            
5 This work was previously published by Barrett et al in Biochemistry261. Barrett, P. J., Sanders, C. R., Kaufman, 
S. A., Michelsen, K., and Jordan, J. B. (2011) NSAID-Based γ-Secretase Modulators Do Not Bind to the Amyloid-β 
Polypeptide, Biochemistry 50, 10328-10342.) 
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aggregates that go on to form the amyloid plaques that are the hallmark of AD 
pathology. 
The well-defined pathology of AD, first described in the mid-1980s (265-268), set 
the stage for the proposal of the “amyloid hypothesis” by John Hardy (269), which 
postulates that accumulation of Aβ in the brain is the primary cause of AD pathology.  
The amyloid hypothesis is strongly supported by the observation that all mutations of 
APP or the Presenilin component of γ-secretase observed in early onset Alzheimer’s 
disease (EOAD) or familial Alzheimer’s disease (FAD) either result in an increase in total 
Aβ levels or in the production of Aβ42 relative to Aβ40 – thus supporting the relationship 
between the production of Aβ42 and the clinical symptoms of AD (263, 269, 270).    
To date, there are only five FDA approved treatments for AD in the United 
States, all of which treat cognitive decline and symptoms of the disease (263). 
Therefore, the development of a disease-modifying agent—one that prevents or 
reverses the pathology of the disease—represents a significant unmet medical need. 
Two promising targets from a drug discovery perspective are β- and γ-secretase.  The 
development of potential therapeutics targeting these two proteins has been extensively 
reviewed (271-273). Among the proposed strategies, development of agents that 
modulate γ-secretase has recently received much attention.  A γ-secretase modulator 
(GSM) is defined as a molecule that changes the relative proportions of the Aβ isoforms 
produced by γ-secretase (particularly Aβ42 vs. the less toxic Aβ40), without altering the 
overall rate of APP processing (263).  The first GSMs originated from non-steroidal anti-
inflammatory drugs (NSAIDs), which were reported to reduce the occurrence of AD in 
patients using these drugs (274-276).  The early NSAIDs, including sulindac sulfide, 
flurbiprofen, and ibuprofen, were shown to reduce the levels of the highly amyloidogenic 
Aβ42 (274, 277, 278).  Recent photoaffinity-cross-linking experiments led to the proposal 
that GSMs bind directly to the transmembrane APP/C99 substrate (279) to form a 
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complex that somehow then modulates γ-secretase cleavage.  The site of GSM binding 
within C99 was proposed to be located in its N-terminal Aβ42 domain. However, recent 
NMR studies from our labs failed to reveal any binding of the GSMs flurbiprofen and 
fenofibrate to monomeric or dimeric C99 in micellar model membranes, with the only 
detectable binding being to C99 aggregates, which was found to be of a non-specific 
and non-stoichiometric nature (280).  More recently, Multhaup et al. have countered our 
findings based on SPR, NMR, and bacterial reporter assay results which they interpret 
as providing proof that the NSAID-based GSM sulindac sulfide binds avidly and 
specifically to both Aβ42 and C99 (281, 282). 
We hypothesize that alternative interpretations are merited for some of the key 
results from Multhaup et al and also that some of their experiments may have had 
unrecognized artifacts.  Concerns are as follows:  The SPR dose/response curves for 
binding of sulindac sulfide to immobilized Aβ42 was seen in that work to be linear over 
the full range tested (5-100 micromolar, figures 2A and S2D in (281)), which is 
inconsistent with the interpretation of binding/dissociation kinetics data derived from the 
same set of experiments leading to determination of an apparent dissociation constant 
(Kd) of 30 μM.  In addition, the authors note in the supplementary information that the 
apparent Kd varied with concentration and that the stoichiometry of the purported 
Aβ42:Sulindac Sulfide complex varied from 0.2:1 to 2:1. Rather than attributing this to 
self-association of the compound itself, the authors concluded that the compound bound 
to multiple binding sites on the Aβ42 peptide. It was also unclear whether the 
immobilized Aβ42 on their SPR sensor chips represented monomeric peptide or whether 
the process of coating the surface with Aβ42 might have locally over-concentrated this 
peptide, such that its sensor-associated structural state reflects an oligomeric or 
aggregated form.  NMR spectra of 100 μM Aβ42 before and after addition of 300 μM 
sulindac sulfide were also presented and showed a profound drug-induced change in the 
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spectrum of the peptide (Figure 3 in (281)).  However, a complete titration series was not 
carried out, which precludes the possible use of this data to support specific and 
stoichiometric complex formation between the GSM and Aβ42.  Moreover, the NMR 
spectrum of Aβ42 in the presence of the drug could be interpreted as reflecting the 
formation of high molecular weight oligomers or aggregates since many peaks were 
seen to disappear.  The possibility that the GSM might itself be aggregated at 300 μM 
was not considered, despite the facts that sulindac sulfide is a very hydrophobic 
compound and that the amyloid-β polypeptides are known to associate non-specifically 
with small molecule aggregates (283, 284).  
Here, we provide additional data in an attempt both to clarify the previously 
published data as well as to provide new data informing on this controversy.  Our results 
support our earlier contention (280) that monomeric GSMs either do not bind monomeric 
or dimeric forms of C99 or Aβ42 at all (in solution, in micelles, and in membranes), or 
bind in a weak and non-specific manner that is likely to be unrelated to their GSM 
activity.  Moreover, these studies revealed that sulindac sulfide forms colloid-like 
assemblies at concentrations above 50µM, a phenomenon that may have been a source 
of experimental artifacts in some previous studies of GSMs. 
 
Materials and Methods 
 
Reagents, Peptides, and Proteins  
Aβ40 and Aβ42 peptides in both isotopically unlabeled and uniformly-15N labeled 
forms were obtained from rPeptide, LLC (Bogart, GA). For all experiments, peptides 
were first “monomerized” as previously described (285, 286) by dissolving lyophilized 
material in 98% formic acid and then immediately evaporating the solvent. This 
“monomerized” material was stored at -20oC and thawed immediately before use.  The 
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compounds used in this study, sulindac sulfide, sulindac sulfone, and flurbiprofen, were 
obtained from Toronto Research Chemicals (North York, ON, CA), MP Biomedicals 
(Solon, OH), and Sigma-Aldrich (St. Louis, MO). 
C99 was recombinantly expressed as described by Beel et al (280).  The 
mammalian C99 vector was cloned into a pET-21a vector and then transformed into the 
BL21(DE3) E. coli strain.  Protein overexpression was induced via the addition of 
isopropyl thiogalactoside to 1mM when cells reached an optical density of approximately 
0.800.  Cells were harvested and lysed, resulting in C99 localization to inclusion bodies.  
The inclusion bodies were solubilized using a 0.2% SDS/8M urea buffer.  C99 was 
purified via IMAC, during which SDS and urea were removed and replaced with 0.05% 
LMPG, a lyso-phospholipid detergent.  C99 was eluted from the IMAC column using a 
buffer containing 250mM imidazole and 0.05% LMPG at pH 7.8.  For all experiments 
performed on C99 in LMPG micelles, the final buffer concentration was 100mM 
imidazole, 10% LMPG, and 2mM EDTA at pH 6.5. 
 
Sample Preparation 
All Aβ40 and Aβ42 samples were prepared by dissolving the “monomerized” 
polypeptide in 20mM NaOH at a concentration of 1mg/ml. The resulting solution was the 
diluted with sample buffer (50mM sodium phosphate, pH 7.0, 10% D2O) to the desired 
concentrations, typically 100μM.   
 C99 reconstitution into lipid vesicles began with protein purification as described 
above, with the only difference being that the final elution buffer consisted of 0.2% SDS 
in lieu of 0.05% LMPG.  Purified C99 in SDS was concentrated using centrifugal 
ultrafiltration to a final concentration of 1mM.  The concentrated C99 solution was then 
mixed with a SDS/lipid mixture of 400mM SDS/75mM POPC/25mM POPG (400mM 
SDS:100mM lipid), resulting in a clear solution.  The C99/SDS/lipid mixture was then 
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subjected to extensive dialysis to remove all SDS present and during which process 
C99/POPC/POPG vesicles spontaneously formed.  The 4L dialysis buffer (50mM 
imidazole and 2.25mM EDTA at pH 6.5) was changed three times daily.  The conclusion 
of dialysis was determined when the C99/lipid solution became cloudy and the surface 
tension of the dialysate indicated complete removal of detergent.  The C99/lipid vesicles 
solution was then extruded using a 50nM filter to generate unilamellar vesicles, 
concentrated to a 1mM:100mM C99:lipid ratio, and flash frozen for later experiments.  
For the NMR studies (GSM titrations), the solution was diluted with buffer to achieve 
100μM C99 plus 10mM lipid.  For vesicle-only control samples, the same dialysis 
procedure was carried out in parallel, minus C99. 
 
CD Spectroscopy 
 Far-UV CD spectra were obtained on an AppliedPhotophysics Chirascan 
spectropolarimeter at ambient temperature. The peptides were analyzed at a 
concentration of 0.5-1mg/ml, using a quartz cuvette with a pathlength of 0.02 cm (far UV 
CD, 180-250 nm); the spectra were corrected for contributions from the buffer.  Each 
spectrum represents an average of 3 scans.  
 
Dynamic Light Scattering 
DLS experiments were conducted on a DynaPro Plate Reader WPR-06 (Wyatt 
Technology Corporation, Santa Barbara, CA) using a laser wavelength of 832.4nm. 
Briefly, 100uL volumes of solutions of Triton X-100, sulindac sulfide, sulindac sulfone, 
and flurbiprofen were prepared (from DMSO stocks) at concentrations of 5, 10, 25, 50, 
100, 200, 300, 400, 600, 800, and 1000μM.  All solutions were prepared so that the final 
DMSO concentration was constant at 2% in all samples.  Triton X-100 was used as a 
positive control, and the intensity of the scattered light was measured as a function of 
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drug concentration (Fig 3.4). All experiments were performed in triplicate at 15oC.  Ten 
acquisitions were performed (10s acquisition time) for each concentration point.  Data 
were processed using the Dynamics 6.10.0.10 software (Wyatt Technology Corporation, 
Santa Barbara, CA).  The average laser light scattering from three experiments were 
plotted versus concentration to obtain the critical micelle concentration (CMC) or “critical 
aggregate concentration”, (CAC).  The CMC of Triton X-100 was determined to be 
approximately 200-300μM, a value consistent with that in the literature (287). 
 
NMR Spectroscopy  
NMR experiments were performed on a Bruker Avance II 500MHz NMR 
spectrometer and a Bruker Avance III 800 MHz NMR spectrometer, both using TCI 
cryoprobes. 19F NMR measurements were performed on the Avance II 500 MHz system 
using an SEF cryoprobe.  All experiments using the amyloid peptides were performed at 
5oC.  Relaxation and diffusion measurements were used to verify the oligomeric state of 
the Aβ peptides used in this study.  It is well know that Aβ40 has a lower propensity to 
form large oligomeric fibril species (288). Thus, this peptide was used to compare the 
behavior of the Aβ42 species in solution.  For 15N relaxation measurements, NMR 
experiments were performed at 500 MHz.  T1 and T2 values were measured as 
described in Kay et al (289). T1 and T2 values for Aβ40 and Aβ42 were determined from 
measurements performed on the 500 MHz system using 100 μM solutions of Aβ40 and 
Aβ42. Peak intensities were measured by integration of the region between 7.5 – 8.8 
ppm.  T1 measurements were made using delays of 2, 20, 50, 100, 200, 300, 400, 600, 
800, 1000, and 1200 ms. T2 measurements were made using delays of 0, 16, 32, 48, 64, 
80, 96, 128, 160, 192, and 240 ms.  The intensities were fit to a single exponential 
function (ܫሺݐሻ ൌ 	 ܫ଴݁ି௧/்) using the program GraphPad Prism (GraphPad Software, La 
Jolla, CA). T1 and T2 values for both Aβ40 and Aβ42 were estimated to be approximately 
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620ms and 150ms, respectively.  The resulting correlation time (τ c) for both molecules 
was then calculated using the following equation (290): 
(5) ݐ௖ ൌ 	
ටల೅భ೅మ ି଻
ସగ௩೙   
where T1 and T2 are the respective relaxation times and ݒ௡is the spectrometer frequency 
in Hertz.  The resulting calculations yielded correlation times of 3.9 ns for both Aβ40 and 
Aβ42, which, at 5oC and taking into account the water viscosity at this temperature 
(approximately 1.5x that at ambient), corresponds to a protein of approximately 4.9 kDa 
– a value consistent with the rotational correlation time for a 4.2 kDa protein (as 
calculated from the Stokes-Einstein equation) (291).  
 To further classify the oligomeric state of the peptides in solution, pulsed field 
gradient diffusion measurements were performed at 500 MHz using a stimulated echo 
experiment (292). Using dioxane in the solution as a reference (as in (293)), solutions of 
Aβ40 and Aβ42 (both 100 μM) were measured with diffusion gradient strengths varying 
between 1% and 90% of maximum value.  The lengths of the diffusion gradient and 
stimulated echo were optimized to give a total decay in the protein signal of ~80%.  The 
spectra were acquired with 32K complex points and a spectral window of approximately 
6500 Hz.  Data was processed using Topspin 2.1 (Bruker Biospin, Billerica, MA).  To 
obtain diffusion decay rates, the dioxane peak and the methyl region of the spectra (0.3-
0.7ppm) were integrated at each data point and fit to equation (9) to determine the decay 
rate: 
(6) ݏሺ݃ሻ ൌ 	ܣ݁ିௗ௚మ  
where the intensities of the protein signals s are plotted as a function of gradient 
strength, g, to enable determination of the decay rate, d. Decay rates were determined 
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to be 1.6 x 10 -4 s-1 for both peptides.  The hydrodynamic radii for Aβ40 and Aβ42 were 
then calculated as in Wilkins et al (293) to both be approximately 16Å, which as in 
Wilkins et al. correspond to a polypeptide chain of approximately 42 residues (293). 
Using this hydrodynamic radius and the viscosity of water at 5 degrees Celsius, the 
diffusion coefficient, D, was calculated using the Stokes-Einstein relationship: 
(7) ܦ ൌ ௄ಳ்଺గఎ௥   
Where KB is the Boltzmann constant, T is temperature (K), η is solvent viscosity in 
kg/m.s at 5oC, and r is the hydrodynamic radius in meters. 
 Titrations of 15N-labeled Aβ40 and Aβ42 were performed on an 800 MHz NMR 
spectrometer at 5oC with 100 μM protein solutions. Titrations were performed with 
sulindac sulfide, sulindac sulfone, flurbiprofen, and DMSO (as a control) and were 
carried out in two modes. First, 50mM ligand stocks were prepared in DMSO-d6. 
Sulindac sulfide and sulindac sulfone were added to 100μM protein solutions at 
concentrations of 5, 10, 50, 100, 300, and 500μM. Flurbiprofen was added at 
concentrations of 500μM and 1mM.  Control DMSO-only titrations were performed for 
each series using the final titration point, which contained 2% DMSO by volume. In 
addition, titrations with sulindac sulfide, sulindac sulfone, and DMSO were performed as 
in Richter et al (281), where one titration data point was acquired using 100μM Aβ42 and 
either 300μM sulindac sulfide, 300μM sulindac sulfone, or DMSO-only control. In each 
case a fresh peptide sample was prepared, the appropriate amount of compound was 
added (from 50mM DMSO-d6 stock), and spectra were acquired immediately at 5oC. 
Time course spectra were acquired at t=0, 1hr, and 24hr.  When it became evident that 
the sulindac sulfide was causing aggregation of Aβ42, a separate time course 
experiment was carried out using identical solutions at t=0, 15min, and 1hr. All two-
dimensional 15N-HSQC spectra were acquired using spectral widths of 12,820 Hz and 
 95 
 
2432 Hz in the direct and indirect dimensions, respectively. Data were acquired using 
1024 X 64 complex data points and 8 scans per increment. Two-dimensional 
experiments were also accompanied by 1D proton NMR spectra so that the 
concentrations of the compounds could be monitored throughout the titration. 
 NMR solubility measurements of sulindac sulfide, sulindac sulfone, and 
flurbiprofen were performed using a 500 MHz NMR spectrometer in experimental buffer 
(50mM sodium phosphate, pH 7.0, 10% D2O) with 2% DMSO-d6.  Briefly, 50mM stock 
solutions of each compound were prepared in DMSO-d6. For each compound, a 1mM 
solution was prepared in buffer. Quickly, serial dilutions were made to a final 
concentration of 5 μM, while keeping the DMSO concentration constant at 2%.  1D 
proton spectra were measured for each concentration using identical parameters.   
 To test whether colloidal aggregates of sulindac sulfide can act as promiscuous 
enzyme inhibitors, β-secretase activity assays were performed in the presence and 
absence of sulindac sulfide and sulindac sulfone.  An NMR-based enzymatic assay was 
designed using a 19F-labeled BACE-1 substrate peptide—EVNLDAEF(CF3)—where the 
trifluoromethyl group is at the meta position on the benzyl ring of Phe.  BACE-1 cleaves 
this peptide between the L and D residues, which results in distinct 19F NMR signals for 
the substrate and product. The assay was conducted in a 96 well plate format, where 
each well contained 220nM of CHO-expressed BACE-1 prepared in 20mM sodium 
acetate buffer, pH 5.0, to which were added sulindac sulfide and sulindac sulfone at 
various concentrations (3.15, 6.25, 12.5, 25, 50, 100, and 200μM) followed by a blank 
DMSO control and a positive control using an inhibitor with a known Ki value. The 
reaction was started by addition of 100μM substrate peptide prepared from a 100mM 
DMSO stock in buffer (20mM sodium acetate, pH 5.0).  The experiment was allowed to 
react for a period of 20 minutes, at which time the reaction was quenched by the addition 
of 300uL of 8M urea. Samples were then transferred from the 96 well plate to NMR 
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tubes for analysis.  19F NMR spectra showed the presence of both substrate and 
product, the peak integrals of which were used to calculate the concentration of each 
species and to assess the degree of inhibition (294).  All experiments were conducted on 
a Bruker Avance III 500 MHz NMR spectrometer with an SEF cryoprobe for 19F direct 
detection. 
 
Surface Plasmon Resonance 
SPR experiments were performed using a Biacore S51 instrument and a CM5 
sensor chip (GE Healthcare).  Monomerized A42 peptide (1mg/ml diluted 1:10 with 
10mM sodium acetate, pH 3.4)   was immobilized to the sensor chip by standard amine 
coupling (with ~3000 response units (RU)).  Compounds were diluted from DMSO stock 
solutions in three different running buffers (50mM sodium phosphate, 100mM NaCl, pH 
7.0, 2% DMSO (0.2% Tween-20, 0.005% Tween-20, and no detergent).  Injections were 
performed for 1min at a flow rate of 30uL/min.  Data were analyzed using the Scrubber 
software (BioLogic Software, Campbell ACT, Australia) and were plotted using 
GraphPad Prism (GraphPad Software, La Jolla, CA). 
 
Transmission Electron Microscopy 
Samples were prepared for transmission electron microscopy (TEM) in an 
identical manner to the NMR samples. Briefly, “monomerized” peptide was dissolved in 
20mM NaOH at a concentration of 1mg/ml. Solutions for TEM were prepared at 100μM. 
Subsequently, sulindac sulfide and sulindac sulfone were added to final concentrations 
of 300μM with a DMSO concentration of 2%. Lastly, a drug-free control sample was 
prepared containing 2% DMSO only. Formvar-coated copper grids were inverted over 
50ul sample droplets for 15 minutes. The grids were then briefly rinsed with one drop of 
ultrapure water, and the excess water was removed by wicking to the side with blotter 
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paper.  Samples were then inverted over drops of 2% aqueous uranyl acetate for 15 
minutes and the grids were subsequently washed over three drops of ultrapure water. 
Following air drying, the grids were examined on a Philips CM120 transmission electron 
microscope (FEI, Inc., Hillsboro, OR) operated at 80kev. Representative images were 
captured using a Gatan Model 830 SC200 CCD camera (Gatan, Inc., Pleasanton, CA). 
 
Results 
Selection of NSAIDs for Study 
The finding that certain NSAIDs decreased the production of Aβ42 produced by 
γ-secretase cleavage led to the observation these compounds had various effects on the 
cleavage of APP. For example, compounds such as ibuprofen, fenofibrate, sulindac 
sulfide, R-flurbiprofen, and indomethacin were shown to decrease the amount of Aβ42 
produced.  Thus, they were considered Aβ42-lowering NSAIDs (see reviews in (283, 
295)).  Other compounds, such as celecoxib functioned to increase the amount of Aβ42 
and were thus termed Aβ42-increasing NSAIDs.  Lastly, several NSAIDs, such as 
naproxen and sulindac sulfone, were found to have no effect on the production of Aβ42. 
The sulindacs were chosen because these were the primary focus of the recently 
published studies (281, 282) that closely concern this paper.  Sulindac sulfide acts as a 
GSM while sulindac sulfone has previously been shown to have no GSM-like effect on 
the production of Aβ42 and serves as a negative control.  The well-characterized GSM 
R-flurbiprofen was also chosen for a limited number of experiments.  It has a much 
higher aqueous solubility (up to ca. 1 mM) than sulindac sulfide and therefore can be 
tested as a representative GSM for experiments that were hindered by the relatively low 
solubility of sulindac sulfide.  
 
 
 98 
 
Verification of the Oligomeric State of Amyloid Peptides 
Because the supposed binding of GSMs to Aβ42 has been invoked to support 
the idea that binding of GSMs to C99 is central to how these compound modulate 
amyloid production , we sought to reproduce results that were previously interpreted 
(281) to indicate that GSMs bind specifically and avidly to monomeric Aβ42.  Amyloid 
peptides, especially Aβ42, are known for their propensity to aggregate and form large 
molecular weight fibrils. For this reason, we first set out to verify the presence of stable, 
monomeric polypeptide in our samples.  The Aβ40 and Aβ42 peptides were first 
“monomerized” as previously described (285, 286) before studies.  CD spectra of Aβ42 
were obtained to verify that limited or no β-sheet structure existed in resulting solutions 
(the presence of which would indicate the formation of fibril-like species). Both peptides 
exhibited predominantly random coil conformations (figure 3.1).   
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Figure 3.1.  Top panel is a figure from Wilkins et al, “Hydrodynamic radii of native 
and denatured proteins measured by pulse field gradient NMR techniques”, 
Biochemistry 38, 16424-16431, which were used in this work to conclude that the 
hydrodynamic radius of Aβ40 and Aβ42 is ~16Å.  The bottom panel is the CD 
spectrum of 100μM Aβ42 in 50mM  sodium phosphate, pH 7.0, 25ºC, which 
indicates that the peptide has a predominantly random coil conformation and a 
very small degree of β-sheet structure. 
 
The oligomeric states of both the Aβ40 and Aβ42 peptides were then assessed 
via NMR diffusion measurements.  As indicated in figure 3.2, the diffusion decay rates of 
both Aβ40 and Aβ42 were seen to be identical, and correspond to a hydrodynamic 
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radius of approximately 16Å, matching that expected for  a ~40 residue peptide (figure 
3.1) (293). This allowed calculation of the absolute diffusion coefficient, D, of both 
peptides (figure 3.2B), which correspond to that of a small protein in an aqueous 
solution.  In addition, we carried out 15N NMR relaxation measurements for both Aβ40 
and Aβ42.  From these values, a rotational correlation time of 3.9 ns was determined at 
5oC (291). This value corresponds to a protein with molecular weight of ~4.9kDa, and 
demonstrates that the peptides populated only the monomeric form as prepared (figure 
3.3). 
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Figure 3.2.  (A) 1H NMR-based translation diffusion data for Aβ42 at Z-gradient 
strengths varying from 0.5 to 42.3 G/cm.  The methyl region of the spectrum 
between 0.7 and 0.3 PPM was integrated for each point to yield relative intensitites 
that were plotted against gradient strength in (B).  The intensities in (A) were 
measured using dioxane as an internal reference and were fit to a single 
exponential to determine the hydrodynamic radius and diffusion coefficient, D, as 
presented in the inset.  Data for the dioxane standard are represented by black 
circles, Aβ40 by blue triangles, and Aβ42 by green diamonds.  Curve fits are 
represented by solid lines of corresponding colors. 
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Figure 3.3.  Aβ42 exists as a monomer under the experimental conditions of this 
work.  15N T1 (A) and T2 (B) relaxation time determinators for Aβ40 and Aβ42.  
Values were extracted by plotting the decay of integrated 1HN intensity between 
8.4-9.8 ppm and fitting a single exponential equation to the data using GraphPad 
Prism.  These values were used to determine a rotational correlation time for both 
peptides of 3.9ns, which corresponds to a peptide of molecular weight of ~4.9 
kDa.  (C) Plot of MW versus correlation time, demonstrating that the Aβ40 and 
Aβ42 species correspond to monomers with molecular weights of ca. 4.9 kDa at 
5ºC (plot adapted from Rossi et al., “A microscale protein NMR sample screening 
pipeline” J. Biomol. NMR 2010, 46, 11-22, and adapted to account for the 
difference in viscosity of water at 5ºC) 
 
Characterization of GSMs  
Sulindac sulfide, sulindac sulfone, and flurbiprofen were characterized by 
dynamic light scattering (DLS) and NMR to determine their solubility and to assess their 
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oligomeric states at the concentrations tested in this and previous work.  Using DLS, 
sulindac sulfide was found to be monomeric below ca. 50 μM.  However, between 50 
and 100 μM, colloidal aggregates of sulindac sulfide clearly form, indicative of a “critical 
aggregate concentration” for this compound in the 50-100 μM range (296).  At much 
higher concentrations (starting at 400 micromolar) sulindac sulfide begins to precipitate, 
which is the cause of the linear increase in laser light scattering above this concentration 
(Figure 3.4).  Sulindac sulfone and flurbiprofen were found to be monomeric up to 
concentrations of 1mM, as the scattering intensity over the entire range of 
concentrations of these compounds was found to be the same as buffer alone. 
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Figure 3.4.  Measurement of the critical aggregation concentration (CAC) by 
dynamic light scattering (DLS).  Scattering intensities were plotted versus 
concentration, and the CAC was determined as the point when the scattering 
intensities began to increase.  The legend is as follows: buffer only (black circles), 
Triton X-100 (orange squares), sulindac sulfide (purple triangles), sulindac sulfone 
(green triangles), and flurbiprofen (green diamonds).  Notice that no increase in 
scattering intensity was observed for buffer, sulindac sulfone, or flurbiprofen.  
However, a significant increase in scattering intensity was observed for a positive 
control (Triton X-100) upon micelle formation at 200-300μM and for sulindac 
sulfide starting above 50μM, indicating that the latter begins to form aggregates at 
concentrations above 50μM, which is consistent with NMR data (Figures 3.5, 3.8, 
and 3.9). 
 
 
As an orthogonal method for measuring compound solubility, 19F NMR 
experiments were performed at concentrations ranging from 5μM to 1mM in aqueous 
buffer and with a fixed concentration of 2% DMSO.  From the NMR spectra in figure 3.5 
it is clear that sulindac sulfide begins to form colloidal aggregates at some point between 
30 and 62μM as evidenced by the significant broadening and decreasing intensity of the 
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NMR signals at and above 62 μM, demarking the “CAC” of this compound.  
 
Figure 3.5.  19F NMR spectra of sulindac sulfide at concentrations of 7.8, 15.2, 31.3, 
62.5, 125, 250, 500, and 1000μM.  Linewidths (in red) at half height (∆ν1/2, in Hz) and 
intensities (in black) of peaks in inset were plotted versus concentrations as 
shown in the upper right inset.  At the 62.5μM point, the peak intensities and 
linewidths change significantly, indicating aggregation of the compound.  The 
large decrease in relative intensity above 250μM is due to precipitation of the 
compound. 
 
On the other hand, both sulindac sulfone and flurbiprofen exhibit no significant changes 
in their NMR spectra (figure 3.6) and appear to remain monodisperse up to 
concentrations of 1mM.  These NMR data confirm and complement the results of DLS 
and show that sulindac sulfide forms colloidal (water soluble) aggregates with a critical 
aggregation concentration in the range of 50-60 μM, whereas sulindac sulfone and 
flurbiprofen remain monomeric up through 500 μM. 
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Figure 3.6.  19F NMR spectra of sulindac sulfone (A) or flurbiprofen (B) at 
concentrations of 7.8, 15.2, 31.3, 62.5, 125, 250, 500, and 1000μM.  Linewidths (in 
red) at half height (∆ν1/2, in Hz) and intensities (in black) of peaks were plotted 
versus concentration (upper right inserts).  The peak intensities scaled linearly 
with concentration and the linewidths are identical through the full range (1mM 
not shown), demonstrating that the compounds remained soluble and do not 
aggregate and/or form colloids in solution.  19F NMR is extremely sensitive to 
DMSO concentration, and the small changes in chemical shift are due to small 
variances in the DMSO concentration due to pipetting errors. 
 
NMR Titrations of Aβ42 with GSMs 
To determine if NMR spectroscopy demonstrates binding of sulindac sulfide to 
monomeric Aβ42, as claimed in previous work (281) NMR titration experiments were 
performed with each compound (using 50mM stock solutions of the drugs in DMSO-d6).  
Control titrations were also performed using DMSO only, which was used to dissolve the 
GSMs in stock solutions.  Figures 3.7-3.9 show 15N-HSQC spectra of Aβ42 titrated with 
sulindac sulfide and flurbiprofen (both are NSAIDS and GSMs), sulindac sulfone (a 
NSAID but not a GSM), and DMSO control.  It is clear that the titrations for all three 
NSAIDs led to only very small spectral changes in the HSQC spectrum of Aβ42 (Figures 
28A-30A) and that these changes are virtually identical to those observed during the 
DMSO control titration (Figure 3.10A).  This data provides no evidence for binding of any 
of the three compounds to monomeric Aβ42.  However, in the case of sulindac sulfide, 
g
A B
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1-D proton NMR spectra showing both the GSM peaks and the aromatic resonances 
from the peptides (Fig. 3.7B) reveal that the peaks from monomeric Aβ42 begin to lose 
intensity at sulindac sulfide concentrations above 50 micromolar—concentrations at 
which we have shown this GSM to form colloidal aggregates.   This is confirmed by 
examining the 1-D 1H NMR projections of the 2-D TROSY data (Figure 3.7C).  Such 
changes were not observed for the flurbiprofen, sulindac sulfone, or for the DMSO 
control (Figures 3.8B-C, 3.9B-C, and 3.10B-C).  These data strongly suggest that colloid 
formation by sulindac sulfide triggers aggregation of Aβ42.  
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Figure 3.7.  Titration of U-15N-Aβ42 with sulindac sulfide. (A) 15N-HSQC spectra of 
Aβ42 upon titration with sulindac sulfide (from a 50mM stock solution in DMSO) at 
concentration ranging from 0 to 0.5mM.  There are no shifts in peaks of these 
spectra beyond what is observed for the DMSO-only control titration (see figure 
3.10).  However, peak intensities decrease at higher sulindac sulfide 
concentrations.  (B)  1H NMR spectra taken at each titration point to allow 
observation of the ligand peaks throughout the titration.  Notice that ligand peaks 
are observable even at the lowest concentration (5μM) and with a nearly 20-fold 
excess of protein but begin to broaden or disappear above 50-100μM, indicating 
aggregation of the compound.  (C) 1-D 1H NMR projections of the HSQC spectra 
shown in (A) illustrate the decrease in amide 1H signal intensity from the peptide, 
which demonstrates that Aβ42 begins to aggregate upon addition of sulindac 
sulfide at concentrations above 50μM. 
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Figure 3.8.  Titration of U-15N-Aβ42 with sulindac sulfone.  (A) 15N-HSQC spectra of 
Aβ42 upon titration of sulindac sulfone at concentrations ranging from 0 to 
0.5mM.  there are no shifts in the peaks of these spectra beyond what is observed 
for the DMSO-only control titration (figure 3.10) and peak intensities do not vary.  
(B) 1H NMR spectra taken at each titration point to allow observation of ligand 
peaks throughout the titration.  It can be seen that the sulindac sulfone peaks 
remain sharp throughout, reflecting the fact that this compound does not 
aggregate at concentrations below 0.5mM.  (C)  1-D 1H NMR projections of the 
HSQC shown in (A) demonstrate that the solubility of Aβ42 remains unchanged at 
all points. 
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Figure 2.9.  Titration of U-15N-Aβ42 with flurbiprofen.  (A) 15N-HSQC spectra of 
Aβ42 upon titration of flurbiprofen at concentrations ranging from 0 to 0.5mM.  
there are no shifts in the peaks of these spectra beyond what is observed for the 
DMSO-only control titration (figure 3.10) and peak intensities do not vary.  (B) 1H 
NMR spectra taken at each titration point to allow observation of ligand peaks 
throughout the titration.  It can be seen that the flurbiprofen peaks remain sharp 
throughout, reflecting the fact that this compound does not aggregate at 
concentrations below 1mM.  (C)  1-D 1H NMR projections of the HSQC shown in (A) 
demonstrate that the solubility of Aβ42 remains unchanged at all points. 
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Figure 3.10.  DMSO control titration spectra of Aβ42.  (A) 15N HSQC spectra of U-
15N-Aβ42 upon addition of DMSO-d6 at 0% and 2% (initial and final concentrations 
in titrations of figures 3.7-3.9).  (B)  1H NMR spectra taken at each titration point to 
allow observation of ligand peaks throughout the titration.  It can be seen that the 
DMSO peaks remain sharp throughout.  (C)  1-D 1H NMR projections of the HSQC 
experiments taken in (A) demonstrate that Aβ42 remains soluble and monomeric 
upon addition of DMSO to 2%. 
 
 
In addition to performing an entire titration series with the NSAIDs, experiments were 
performed as in Richter et al. (281) where a single point was examined at 1:3 
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protein:ligand concentration (100μM Aβ42 plus 300μM of either sulindac sulfide, 
sulindac sulfone, or 2% DMSO control).  Upon addition of 300 μM sulindac sulfide, and 
by the time the sample could be transferred to the instrument and the HSQC experiment 
recorded, some peaks from Aβ42 had begun to disappear (figure 3.11). This 
phenomenon was monitored over the next hour. After 15 minutes, nearly all of the Aβ42 
had aggregated and become NMR-invisible.  By 1 hour, none of the 15N-HSQC signals 
were visible in NMR spectra.  This effect was not observed with sulindac sulfone, 
flurbiprofen, or DMSO (data not shown).  To investigate the whereabouts of the Aβ42 
peptides, the NMR samples were submitted for transmission electron microscopy (TEM), 
the results of which are also shown in Fig. 3.11 D, E, and F.  Clearly, the addition of 
sulindac sulfide at concentrations where it forms colloidal aggregates induced the 
formation of Aβ42 fibrils, whereas the addition of an identical concentration of DMSO 
(Fig 3.11F) or monomeric sulindac sulfone (data not shown) had no effect on the 
oligomeric state of Aβ42. 
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Figure 3.11.  Time course 15N-HSQC spectra of 100μM U-15N-Aβ42 following 
addition of sulindac sulfide to 0.3mM.  Panels A, B, and C show spectra taken of 
0.1mM Aβ42 alone (red) and upon addition of sulindac sulfide (blue) at times = 0, 
15 min, and 1 hr, respectively.  Notice the decrease in intensity of all the blue 
peaks as Aβ42 begins to form aggregates.  Panels D, E, and F show transmission 
electron micrographs (66000x) of 0.1mM Aβ42 NMR samples fixed to a TEM grid ~ 
2 hr after addition of (D) 0.3mM sulindac sulfide, (E) 0.3mM sulindac sulfide alone 
(no protein, 11600x) and (F) DMSO only to a final concentration of 2%, matching 
that in (D) and (E) (dark blob in (E) and (F) is grid bar included for camera gain).  In 
(D), fibrils of Aβ42 are clearly visible. 
 
We also looked for direct interaction of three NSAIDs with Aβ42 using surface 
plasmon resonance (SPR).  Previously published results from Richter et al (281) 
suggested that sulindac sulfide binds specifically to Aβ42. However, upon closer 
inspection of the SPR data presented in the previous work, it can be observed that 
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binding of sulindac sulfide to immobilized Aβ42 was non-saturable over the 
concentration range tested, suggestive of very weak and/or non-specific binding.  To test 
this hypothesis, we performed SPR experiments in a similar manner as presented in 
Richter et al. using immobilized Aβ42 peptide. For our studies, we also incorporated 
varying amounts of Tween-20 in the running buffer—zero detergent (as in the Richter et 
al.), 0.005% (40 μM, below its CMC of 60μM) and 0.2% (1.6 mM, above CMC) to 
illuminate whether drug and/or protein aggregation was a factor in the observed SPR 
response. The results for sulindac sulfone illustrate the patterns expected in the absence 
of binding (Figure 3.12, left). It can be seen that the SPR traces for flurbiprofen (Figure 
3.12B, right), even up to 1 mM, are very similar to those of sulindac sulfone, indicative of 
no binding.   
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Figure 3.12.  SPR analysis of sulindac sulfone (left) and flurbiprofen (right) with 
immobilized Aβ42.  Overlays of SPR sensograms obtained from injections of 
compounds into solutions containing 50mM sodium phosphate, 50mM NaCl, pH 7 
with (A) No detergent, (B) 0.005% Tween-20 and (C) 0.2% Tween-20.  Aβ42 was 
immobilized with ~3000 response units (RUs).  Sulindac sulfone or flurbiprofen at 
the indicated concentrations were injected for 60s at a flow rate of 30μL/min.  
None of the binding curves saturate, indicating that the observed response is due 
to non-specific binding. 
 
 
In the case of sulindac sulfide (Figure 3.13), the data is more complex.  In the 
absence of detergent, sulindac sulfide induces a biphasic response suggestive of a rapid 
binding event followed by a slower second binding event.  This second phase is 
eliminated when the titration is carried out in the presence of a sub-critical micelle 
concentration (CMC) of detergent, indicating that the slow binding seen in Figure 3.13A 
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likely represents non-specific association of sulindac sulfide with Aβ42 on the sensor 
chip—association that can be reduced in the presence of another hydrophobic small 
molecule (i.e. Tween-20 monomers).  When the detergent concentration (Tween-20) is 
raised still higher to >CMC, it is seen that the SPR response (Figure 3.13C) is 
comparable to the negative control SPR response observed at similar concentrations of 
sulindac sulfone.  This indicates that the rapid binding event observed in Figs. 3.13A and 
3.13B is of colloidal aggregates of sulindac sulfide to Aβ42.   Sub-micellar 
concentrations of detergents (as in 3.13B) do not break up those soluble aggregates, but 
the presence of detergent micelles (as in 3.13C) effectively dissolves the aggregates, 
which is seen to eliminate binding. 
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Figure 3.13.  SPR analysis of sulindac sulfide with immobilized Aβ42.  Overlays of 
SPR sensorgrams obtained from injections of sulindac sulfide in 50mM sodium 
phosphate, 50mM NaCl, pH 7, with (A) no detergent, (B) 0.005% Tween-20, and (C) 
0.2% Tween-20.  Panel D shows corresponding sensograms of sulindac sulfone 
used as a negative control.  Aβ42 was immobilized with ~3000 response units 
(RUs).  Compounds at indicated concentration were injected for 55s at a flow rate 
of 30μL/min at 25ºC. 
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Inhibition of β-Secretase by Sulindac Sulfide 
The formation of water soluble colloidal drug aggregates is a commonly 
encountered phenomenon (283, 284, 297, 298).   Moreover, such aggregates are known 
to often have very general and non-specific activities as enzyme inhibitors; sometimes 
being referred to as “promiscuous inhibitors”(297, 299).  To provide additional 
verification of the nature of the aggregates formed by sulindac sulfide at concentrations 
about 50 μM we tested to see whether these aggregates have enzyme inhibitory activity.  
β-secretase (BACE-1) was used as the test enzyme for this experiment.  Indeed, we 
found that sulindac sulfide began to significantly inhibit BACE-1 at concentrations around 
50μM, with near complete inhibition being approached at 200μM (Fig 3.14). No inhibition 
was observed with sulindac sulfone, which we showed above does not form aggregates, 
at least not below 1 mM.  We also found that the level of inhibition with sulindac sulfide 
was significantly reduced by doubling the BACE-1 concentration from 220nM to 440nM. 
Such acute sensitivity to enzyme concentration is a common trait of aggregation-based 
inhibitors (283, 284, 297, 298, 300), which inhibit enzyme action through a non-specific 
binding type mechanism (300). These colloidal aggregates can bind to proteins with high 
affinity and can envelop the protein, preventing substrate access and thus inhibiting 
protein function (297, 299).  Maintaining a constant compound concentration and 
doubling the enzyme concentration can allow this effect to be at least partially overcome, 
resulting in decreased inhibition of the enzyme (297). These combined results indicate 
that not only do aggregates formed by sulindac sulfide trigger fibrillization of Aβ42, but 
also that these aggregates share properties in common with other “promiscuous 
inhibitors”. 
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Figure 3.14.  Inhibition of β-Secretase by sulindac sulfide.  (A) 19F-NMR enzymatic 
assay showing the substrate and product of the cleavage reaction in the presence 
of varying concentrations of sulindac sulfide.  Notice that significant inhibition of 
the enzyme is observed at 50μM sulindac sulfide (near its CAC), with near 
complete inhibition being observed at 200μM.  The red trace is a control inhibitor 
of known Ki (400nM).  (B) Enzymatic assay run identically but in the presence of 
varying concentrations of sulindac sulfone.  No inhibition of BACE activity is 
observed.  (C)  Schematic of BACE cleavage reaction using a CF3-labeled 
phenylalanine (cleaved site depicted by arrow).  In both cases 220nM enzyme and 
100μM substrate were used.  Reactions were initiated by addition of substrate and 
were quenched by addition of 8M urea after 20 mins. 
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NMR Titrations of Membrane-Associated C99 with GSMs 
In a previous study, we showed that certain GSMs did not bind to C99 monomers 
and dimers in micellar model membranes (280).  Here, we extend this observation to 
C99 reconstituted into bilayered lipid membranes.  Sulindac sulfide, sulindac sulfone, 
and flurbiprofen each include fluorine atoms, potentiating the use of 19F NMR to monitor 
binding.  19F NMR chemical shifts are exquisitely sensitive to even very minor changes in 
local environment.   C99 was reconstituted into lipid vesicles with a protein to lipid ratio 
of 1:100 (100μM C99:10mM POPC/POPG).   Vesicles were then titrated with sulindac 
sulfide, sulindac sulfone, and R-flurbiprofen.  19F NMR spectra were acquired for each 
compound in the presence of protein-free vesicles and in the presence of an identical 
concentration of vesicles containing reconstituted C99 (100 µM). 
Unfortunately, no 19F signal could be detected for sulindac sulfide in both the 
absence and presence of C99, indicating that this compound binds avidly to the vesicles 
whether the protein is present or not.  Vesicles represent a solids-like environment from 
an NMR standpoint such that a combination of chemical shift anisotropy and 1H-19F 
dipolar coupling lead to extensive linebroadening and disappearance of signals when 
sulindac sulfide binds to the vesicles.  However, the results were more clearly 
interpretable for an alternative GSM, fluribiprofen, and for the negative control, sulindac 
sulfone.   These compounds yield sharp 19F NMR peaks in the presence of protein-free 
vesicles (Figure 3.15), which indicates that these compounds either do not bind to lipid 
bilayers at all or bind only weakly such that exchange between solution and the 
membrane is rapid on the NMR time scale and such that the free population 
predominates.  When C99 is also present in the vesicles at a C99-to-drug mole-to-mole 
ratio of 5:1, it can be seen in Figure 3.14 that there are no changes in the spectra 
relative to protein-free conditions: chemical shifts, linewidths, and peak intensities are 
unchanged by the presence of the protein.   This indicates that sulindac sulfone and 
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flurbiprofen do not bind to C99 even when the protein is present at a five-fold molar 
excess over the 20 μM drug concentration. 
  
 
Figure 3.15.  Comparison of 19F spectra of flurbiprofen (A) and sulindac sulfone (B) 
in the presence of bilayered lipid vesicles in the absence (black) and presence 
(red) of C99.  (A)  The samples contained 20μM flurbiprofen both in the absence 
(black) and presence (red) of 100μM C99 incorporated into 10mM POPC/POPG 
vesicles (1:100 C99:lipid).  (B)  The samples contained 20μM sulindac sulfone in 
both the absence (black) and presence (red) of 100μM C99 in vesicles.  All control 
samples (black) contained only 10mM phospholipid.  The lack of change in both 
sets of spectra indicates that no interaction exists between compounds and C99. 
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Discussion 
 
 The subject of substrate-targeting GSMs has been a topic of extensive research 
and discussion over the past several years.  Based largely on photoaffinity-crosslinking 
experiments, the initial paper by Kukar et al. (279) proposed that NSAID-type GSMs 
targeted the APP substrate (C99) of γ-secretase.   However, a variety of evidence has 
been presented that disfavors this interpretation (see review in(295)).  As described in 
the introduction, this evidence includes previous results from our lab indicating that non-
aggregated C99 in model membranes does not bind GSMs (280).  In our previous work 
we also presented data suggesting that C99 was very likely to have been in an 
aggregated form in critical experiments of the original Kukar et al. studies (279).  While 
GSMs do appear to bind to aggregated C99 (280), this is unlikely to be relevant to 
processing of C99 by γ-secretase in vivo.  Moreover, the binding was seen to be non-
specific in nature.   
 Our previous work was disputed in a pair of papers by the Multhaup lab (281, 
282) which presented data that was interpreted as demonstrating that GSMs, sulindac 
sulfide in particular, specifically recognize and bind to both membrane-associated C99 
and the water soluble monomer form of Aβ42, the latter of which includes the putative 
GSM binding site proposed in the original Kukar et al. work (279).   In the introduction, 
we hypothesized that key results and conclusions in the Multhaup papers may have 
reflected experimental artifacts due to the poor behavior of sulindac sulfide in aqueous 
solutions.  The results of this work support this hypothesis based on the two primary sets 
of results, both of which are closely related to our observation that the GSM sulindac 
sulfide forms colloidal aggregates with a CAC of roughly 50-60 μM.  In a first set of 
results, titrations of monomeric Aβ42 by GSMs sulindac sulfide and R-flurbiprofen were 
followed by NMR spectroscopy, which yielded no evidence for binding of the monomeric 
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drugs to monomeric Aβ42.   However, it was found that the colloidal aggregates formed 
by sulindac sulfide at concentrations above 50-60 μM induce aggregation of Aβ42.  
Based on this result we believe that the one point titration presented by the Multhaup lab 
(281) showing dramatic changes in the NMR spectrum of Aβ42 upon addition of 300 μM 
sulindac sulfide represents the observation of aggregated Aβ42 formed in response to 
the presence of colloidal aggregates of sulindac sulfide.   
 The second set of results involves our repetition of SPR experiments (see Fig 2 
in (281)) in which binding of sulindac sulfide to immobilized Aβ42 was tested over a 
range of drug concentration from 5 to 100 μM.  We reproduced the observation that 
sulindac sulfide, but not the negative control sulindac sulfone, induces a strong and dose 
dependent SPR response.  However, we also observed that there was no SPR response 
beyond what was observed for negative control conditions when the sulindac sulfide 
titration was repeated in the presence of Tween-20 micelles.  This strongly suggests the 
binding of sulindac sulfide to Aβ42 observed in the earlier work represents non-specific 
association these two compounds.  Such association is highest when sulindac sulfide is 
in its colloidal form (at concentrations >50μM) and may also be promoted by the 
structural properties of sensor chip surface-associated Aβ42, which may itself have 
aggregate-like properties as a result of being locally concentrated at on the sensor chip 
surface.   Association between the GSM and surface associated Aβ42 is eliminated by 
the presence of detergent micelles that can disperse the colloidal drug and can also coat 
exposed hydrophobic sites on sensor surface-associated Aβ42, making such sites less-
susceptible to non-specific hydrophobic interactions with hydrophobic compounds such 
as sulindac sulfide.   
 Multhaup et al. also carried out SPR experiments in which titration of immobilized 
C99 with sulindac sulfide also led to a linear dose/response curve, which was interpreted 
as being in support of specific binding (282). Similar SPR experiments carried out on 
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immobilized C99 also led to a linear dose/response curve.  In addition to the fact that the 
linearity of the data precludes the conclusion that a specific complex is forming, we 
believe that there was also a serious artifact in their experiment.  In that work, the sensor 
chips were coated with C99 and then subjected to experiments under, in both cases, 
essentially membrane- and micelle-free conditions. (Tween-20 was present during all 
these steps, but only at 40 μM, which is below its critical micelle concentration of 60 μM). 
However, C99 is an integral membrane protein which is expected to be insoluble under 
aqueous conditions in the absence of detergent micelles or some other membrane-
mimetic medium.  Therefore, the immobilized C99 present in the SPR experiments of 
(282) was almost certainly in an aggregated form.   We have previously shown that 
aggregated C99 can bind GSMs in a non-specific fashion (280) and so it is no surprise 
that this is what was seen in the more recent work (282).  In the present work, we 
observed that the GSM R-flurbiprofen exhibits no binding to C99 reconstituted lipid in 
vesicles.  This result extends the conclusions from our earlier observations of the lack of 
GSM binding to non-aggregated C99 in micellar model membranes to non-aggregated 
C99 in actual lipid bilayers.  
 One additional set of experiments from Multhaup and co-workers that yielded 
support for sulindac sulfide binding to C99 in membranes was a series of ToxR 
experiments carried out in E. coli (281).  In those experiments homodimerization of C99 
was assessed following expression into E. coli based on coupling homodimerization of 
C99 to transcriptional activation of a gene that expresses a colorimetric reporter enzyme.  
Using this assay, it was seen that sulindac sulfide reduces apparent dimerization of C99 
in E. coli in a dose-dependent fashion, consistent with inhibition of dimerization of C99 
by GSM binding.  These studies were carefully carried out and can indeed be interpreted 
as being supportive of GSM/C99 binding.  However, when conducting in vitro 
experiments involving GSM drugs, living cells, and an indirect phenotype-based assay 
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the possibility cannot be ruled out that the GSM induces a positive assay response as a 
result of off-target drug effects that lead to the artifact-based activation of the assay 
response (i.e., induction of reporter enzyme expression).  In light of the biophysical 
results of this paper, we suggest that this alternative explanation of the ToxR data is very 
likely applicable.   
 The experiments and results summarized above lead to the conclusion that the 
GSM sulindac sulfide does not bind to Aβ42 when both compounds are in monomeric 
form.  On the other hand, non-specific binding between aggregates of Aβ42 or with 
colloidal aggregates of sulindac sulfide appears to occur.  Promiscuous binding of small 
molecule aggregates to proteins, often accompanied by inhibition of protein function, is a 
very common occurrence (283, 284, 297, 298).  Indeed, in this study aggregated 
sulindac sulfide was found not only to bind to Aβ42, but also to inhibit β-secretase (here 
used as a representative enzyme).  It has previously been shown that Congo red can 
form colloidal micelle-like aggregates that bind to Aβ and induce its aggregation (284).  It 
has also been observed that a number of drug-like molecules form colloidal aggregates 
that interact with amyloid-forming yeast prion proteins in a way that inhibits fibril 
formation(298). 
 Evidence is accumulating that NSAID-based GSMs target a component other 
than the APP substrate in the amyloid cascade (review in (295)). Previous publications 
have suggested that GSMs act by causing conformational changes within Presenilin 1 
(PS1)(301-303), or by altering membrane architecture and thereby changing the manner 
in which γ-secretase cleaves its APP substrate (304).  More recent studies have 
indicated that the action of GSMs may be allosteric in nature.  Uemura et al 
demonstrated that GSM-induced conformational changes in PS1 only occur in the 
presence of substrate, suggesting that substrate binding to γ-secretase uncovers an 
allosteric site for GSM binding that is only present in the substrate-enzyme complex 
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(305).  Another recent study focused on a mutational analysis of APP and demonstrated 
that mutations in the GxxxG motif (the proposed GSM binding site) still caused an effect 
on Aβ42 production upon treatment with GSMs (306). The compounds were then shown 
to display differential or no effects on Aβ42 and Aβ38 levels when PS1 mutants were 
used. These conclusions contradict a substrate-targeted model of GSM action and 
instead suggest that these molecules target the γ-secretase enzyme itself or the 
enzyme-substrate complex (306). Taken as a whole, the evidence is becoming 
overwhelming that GSMs do not target the γ-secretase substrate, at least not in the 
absence of complexed γ-secretase. 
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CHAPTER IV 
 
BINDING OF CHOLESTEROL PROMOTED C99 PARTITIONING TO CHOLESTEROL 
RICH MEMBRANE DOMAINS6 
 
Introduction 
The long term production and accumulation of Aβ in the human brain is closely 
related to the etiology of Alzheimer’s disease (307, 308).  The amyloidogenic pathway 
involves the β-secretase-mediated proteolysis of APP to liberate its transmembrane C99 
domain which is in turn cleaved by γ-secretase to release Aβ.  Elevated cholesterol 
levels appear to promote this pathway (309-314).  Previous studies suggested that C99 
could potentially bind cholesterol utilizing a modified cholesterol recognition amino acid 
consensus sequence (CRAC) motif (223).  CRAC motifs are known residues that 
facilitate the binding of cholesterol (315, 316).  This CRAC-like motif is located in the N-
helix/N-loop/TMD structural element of C99.  Due to the low solubility of native 
cholesterol, previous work utilized the soluble cholesterol analogue β-cholbimalt to 
determine the binding region.  Saturable binding was shown for the residues in the N-
loop, specifically residues V695-G700 by NMR chemical shift perturbation titration 
analysis.  The Kd of this binding was a modest 28 ± 14 mol% (28).  Although possessing 
a low solubility, a similar initial titration was performed with cholesterol (up to 5 mol%).  
Chemical shift perturbation analysis showed that similar residues interacted with β-
Cholbimalt and cholesterol, though a full titration with cholesterol was not performed.     
                                                            
6 (This section is adopted from published work by Barrett et al in Science26. Barrett, P. J., Song, Y., Van 
Horn, W. D., Hustedt, E. J., Schafer, J. M., Hadziselimovic, A., Beel, A. J., and Sanders, C. R. (2012) The amyloid 
precursor protein has a flexible transmembrane domain and binds cholesterol, Science 336, 1168-1171. and a 
manuscript by Barrett et al submitted for publication) 
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Results below will show that C99 forms a 1:1 complex with cholesterol with an 
affinity (Kd = 5.1 ± 1.2 mol%)(26) that is well within the known range of cholesterol 
concentrations in mammalian membranes (317-320).  The binding of cholesterol by C99 
is an interesting topic since both β- and γ-Secretase are thought to reside in cholesterol 
rich membrane domains.  By showing that C99 can specifically bind cholesterol, it 
suggests that full length APP can as well.  Better understanding of the C99 (and 
APP)/cholesterol complex could offer a unique therapeutic approach to block the 
movement of APP to these cholesterol rich domains and ultimately Aβ production. 
Based on this fact and many reports that the amyloidogenic pathway is 
associated with cholesterol rich domains (309-314), the formation of C99-cholesterol 
complexes has been hypothesized to enhance partitioning of C99 into cholesterol-rich 
raft (Lo) domains from the surrounding bulk membrane (Ld) domain, thereby promoting 
its cleavage by γ-secretase to release Aβ (26, 28, 310).  Here we test whether C99 has 
an intrinsic preference to partition into raft-like Lo phase membrane domains and 
examine whether various sterol binding partners can regulate partitioning of the protein 
between Lo and Ld phase domains. 
 
Materials and Methods 
 
Reconstitution of Wild Type C99 in Bicelles and Titration With Cholesterol as Monitored 
by 
1
H,
15
N TROSY NMR   
The 
15
N labeled-C99 from 1 g of cell pellet was bound to and purified on 2 mL Ni-
resin as described above. The pure protein on the resin was then equilibrated with 1% 
isotropic q=0.3 dimyristoylphosphatidylcholine/dihexanoylphosphatidylcholine 
(DMPC/DHPC) bicelles plus 10 mM imidizole, pH 7.8 (where q is the DMPC to DHPC 
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mole ratio).  The protein was then eluted from the column with 7 mL of elution buffer 
containing 2% isotropic DMPC/DHPC bicelles and 250 mM imidazole, pH of 7.8.  5 mL 
of protein solution was collected and concentrated to 0.5 mL by centrifugal ultrafiltration 
using a 10 kDa MWCO cutoff filter.  D2O was then added to 10% (v/v) for the NMR lock 
and EDTA was added to a concentration of 1 mM. The pH of the sample was lowered to 
4.5 with acetic acid.  The NMR sample therefore contains 20% DMPC-DHPC bicelles 
(q=0.3), 30 mM acetic acid, 1 mM EDTA, 10% (v/v) D2O and approximately 0.25 mM 
C99.  Another four samples were prepared in parallel that contained cholesterol.  These 
samples were prepared by eluting C99 from the resin using bicelle solutions that 
contained 2.5, 5, 10, or 20 mol% cholesterol (relative to DMPC).  Cholesterol-containing 
bicelle solutions were prepared by co-dissolving DMPC and cholesterol in chloroform, 
removing all solvent under high vacuum, and then mixing with DHPC and buffer, 
followed by freeze-thaw cycles until the solutions became transparent. 
1
H,
15
N-TROSY 
spectra were acquired for each sample at 318K using a Bruker 600 MHz Bruker NMR 
spectrometer (Figure 4.1).  The chemical shifts for three peaks that exhibited relatively 
large cholesterol-induced shifts were plotted as a function of the amount of cholesterol 
(Figure 4.1).  The data were fit using Origin 8.0 (OriginLab Corp. Northampton, MA) by a 
single binding site model with the equation of y=X*Bmax/(Kd+X), where y is change in 
chemical shift (relative to 0 cholesterol conditions), X is the cholesterol concentration, 
Bmax is the maximum change in chemical shift observed for a given resonance upon the 
saturation of binding by cholesterol, and Kd is the dissociation constant.  While the data 
presented in Figure 4.3 were collected at pH 4.5, a titration was also carried out at pH 
7.0 (where NMR spectral quality for C99 in bicelle solutions is of lower quality), which 
verified that cholesterol binds with the same avidity at both pH values.  
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Scanning Alanine Mutagenesis to Map the Cholesterol Binding Site   
The TROSY NMR peaks of C99 that exhibited the largest changes in chemical 
shifts in response to cholesterol binding are located in the N-loop, N-helix, and 
extracellular end of the transmembrane domain (Figure 4.3C). To pinpoint which 
residues are specifically involved in binding cholesterol we carried out alanine-scanning 
mutagenesis for residues 690 to 710.  Each alanine mutant was prepared for
1
H,
15
N-
TROSY NMR as described in the previous section, with a full cholesterol titration being 
carried out in some cases (F691A, E693A, G696A, G700A, G704A, G708A, G709, and 
V710A).  For other mutants, samples were examined at only 0 and 10 mol% cholesterol 
concentrations, (WT C99 was seen to be nearly saturated by cholesterol at 10 mol%, 
Fig. 4.3B).  Spectra for each mutant in the absence of cholesterol were overlayed with 
the spectrum of WT C99 (figure 4.1), which shows that in no case was a global change 
in the conformation of C99 induced by the mutation of a wild type residue to Ala.  
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Figure 4.1.  Comparisons of the 1H-15N TROSY spectra from each alanine mutant 
form of C99 with the spectrum for wild type C99.  The 600 MHz 1H-15N TROSY 
spectrum (red) of each alanine mutant form of C99 (for scanning Ala-mutagenesis 
in the range of residues 690-710) is superimposed on the spectrum of C99 (black).  
The samples contain 20% DMPC-DHPC bicelles, 30mM acetic acid, 10% (v//v) D2O, 
1mM EDTA, and approximately 250μM C99 at pH 4.5. 
 
To assess impact of each mutation on cholesterol binding, the spectrum from 
each cholesterol-free sample was overlayed with the spectrum (or spectra) from a 
cholesterol-containing sample (figure 4.2). The magnitude for the changes in resonance 
positions for the amide peaks of E693, Gly700, and Gly704 were in each case measured 
and compared to the corresponding changes for wild type C99.  If the magnitude of the 
cholesterol-induced changes in resonance frequency for a given mutant was 80-100% 
that observed for wild type, the mutation site was judged to have wild type-like binding 
affinity (green sites in Figure 4.3E).  If the observed peak changes were 20-80% relative 
to those observed for WT, the mutant was judged to be moderately-impaired in terms of 
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cholesterol binding (yellow sites in Figure 4.3E).  If 10 mol% cholesterol induced 
negligible changes in peak positions (<20% of the changes seen for WT) the mutant was 
judged to have little affinity for cholesterol, reflecting a key role for the mutated residue in 
cholesterol binding (red sites in Figure 4.3E). 
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Figure 4.2.  Cholesterol-induced changes in the NMR spectrum for each alanine 
mutant. Cholesterol-induced changes in the NMR spectrum for each alanine 
mutant form of C99 in bicelles. The 1H-15N TROSY spectra of each alanine mutant 
examined in the Ala-scanning mutagenesis study is shown in the presence (red) 
and absence (black) of 10 mol% cholesterol. 
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Materials for Lipid Vesicles   
Dihexanoylphosphatidylcholine (DHPC), dimyristoylphosphatidylcholine (DMPC), 
1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), dioleoylphosphatidylcholine (DOPC), 
distearoylphosphatidylcholine (DSPC), palmitoyl-sphingomyelin (SM), and cholesterol 
(Chol) were purchased from Avanti Polar Lipids, Inc (Alabaster, AL).  Coprostanol was 
purchased from Steraloids Inc (Newport, RI).  The lipophilic tracers 3,3’-
dioctadecyloxacarbocyanine percholorate (‘DiO’, DiOC18) and fluorescent dyes Alexa 
Fluor 488 C5 maleimide and Alexa Fluor 546 C5 maleimide were purchased from 
Invitrogen (Grand Island, NY).  The fluorescent lipid 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rho-PE) 
was purchased from Avanti Polar Lipids, Inc.  Lipid and fluorescent lipophilic tracer 
stocks were prepared to concentrations of 10-25 mg/ml by solubilizing the powder in 
chloroform in amber glass vials and stored at -20ºC. 
 
Preparation of Alexa-Modified C99   
Wild type C99 has no cysteine residues.  Selected residues (F675 or H732) were 
mutated to cysteine using a C99-encoding plasmid (28) and the QuikChange protocol 
(Stratagene, La Jolla, CA, USA) utilizing whole plasmid PCR.  The F675C and H732C 
mutation sites were selected on the basis that both sites are located in dynamic regions 
of the protein: F675 is located at the extreme (and extracellular) N-terminus and H732 is 
located in the cytosolic dynamic loop that connects the transmembrane helix to the C-
terminus.  Fluorescent labeling efficiency was high for both sites.  Cholesterol binding 
knockout mutations were selected based on previous binding studies (26, 28).  The 
single-Cys mutant form of C99 (WT or cholesterol knockout mutant background) was 
overexpressed and purified as described for wild type in 0.2 % SDS (26, 28).  Following 
purification, the pH was lowered to 6.5 and single-cysteine mutants were concentrated to 
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ca. 0.5mM in 0.5mL.  The protein was then reduced with 2.5 mM DTT, with gentle 
agitation at room temperature for 24 hours to ensure complete reduction of any disulfide 
bonds.  An aliquot of the protein was then diluted 100 fold (to a ca. 5 μM final 
concentration) in reconstitution buffer (40mM HEPES, 150 mM NaCl, 5% SDS, pH 7.5) 
to a final volume of 0.5 mL.  A 10 mM stock of Alexa Fluor 488 C5 maleimide or of Alexa 
Fluor 546 C5 maleimide was prepared by solubilizing the powder in DMSO as instructed 
by Invitrogen.  Alexa fluorophores were individually added to the 5 μM C99 sample by 
adding 10 μL of the stock solution, resulting in a final fluorophore concentration of 1mM.  
The sample was then covered with argon, sealed with parafilm, wrapped in aluminum 
foil, and gently tumbled overnight.  Labeled samples were then reconstituted into 
proteoliposomes. 
 
Reconstitution of Alexa-Modified C99 into Unilamellar Vesicles   
The protocol for reconstitution of C99 into unilamellar vesicles (for use in 
preparing GUVs, see next section) was adopted from P. Bassereau’s method (321).  
Dehydrated lipid films, which included fluorescent lipid probes (less than 1 mol%) and 
coprostanol (when appropriate), were formed in glass culture tubes 24 hours prior to 
reconstitution.  Lipids in chloroform were then added to the glass culture tubes at the 
desired molar ratios and vortexed under a stream of nitrogen until all chloroform was 
removed (approximately 2-3 minutes), which resulted in the formation of a lipid film.  The 
glass culture tube was them further dehydrated overnight in the dark in a glass 
desiccator under a constant vacuum (~60 torr) to ensure the evaporation of any residual 
chloroform.  The lipid film was then rehydrated by adding reconstitution buffer (RB) to a 
final volume the same as the amount of chloroform initially used.  After addition of the 
RB, the sample was vortexed for 10 minutes to ensure formation of a mixed micellar 
solution.  After vortexing, Alexa-modified C99 (in 1x RB with 5% SDS) was added to the 
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mixed micelle solution to a final lipid to protein ratio of 400:1.  The Alexa-modified 
C99/mixed micelle solution was then covered with argon, sealed with parafilm, wrapped 
in aluminum foil, and allowed to gently tumble at room temperature for at least 30 
minutes in a 15 mL Falcon tube.  160 mg of wet, pre-washed SM-2 adsorbent BioBeads 
from BioRad were then added per 500 μL of sample.  (BioBeads were pre-washed with 
at least 20 mL of 40 mM HEPES, 150 mM NaCl, pH 7.5 buffer.)  The sample was then 
covered with argon gas, sealed with Parafilm, wrapped in aluminum foil, and allowed to 
gently tumble overnight.  The following morning, the solution was transferred into dialysis 
tubing (Spectra/Por 2, 6.4 mm flat width, molecular weight cut-off of 12-14 kDa) and then 
dialyzed versus 4L of dialysis buffer (10 mM HEPES, pH 7.5) in the dark.  The samples 
were then allowed to dialyze for 3 days, with daily changes of the dialysis bath.  Once 
dialysis was complete, samples were stored in an Eppendorf tube, covered with argon, 
sealed with Parafilm, and wrapped in aluminum foil.         
 
Formation of Giant Unilamellar Vesicles (GUVs)     
Lipid and fluorescent lipophilic tracer chloroform stocks were removed from 
storage at -20ºC and warmed to room temperature.  Fluorescent lipophilic tracers were 
protected from exposure to light.  While the stocks were warming, indium tin oxide (ITO) 
covered glass cover slips were cleaned using water and 70% ethanol and then dried 
with Kimwipes.  Slides were placed on a 55ºC hot plate to finalize drying.  For each 
sample, the required volumes of lipid chloroform stocks were mixed with 160μL of 
chloroform to form a final lipid weight of 0.35 mg.  Three ternary lipid mixtures were used 
for these studies: 8:1:1 POPC/SM/Chol (disordered Ld phase only, no phase separation), 
2:1:1 POPC/SM/Chol, (small punctate liquid ordered Lo domains and large continuous 
disordered Ld domains), and 1:2:2 POPC/SM/Chol (large continuous Lo domains and 
small punctate Ld domains).  These ratios were based on recently published phase 
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diagrams the for ternary mixture of POPC/PSM/Chol(322-324).  Lipophilic tracers were 
added to a total molar concentration of less than 1 mol%.  For coprostanol containing 
samples, quaternary mixtures of lipids were made in the same fashion by adding 
appropriate volumes of coprostanol stock.  Lipids in chloroform were mixed using a 
Hamilton syringe.  To create the lipid film on the indium tin oxide (ITO) slide, 80 μl of the 
lipid mixture was added to the ITO slide and, using a glass Pasteur pipette, was gently 
drawn back and forth, allowing for chloroform evaporation and the formation of a dry lipid 
film.  Samples were placed in the desiccator with a vacuum pressure of ~60-70 mm torr 
overnight in the dark.  After all residual chloroform was removed, the ITO slides were 
prepared for GUV formation via electroswelling (325, 326).  If C99 was being 
incorporated into the GUV, C99-containing unilamellar vesicles (prepared as described 
in the preceding section) were placed on the ITO slide in 2μL droplets (approximately 6-
8 drops per slide).  After all droplets had been deposited, the slides were returned to the 
vacuum-connected desiccator for 15 minutes to allow the water from the vesicle 
solutions to evaporate.  Once all liquids were evaporated from the ITO slides, a rubber 
O-ring with a diameter of approximately 4 cm was placed directly over the dry lipid film.  
For support, 4 small O-rings (approximately 1 cm in diameter) were placed in the four 
corners around the center O-ring.  500 μL of an electroformation solution of 100 mM 
sucrose was added to the large O-ring, followed by the sandwiching of another ITO slide 
(lipid film down) on top, creating an electroformation chamber.  Care was taken to 
ensure that no air bubbles were present in the chamber.  The chamber was sealed by 
placing two small binder clips on either side of the large O-ring.  The ITO slide was then 
attached to two aluminum bus bars, with the lipid film side facing the aluminum bar using 
a binder clip.  The electroformation assembly was then attached to a form generator and 
placed in a 50 ºC incubator.  The form generator emanates a sinusoidal shaped wave 
with a frequency of 10 Hz and 1 volt.  This leads to formation of GUVs in the 500 µL 
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sucrose solution. The electroformation procedure was performed for 1-2 hours.  In 
addition to the electroformation assembly, a 50ml Falcon tube containing 10-40 mL of 
100 mM glucose was placed in the incubator during electroformation.  It was important to 
keep the 100 mM glucose solution at the same temperature as the forming GUVs, as 
temperature differences could disrupt GUV formation later in the procedure.  Following 
electroformation, 3 ml of the 100mM glucose was added to a glass culture tube.  The 
500 µL100 mM sucrose GUV solution was added to the 3 ml 100 mM glucose buffer and 
allowed to cool and settle for 20 minutes. The difference in the density of the sucrose 
solution within the GUV and the glucose solution outside the GUV results in a density 
gradient, which effectively concentrates the vesicles.  A 15 μL aliquot was then taken 
and placed in the middle of a square glass cover slip.  A second cover slip was placed 
on top and the chamber was sealed with vacuum grease in order to create an imaging 
chamber for confocal microscopy. 
 
Confocal Imaging   
All fluorescence microscopy images were taken on a Zeiss 510 Laser Scanning 
Confocal Microscope (Carl Zeiss MicroImaging, Inc., Thornwood, NY) using a 40x 1.4 
NA Zeiss Plan-Neofluar objective with the confocal pinhole open.  Fluorophores were 
excited using the 488 nm line of a 40mW Argon laser and a 543 HeNe lasers.   
Fluorescence emission was detected using filter sets provided by the manufacturer.  All 
GUV images were obtained at room temperature.  Images were processed using the 
ImageJ software package (327).If needed, contrast and brightness were enhanced using 
a linear histogram stretch.  All images were then filtered using a Gaussian blur with a 
sigma value of 2 μM (scaled units).  GUVs containing both fluorophores (either Rho-PE 
and DiOC18, Rho-PE and C99-Alexa488, or DiOC18 and C99-Alexa546) were selected 
for imaging.  Imaging was carried out by first collecting a whole field, low zoom image 
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showing multiple GUVs.  Then, individual GUVs were imaged with higher zoom for 
analysis.  Multiple independent proteoliposome preparations were used for experiments 
with both WT and most mutant forms of C99 to ensure reproducibility.   
For quantification of the partitioning of C99 between Ld and Lo phases, both in the 
absence and presence of coprostanol, we compared the total pixel intensity from C99 
fluorescence in a fixed area of the Ld phase to the total pixel intensity from an identical 
area from the raft phase Lo.  Pixel intensities both inside and out of raft domains were 
determined using imageJ software with a square region of interest (ROI) of 2.5 μM2.  
Both intensities were corrected for background C99 fluorescence that was observed 
within the GUVs.  Background intensity values were determined for each individual GUV 
used during quantification.  The fluorescent intensity from the inside of each GUV (using 
the same ROI as above) was determined by examining an image showing the equatorial 
cross section of that GUV.  This intensity value accounts for any fluorescence derived 
from C99 that was trapped inside the GUV during electroformation as SUVs.  The 
background intensity value was then subtracted from both the Lo and Ld phases to 
generate background normalized intensity values.  The corrected intensity values are 
proportional to the concentration of C99 present in each phase.  We believe this interior 
population of C99 is in the form of smaller vesicles trapped inside the GUVs (rather than 
being fused with the GUVs) during the electroformation process (above section).  The 
ratio of the intensity measured in the Lo phase to the intensity measured in the Ld phase 
gives the concentration ratio for C99 between these two phases (the partition 
coefficient).  Values reported were obtained by averaging multiple GUVs over multiple 
proteoliposome preparations, accounting for the variability seen between different 
experimental preparations.  Statistical analysis was performed using Prism software by 
using a one way ANOVA with Newman Keuls post-analysis during the comparison 
between WT C99 partitioning in the absence and presence of coprostanol.  
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Summaries of the various GUV experiments conducted in this study are given in 
Tables 2 and 3. 
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Determination of Kd for Binding of Coprostanol to C99 in Bicelles 
900 MHz solution NMR spectroscopy was used to monitor binding of coprostanol 
to uniformly 15N-labeled C99 (0.2 mM) in DHPC-DMPC bicelles (20% w/v DHPC+DMPC, 
DMPC:DHPC = 1:3).  Coprostanol-containing samples (titration points) were prepared 
using the exact same methods as used to prepare samples for cholesterol titration of 
C99 in previous work (26).  As in previous work, titrations were monitored by collecting a 
2-D 1H,15N-TROSY spectrum for each titration point. Coprostanol-dependent chemical 
shifts were then plotted as a function of the concentration of coprostanol and fit by the 
model for 1:1 ligand-protein complex formation using ORIGIN 8.0 (OriginLab Corp., 
Northampton, MA) software in order to determine the Kd for 1:1 complex formation 
between C99 and coprostanol (see Fig. 4.5). 
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Results 
 
C99 can Specifically Bind Cholesterol in Bicelles 
 During structure determination of C99, it was found that the N-helix/N-loop/TMD 
formed a putative ligand binding pocket (26).  Previous studies suggested that this 
region of C99 could specifically bind the soluble cholesterol analogue β-Cholbimalt and 
potentially native cholesterol (28).  Titrations of C99 with cholesterol were carried out 
using bicelles as the model membranes because this medium is able to solubilize 
cholesterol up to ~20 mol%.  Cholesterol titration of C99 results in substantial changes in 
NMR resonance positions for a subset of C99 peaks (Fig 4.3A).  The shifts in these 
peaks saturate at high cholesterol concentrations and can be fit by a 1:1 binding model, 
indicating a Kd of 5.1 ± 1.2 mol% (Fig 4.3B).  This falls within the range of cholesterol 
concentrations in mammalian plasma and organelle membranes (328), supporting the 
physiological relevance of this complex.  Full-length APP is likely to bind cholesterol with 
an avidity similar to C99 because its ectodomain is expected to have no influence on the 
architecture of the cholesterol binding site.   
 The resonances in C99 exhibiting the most profound chemical shifts in response 
to cholesterol are all localized to the N-helix, N-loop, and extracellular end of the TMD 
and include G700, G704, and G708 (Fig 4.3C).  To identify residues critical to 
cholesterol binding, we employed alanine scanning mutagenesis to replace each residue 
in the 690-710 range, followed by cholesterol titrations (Fig 4.3, D and E, and figs 4.1 
and 4.2).  Mutations at some sites eliminated detectable cholesterol binding, even at 20 
mol% cholesterol (Fig 4.3E).  The cholesterol binding site of C99 involves residues from 
the N-helix, N-loop, and TMD and is different from previously characterized cholesterol 
binding sites in proteins (329).  Based on Fig 4.3C, it is likely that N698 donates a 
hydrogen bond to the hydroxyl head group of cholesterol, whereas E693 accepts a 
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hydrogen bond.  Also essential to cholesterol binding are G700 and G704, located in 
tandem GxxxG motifs of the TMD and, to a less degree, G708.  GxxxG motifs and the 
related GxxxGxxxG glycine zipper sequence have long been recognized as common 
structural elements that can drive homo- and hetero-oligomerization of membrane 
proteins (330-332).  Though there has been much interest in the possibility that these 
motifs drive homodimerization of C99 (14-16, 332, 333), our observation that the GxxxG 
motifs are critical for cholesterol binding indicates an additional, and novel, role for these 
motifs in C99. 
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Figure 4.3.  Cholesterol binding to C99 in bicelles.  (A) Cholesterol titration of U-
15N-C99 in DHPC-DMPC bicelles, as monitored by 1H, 15N-TROSY NMR.  
Cholesterol was varied from 0 to 20 mol% (relative to total moles of lipid).  (B)  
Changes in amide 1H NMR chemical shifts for E693 (black), G700 (light blue), and 
G704 (red) in response to cholesterol titration of wild-type C99.  Also shown are 
the fits of a 1:1 binding model to each data set, with resulting Kd values for 
complex formation indicated as well.  Units of mole percent are appropriate to 
describe the binding of two molecules that are both associated with model 
membranes {mole percent = [moles cholesterol/(moles DMPC + moles 
cholesterol)] X 100}.  (C)  Changes in 1H NMR chemical shifts for wild-type C99 in 
response to the addition of cholesterol to 20 mol% concentration.  Results are 
shown for residues at or near the cholesterol binding site.  (D) Titration of the 
G700A mutant form of C99 with cholesterol.  (Data for other C99 mutants shown in 
figure 4.2).  (E) Results of Ala-scanning mutagenesis.  Residue color indicates the 
impact on cholesterol binding of substituting each position in the 690 to 710 
range, as assessed by NMR.  Red indicates that mutation to Ala for that site 
eliminates binding, yellow indicates significantly attenuated binding, and green 
indicates that mutation results in little change in cholesterol binding affinity. 
 
C99 can Specifically Bind Coprostanol in Bicelles 
The discovery that C99 can specifically bind cholesterol suggests that it may also 
bind various cholesterol analogues or sterols with different phase partitioning properties.  
Drawing on a body of previous work on the phase partitioning of cholesterol metabolites 
and analogs (334-336) we sought a compound that would compete with cholesterol for 
binding to C99 without promoting Lo phase partitioning.  This led us to investigate 
coprostanol, a compound that is chemically identical to cholesterol except that the C5-
C6 double bond has been stereospecifically reduced (fig 4.4).   
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Figure 4.4.  Chemical structures of cholesterol and coprostanol. 
   
This sterol has a distinct preference for the fluid phase relative to Lo (334-336).  We first 
tested binding of coprostanol to C99 in bicelles using NMR spectroscopy (Fig. 4.5) and 
found that it binds to C99 with the same affinity (4.5 ± 0.6 mol%) as cholesterol (5.1 ± 
1.2 mol%) under identical conditions (26).   
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Figure 4.5.  Binding of coprostanol to C99 in bicelles.  (A) An overlay of five 1H,15N-
TROSY NMR spectra from titration samples with increasing coprostanol (from 0 
mol% to 15 mol%).  The inset highlights the resonance from G700, which showed 
significant changes in chemical shift in response to coprostanol.  (B) Changes in 
backbone amide 1H NMR chemical shifts for G700 (black), G709 (cyan), and F690 
(red) in response to coprostanol titration of WT C99.  Also shown are fits of the 1:1 
binding model to each data set along with the determined Kd values for complex 
formation.  Note that units of mole percent are appropriate to describe the binding 
of two molecules that are both associated with model membranes, where mole 
percent= [mol cholesterol/(mol DMPC + mol cholesterol)] x 100. 
 
The C99 backbone amide 1H-15N peaks that were most responsive to coprostanol 
binding largely overlap with peaks previously seen to shift the most in response to 
cholesterol, indicating that both sterols bind to essentially the same site on C99 (fig. 4.6).  
However, the directions and magnitudes of the induced shifts in peak positions seen for 
coprostanol are in some case significantly different than those observed for cholesterol 
(fig. 4.6).  Of particular note is the difference in the induced chemical shift changes in the 
resonance from Gly709, a site located in the flexible hinge contained within the C99 
TMD.  This result suggests that these sterols induce distinct changes in the structure of 
C99 that may alter the end to end distance and dynamics of its TMD. 
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Figure 4.6.  Changes in the NMR spectrum of C99 in response to cholesterol and 
coprostanol.  (A) Comparison of the 1H,15N-TROSY NMR spectra of C99 in DHPC-
DMPC bicelles in the presence of 10 mol% coprostanol (green) and 10 mol% 
cholesterol (red).  The black reference spectrum for C99 in the absence of either 
cholesterol or coprostanol.  The red and black spectra were collected at 900 and 
600 MHz, respectively, and have been reported in previous work (26), while the 
green (coprostanol) spectrum was collected for this study at 900 MHz.  Note that 
10 mol% coprostanol and 10 mol% cholesterol are both 2X higher concentrations 
than their respective measured Kd for binding to C99 under the conditions of these 
experiment.  (B)  Changes in the composite chemical shift (relative to ligand-free 
conditions) induced by 10 mol% cholesterol vs. changes induced by coprostanol.  
The composite chemical shift assesses the magnitude of ligand-induced peak 
shift in both dimensions (corrected for the 10-fold difference in resonance 
frequencies for 1H vs. 15N) as described: 
 
∆δcomposite = [ (induced change in 1H shift)2 + (0.1 * induced change in 15N shift)2 ]1/2 
 
 
C99 Partitions to Cholesterol Rich Domains in GUVs 
The phase partitioning of C99 in giant unilamellar vesicles (GUVs) containing 
coexisting liquid-ordered (Lo) and fluid (Ld) phase membrane domains was visualized 
using fluorescent microscopy(337).  GUVs were prepared (338) using a 2:1:1 ternary 
mixture of 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), palmitoyl-sphingomyelin 
(SM), and cholesterol that forms membranes with separated Ld and Lo phase domains 
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(339-341).  The total cholesterol concentration in these vesicles was 25 mol%, well 
within the range of cholesterol levels of mammalian plasma membranes (342-345).  
Phase separation was verified by imaging GUVs doped with Ld-specific and Lo-specific 
fluorescent marker lipids.  Lo domains appear as mobile, round, and smooth-edged 
domains within the surrounding Ld membrane (Fig. 4.7A and fig. 4.8A).  Alexa488-
tagged C99 was reconstituted into these mixed phase GUVs at a 1:400 protein:lipid 
molar ratio, a concentration at which C99 is known to be monomeric (346).  While the 
presence of some degree of heterogeneity in the composition of the GUVs is typical for 
phase-separated ternary lipid mixtures (347),  C99 was seen to strongly partition into the 
Lo domains in most of the vesicles (Fig. 4.7B and table 2).  Within these vesicles the 
measured ratio of concentrations of C99 in the Lo phase relative to the Ld phase was 15 
± 5.5.  Efficient partitioning of C99 to the Lo phase was also observed in GUVs 
composed of 1:2:2 POPC:SM:cholesterol, in which phase separation of a reciprocal 
nature occurs in which the Ld phase forms punctate domains that are surrounded by a 
continuous Lo phase (fig. 4.8B).   
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Figure 4.7.  C99 is strongly enriched in raft-like Lo domains of GUVs containing co-
existing Ld and Lo domains.  (A) GUVs composed of a 2:1:1 molar ratio of 
POPC/SM/cholesterol were doped with tracer amounts of the Ld phase marker 
rhodamine-phosphoethanolamine (Rho-PE, magenta) and the Lo phase marker 
DiOC18 (cyan).  (B) C99 labeled with Alexa488 (yellow) at site F675C was 
incorporated into GUVs composed of a 2:1:1 molar ratio of POPC/SM/cholesterol.  
Ld domains were labeled with Rho-PE (magenta).  Scale bars, 5 microns. 
 
 
In control experiments partitioning of C99 to the Lo domains was seen to be independent 
both of the fluorescent lipid probes used to mark the Ld and Lo domains (fig. 4.9A) and 
also of the site of fluorophore attachment to the protein (fig. 4.9B).  Moreover, in other 
control experiments C99 was seen to be uniformly distributed in GUVs containing only a 
uniform Ld phase (fig. 4.8B), indicating that C99 does not itself trigger phase separation.   
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Figure 4.8. Partitioning of lipids and C99 in GUVs of varying lipid and C99 
compositions.  (A)  Protein-free GUVs comprised of 8:1:1 POPC/SM/Chol show no 
visible phase separation of the disordered phase marker Rho-PE (magenta) and Lo 
phase marker DiOC18 (cyan), indicating that this mixture generates a uniform 
disordered Ld phase, as expected (322-324).  (B) Protein-Free GUVs consisting of 
1:2:2 POPC/SM/Chol contain co-existing Ld (marked with Rho-PE, magenta) and Lo 
(marked with DiOC18, cyan) phases.  Note that this mixture was dominated by a 
continuous Lo phase, with punctuate disordered Ld domains. (Inverse of the case 
for the 2:1:1 mixture of Fig. 4.7).  The merged images show both fluorophores.  (C, 
D) Observation of Alexa 488-labeled C99 (yellow) in GUVs comprised of 8:1:1 (C) 
or 1:2:2 POPC/SM/Cholesterol (D).  In both cases disordered domains are labeled 
with Rho-PE (magenta).  In all cases C99 was fluorescently labeled with Alexa 488 
(yellow) at F675C.  Note that the mixture in panel D was dominated by a 
continuous Lo phase, with punctuate disordered Ld domains.  Scale bars, 5 
microns.  
 
Preferred partitioning into Lo domains was also observed for C99 using vesicles 
composed of 2:1:1 DOPC/DSPC/cholesterol (fig. 4.9C and table 2), indicating that the 
domain preference of the protein does not require the presence of sphingomyelin.  
Collectively, these results indicate that C99 has an intrinsic and pronounced preference 
for raft-like Lo phases in model membranes and that this phenomenon does not require 
other protein co-factors or posttranslational modifications such as palmitoylation (348). 
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Figure 4.9.  Control experiments demonstrate that the localization of C99 to Lo 
domains is independent of the fluorophores used to label the protein, the position 
of the dye on the protein, the lipophilic dye used to highlight the Lo/Ld domains, or 
of the presence of SM and POPC.  Experiments were performed to show that only 
cholesterol binding, and not the presence of other lipids or the fluorophores used, 
drive C99 partitioning to Lo domains.  (A) Alexa546-labeled C99 (yellow) was 
incorporated into GUVs comprised of 2:1:1 POPC/SM/cholesterol.  DiOC18 was 
used to label Lo domains (cyan).  C99 was labeled at position F675C.  C99 co-
localizes with DiOC18 in Lo (raft-like) domains.  These studies show that C99 
partitioning into Lo domains is independent of both the fluorescent dye used to 
label C99 and the lipophilic marker of lipid domains.  (B) Alexa 488-labeled C99 
(yellow) was incorporated into GUVs comprised of 2:1:1 POPC/SM/cholesterol.  In 
the top panel, C99 was labeled at mutation site F675C and in the bottom panel C99 
was labeled at mutation site H732C.  Ld domains were marked with Rho-PE 
(magenta).  C99 partitions to Lo (raft-like) domains in both cases.  These studies 
show that our choice of sites for mutation to cysteine and subsequent fluorescent 
labeling did not impact C99 partitioning.  (C)  Alexa 488-C99 (yellow) was 
incorporated into GUVs comprised of 2:1:1 DOPC/DSPC/cholesterol.  As with the 
2:1:1 POPC/SM/Cholesterol mixture, the 2:1:1 DOPC/DSPC/cholesterol lipid 
mixtures also exhibit the presence of coexisting Ld and Lo domains (349).  Ld 
domains were marked with Rho-PE.  C99 was labeled at position F675C.  As for 
the case of GUVs prepared from POPC/SM/cholesterol, C99 partitions to Lo 
domains.  These studies indicate that POPC and SM are not required to support 
C99 partitioning to Lo domains.  Scale bars, 5 microns. 
 
Effects of Mutations on C99 Partitioning 
Since C99 has the capacity to directly bind cholesterol, we hypothesized that this 
interaction may regulate its domain preference.  This was tested by experiments using 
two mutant forms of C99 that do not bind cholesterol (26). Alanine substitution of 
ectoplasmic (E693A) or TMD (G704A) residues critical for cholesterol binding produced 
a striking shift in the domain preference of C99 towards the Ld phase in phase-separated 
GUVs (Fig. 4.10 and fig. 4.11).  As a control, we also examined the G696A C99 mutant, 
which involves a site proximal to E693 and G704 but that exhibits wild type-like 
cholesterol binding (26).  Consistent with its unaltered cholesterol binding activity, the 
G696A mutant preferentially partitioned to Lo domains in the same manner as the wild 
type protein (Fig. 4.9 and fig. 4.11).  These results show that the preferential partitioning 
of C99 into Lo domains is absolutely dependent on retention of an unperturbed 
cholesterol binding site.   
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Figure 4.10.  Mutations that abolish cholesterol binding to C99 (G704A and E693A) 
shift partitioning of C99 from Lo domains into Ld domains, whereas a control 
mutation (G696A) that preserves cholesterol binding has little effect on the 
partitioning of C99.  Wild type or mutant forms of Alexa 488-labeled C99 (yellow) 
were incorporated into GUVs composed of 2:1:1 POPC/SM/cholesterol containing 
tracer levels of the Ld domain marker Rho-PE (magenta).  Scale bars, 5 microns. 
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Figure 4.11.  Partitioning of fluorescently labeled C99 containing mutations at its 
cholesterol binding site in GUVs composed of lipid mixtures having varying phase 
compositions.  The 8:1:1 POPC/SM/Cholesterol GUVs do not exhibit visible phase 
separation (disordered phase only).  The 1:2:2 POPC/SM/cholesterol GUV’s exhibit 
phase separation between Ld and Lo domains.  At this composition, Lo represents 
the dominant (continuous) phase and the disordered Ld phase domains now 
appear as punctae.  (A) Distribution of wild type and mutant forms of C99 (yellow) 
in GUVs comprised of an 8:1:1 POPC/SM/cholesterol mixture.  Ld domains were 
marked with Rho-PE (magenta).  C99 and its mutants were labeled with Alexa 488 
(yellow) at site F675C.  As in Fig. 4.9, phase separation was not observed in these 
GUVs.  The cholesterol binding site mutants G704A or E693A were uniformly 
distributed on the GUV surface.  Similar results were obtained for wild type C99 
and the G696A mutant, which binds cholesterol normally. These results indicate 
that when no lipid phase separation is present, C99 (with or without an intact 
cholesterol binding site) is uniformly distributed within the GUVs.  (B)  
Distribution of wild type and mutant forms of C99 (yellow) in GUVs comprised of a 
1:2:2 POPC/SM/cholesterol mixture.  Ld domains were marked with Rho-PE 
(magenta).  C99 and its mutants were labeled with Alexa 488 (yellow) at site 
F675C.  At this lipid composition, the GUV surface is dominated by a continuous 
Lo domain with punctate Ld domains.  WT and G696A (which binds cholesterol 
normally) both localize to the Lo domain.  E693A and G704A (cholesterol binding 
mutants) do not partition to the Lo domains, indicating that cholesterol binding is 
essential for C99 partitioning to Lo domains.  Scale bars, 5 microns.   
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Coprostanol Reduces Partitioning of C99 to Cholesterol Rich Domains 
To determine whether coprostanol can compete with cholesterol binding and 
thereby alter the phase preference of C99, we conducted GUV experiments in which the 
total sterol concentration (cholesterol+coprostanol) was fixed at 25 mol%.  The ratio of 
cholesterol and coprostanol was then varied by including coprostanol up to 5 mol%, the 
concentration beyond which phase separation in GUVs is strongly reduced.  Upon 
reconstitution of fluorescently labeled C99 into these GUVs, a coprostanol-dependent 
reduction in the partitioning of C99 to the Lo domains was observed (Fig. 4.12, fig. 4.13, 
and table 3).  Given that cholesterol and coprostanol bind to the same site on C99 and 
with similar affinity, the 5-fold reduction in the partitioning coefficient seen at 5 mol% 
coprostanol and 20 mol% cholesterol relative to coprostanol-free conditions is consistent 
with the effects of competitive binding between the sterols for C99.  Binding of 
coprostanol to C99 thus reverses the phase preference of this protein compared to the  
cholesterol-complexed form. 
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Figure 4.12.  Incorporation of coprostanol into cholesterol-containing GUVs 
induces a shift in localization of C99 away from raft-like Lo phase and into Ld 
phase domains in a dose-dependent manner.  (A) In the top 3 panels, C99 was 
incorporated into GUVs containing 50 mol% POPC, 25 mol% SM, and the indicated 
mol% concentrations of cholesterol and coprostanol.  The bottom panel 
represents a control sample in which the cholesterol concentration was 20 mol%, 
but coprostanol was absent: 55:25:20 mol% POPC/SM/cholesterol.  Disordered 
domains are marked by Rho-PE (magenta).  C99 was fluorescently labeled with 
Alexa488 (yellow) at F675C.  Scale bars, 5 microns.  (B)  Quantification of changes 
in C99 partitioning to raft-like Lo domains with increasing levels of coprostanol.  
The partition coefficient is defined as (mol% C99 in the Lo domain)/(mol% C99 in 
the Ld domain), as determined from multiple GUVs for each of the lipid 
compositions shown in panel A.  The error bars indicated standard deviation, N is 
the number of GUVs used for quantification, n.s. indicates lack of a statistical 
variation, and ** and *** indicates that statistical P values are less than 0.001 and 
0.01, respectively.   
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Figure 4.13.  Lo phase separation in POPC/SM/cholesterol lipid mixtures.  
Disordered Ld domains are marked by the non-raft marker Rho-PE (magenta).  Lo 
domains are highlighted by DiOC18 (cyan).  The addition of varying amounts of 
coprostanol, from 2.5 mol% to 5 mol%, does not impact phase separation or Lo 
(raft-like) domain formation.  Scale bars, 5 microns. 
  
Discussion 
 The finding that GxxxG motifs within the TMD of C99 play a crucial role for 
cholesterol binding elucidates a totally novel mechanism for these motifs, implicating 
them in more than potentially just protein homo- and hetero-oligomerization.  It should be 
added that the G700AIIG704 segment of C99 has also been shown to be important in 
establishing the production ratio between long and short forms of the Aβ polypeptide by 
γ-Secretase (14, 15) and in making that ratio susceptible to alterations by druglike small 
molecules known as GSMs (279, 350). 
 A space-filling surface representation shows that G700 and G704 are located on 
the outer face of the curved TM helix and result in that face of the helix having a locally 
flat surface (Fig 2.7C), which is probably optimal for van der Waals interactions with 
cholesterol, which itself is relatively flat.  Pairing the surface afforded by the GxxxG 
motifs with a rigid cholesterol molecule is expected to be entropically advantageous 
compared with association with more flexible lipids. 
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 Binding of cholesterol to C99 appears to rely on the flexibility of the N-loop to 
allow induced fit conformational changes required to optimize interactions of cholesterol 
with key residues in this loop and in the N-helix (Fig 4.14).  This is supported by 
observation of a number of N-loop residues for which substantial changes in NMR 
resonance chemical shifts are observed in response to cholesterol binding (e.g. S697, 
see fig 4.5D) but do not appear to make direct connects with the lipid (Fig 4.5E). 
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Figure 4.14.  In the top panel residues are colored according to the importance of 
each site in cholesterol binding, as judged by mutation of each site to alanine 
(from figure 4.3, green: mutation to alanine leads to no change in cholesterol 
binding affinity; yellow: intermediate change; red: mutation to alanine eliminates 
detectable cholesterol binding).  The conformer of C99 illustrated in the top panel 
was selected from among the 30 lowest energy conformers from structural 
determination.  In the top right panel, cholesterol has been manually docked 
against the flat surface of C99’s TMD provided by the GxxxGxxxG motif.  We 
speculate that cholesterol initially binds C99 in this mode, followed by a 
conformational change involving the N-helix and N-loop that lead to the 
completion of complex formation.  The lower left panel is a cartoon illustrating the 
expected topology of the final complete complex, highlighting important residues 
involved in binding.  The two panels on the lower right illustrate the sort of 
reorientation the N-helix is expected to undergo during cholesterol binding, 
indicated by black arrows.  This reorientation would be enabled by conformation 
changes in the N-loop, which is not depicted.  The orange sites in the two panels 
on the lower right highlight F691, E693, D694, N698, G700, G704, and G708; all 
residues important in cholesterol binding (top left panel). 
 
 The literature suggests plausible mechanisms by which complex formation 
between C99 or APP and cholesterol contributes to amyloidogenesis and AD.  First, 
there are numerous reports that β- and γ-Secretase associate with cholesterol rich 
membrane domains often referred to as lipid rafts (119, 310, 351).  Association of 
C99/APP with cholesterol may favor partitioning of the protein into membrane domain 
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enriched in the proteases of the amyloidogenic pathway.  Secondly, cholesterol binding 
to C99 may play a cofactor role to promote substrate recognition or catalysis.  The 
addition of cholesterol to purified γ-Secretase in model membranes enhances the 
cleavage rate of purified C99 in lipid vesicles (352).  Third, given that the α-Secretase 
cleavage site (K687) is immediately adjacent to the cholesterol binding site, direct 
binding of cholesterol to APP could reduce non-amyloidogenic cleavage by α-Secretase 
(41, 42).  Finally, the cholesterol binding site in C99 is contained within its amyloid-β 
domain (C99 residues 672-711 correspond to Aβ40), such that complex formation 
between cholesterol and Aβ may contribute to known profibrillogenic effects of 
membrane cholesterol (131). 
To test the hypothesis that cholesterol binding by C99 favors partitioning of the 
protein into cholesterol rich domains, we utilized the giant unilamellar vesicle (GUV) 
system.  When incorporated into GUVs containing a 2:1:1 ratio or a 1:2:2 ratio of 
POPC/SM/Cholesterol, C99 strongly partitioned to the Lo domain, as indicated by the 15 
± 5.5 fold enrichment of C99 in the Lo phase compared to the Ld phase.  We found that 
this partitioning was contingent solely upon the binding of cholesterol by C99, as 
mutations that abolished this binding event were the only variable to prevent C99 
partitioning to Lo domains.   
The finding that C99 preferentially partitions to a high degree into Lo domains is 
remarkable given that helical transmembrane proteins or peptides studied to date exhibit 
low partitioning into the cholesterol-enriched, ordered environment characteristic of this 
phase (337, 353-357).  This suggests that the transmembrane domain (TMD) of C99 has 
unique properties that facilitate its efficient targeting into rafts.  The simplest explanation 
for our findings is that direct interaction of C99 with cholesterol drives entry into the 
cholesterol-enriched Lo phase.   However, cholesterol is only moderately enriched in Lo 
domains relative to co-existing Ld domains (< 3-fold) (340, 341, 347).  Assuming equally 
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avid binding of cholesterol to C99 in both phases and a 3-fold enrichment of cholesterol 
in the Lo domain, the binding energetics can account for a maximum enrichment of C99 
in the Lo phase of only 3:1, well below the observed 15-fold concentration difference.  
Therefore, while cholesterol binding is essential for the Lo phase preference of C99 there 
must be at least one colluding factor.  The most likely possibility is that cholesterol 
binding to C99 induces a structural change in the protein that results in reduced free 
energy for the protein-cholesterol complex in the Lo phase relative to the fluid phase.  
The 1H,15N-TROSY NMR spectrum of C99 has been shown to undergo significant 
changes in response to cholesterol binding (26), consistent with this possibility. 
This work confirms the hypothesis that binding of cholesterol to C99 activates 
partitioning of the protein into raft-like Lo membrane domains. Based on these findings, 
we hypothesize that cholesterol functions as an important regulator of the partitioning of 
C99 in intact cells.  The plasma and endosomal membranes have sufficient cholesterol 
contents to constitutively activate raft partitioning of C99 (>15 mol%, which is more than 
three times the Kd for cholesterol binding to C99 (342-345) (26, 346)).  On the other 
hand, the membranes of the Golgi and endoplasmic reticulum contain levels of 
cholesterol that vary in the range of the Kd for cholesterol binding (342-345), suggesting 
that modest changes in cholesterol concentration may dynamically regulate partitioning 
of C99 between fluid and Lo domains.  Given that full length APP contains the same 
cholesterol binding domain as C99, these observations may also apply to APP, although 
palmitoylation of APP outside its C99 domain also appears to be important in 
determining its membrane sorting (358).  Our observations shed considerable light on an 
array of previous data suggesting that amyloidogenic processing of C99 and APP is 
promoted by elevated cholesterol and is preferentially localized to raft-like Lo membrane 
domains (359-364), whereas non-amyloidogenic processing is reduced by elevated 
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cholesterol and is preferentially localized to bulk (fluid phase-like) membranes (365, 
366). 
The observation that competitive binding of coprostanol to the cholesterol binding 
site of C99 triggers reversal of the protein’s phase preference demonstrates the 
possibility of manipulating the phase partitioning of integral membrane proteins with 
pharmacological agents.  While the affinity of coprostanol for C99 is insufficient for use 
of this compound under physiological conditions, it may serve as a lead for compounds 
that target the cholesterol binding site.  Importantly, such compounds could potentially 
serve as Aβ-lowering agents to help prevent or treat Alzheimer’s disease.  Moreover, our 
findings suggest it should be feasible to develop additional compounds that alter the 
membrane phase/domain preferences of other membrane proteins for therapeutic, cell 
biological, or biotechnological purposes. 
 
Acknowledgment 
  This work was supported by NIH grants PO1 GM080513, RO1 GM106672, and 
F31 NS077681 (P.J.B.).  We also thank Sarah Veatch, Daniel Huster, Andrew Beel, 
Catherine Deatherage, Wade Van Horn, and Ilya Levental for useful comments.  
 
 
 
 
 
 
 
 
 
 170 
 
CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Summary of This Work 
 The results of the work provided in the above studies divulge new avenues for 
therapeutic intervention or prevention for Alzheimer’s disease.  We found that the 
transmembrane domain of APP is both curved and flexible, properties not often found 
during membrane protein structure determination.  By obtaining a 3D structure of the 
direct precursor to the Aβ peptide (C99), better therapeutic agents can now be 
developed that will specifically interact with APP, potentially limiting the toxic side effects 
of inhibiting the cleavage of off-target γ-Secretase substrates, such as Notch.  In addition 
to allowing for more potent drug design, the results of the structural studies provide 
valuable insight into the mechanisms behind γ-Secretase processing of APP, yielding a 
fundamental understanding of how intramembraneous proteolysis occurs.   
 While the structural studies give insight into the physical properties of C99 that 
promote Aβ generation, the cholesterol studies provide functional information of a 
mechanism that may promote the overproduction of Aβ in AD.  We were able to show 
that the transmembrane domain of APP can specifically bind cholesterol, lending 
credence to the hypothesis that APP may serve as a putative cholesterol sensor in the 
cell membrane.  By obtaining definitive evidence that C99 partitions to cholesterol rich 
membrane domains, where it is known that key enzymes that generate Aβ reside, there 
is the potential for developing novel therapeutics to disrupt this partitioning.  In fact, the 
coprostanol studies already provide a foundation that this phenomenon of membrane 
partitioning is a potential druggable target worthy of further studies. 
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 This chapter will consider in more detail all of these findings, examining what the 
deeper meaning of the findings are, and in some cases, suggesting new ways to 
interpret the results.  In all, the results of these experiments provide evidence of how the 
structure and function of C99 may contribute to the pathogenesis of AD, and how 
targeting specific aspects of the structure or function may lead, potentially, to regulating 
Aβ production.  
 
Implication of Results 
 
Structural Regulation of Aβ Production 
 Our results reveal that the 3D structure of the TMD of APP has many unique and 
unforeseen structural features.  Significantly, the transmembrane helix was found to be 
highly curved, with the apex of curvature occurring at two consecutive glycine residues 
(G708 and G709), which are located in the middle of the TMD.  While the average 
distance from the beginning to end of the TMD is roughly 35Å, DEER EPR studies 
revealed that the TMD is highly flexible, and can adopt structures that accommodate 
distances from end-to-end of the TMD that reach extremes of 20-40Å.  This large 
window of end-to-end distance for the TMD may account, at least partially, for the wide 
variety of functions in which APP has been shown to be involved.  We hypothesize that 
this curvature is vital for proper processing of APP by γ-Secretase, which has been 
shown to most likely accommodate a curved substrate best (256).  Based on our 
docking studies of the experimentally determined 3D structure of C99 into the cryo-EM 
structure of γ-Secretase (See figure 2.11), it appears that G708 and G709 are positioned 
at a curved site within presenilin, positioning the initial ε-cleavage site in the proximity of 
the active site.  The flexibility found within the curved TMD of APP may facilitate the 
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processive cleavage event of γ-Secretase processing, by permitting the new γ-
Secretase cut sites to be preferentially exposed within the active site of the enzyme.  
In addition to permitting proper γ-Secretase cleavage of APP, a flexibly curved 
TMD may play a role in organelle sorting of APP as it moves from the ER to the plasma 
membrane.  It is known that as proteins move from the ER to the plasma membrane, the 
properties of the membranes change.  The membranes initially appear thin with less 
cholesterol in the ER.  They exhibit moderate thickness and cholesterol in the TGN.  
Finally, membranes at the plasma membrane contain the thickest membranes with the 
highest cholesterol levels (110).  Possessing a flexible TMD would allow APP to 
accommodate more readily to changes in membrane thickness.  Work from Hartmann et 
al showed that Aβ40 was preferentially formed in the TGN and endosomal 
compartments, while the more toxic Aβ42 species was generated in the ER (110).  
These findings suggest that organelle sorting may play a role in Aβ generation, and 
specifically, the generation of Aβ polypeptide species.  Based on our findings that C99 
can bind cholesterol, this raises the possibility that even slight alterations in cholesterol 
levels within the ER and TGN may have an impact on regulating APP trafficking and Aβ 
generation.  Membrane thickness is also different between Ld and Lo phases of the 
membrane, with Lo domains having an increased thickness (~35Å) when compared to Ld 
domains (~28Å) (124, 367, 368). This suggests that on average, it is energetically 
favorable for the TMD of APP to exist in Lo domains, due to the matching hydrophobic 
thickness, however, due to the flexibility of the TMD it can accommodate the thickness of 
Ld domains.   
 It is the flexible nature of the TMD that may also account for the variance of 
phase preference when bound to cholesterol (Lo phase) or coprostanol (Ld phase).  The 
results from the GUV studies showed that C99 had a ~15 fold increased preference for 
cholesterol rich domains over the bulk membrane.  Based on the relative distribution of 
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cholesterol between the two phases (Lo domains have only a modest 2 fold enrichment 
in the Lo phase (229)), an additional property beyond simple cholesterol binding must 
account for the increased abundance of C99 in this phase.  In fact, previous studies of 
membrane protein partitioning in GUVs showed low or only modest enrichment in the Lo 
phase (369, 370), making our findings very different.  In conjunction, a mechanism of 
decreasing the preference for Lo domains in the presence of coprostanol must be 
accounted for.  An explanation for both phenomenon may be found within the structural 
data and the NMR titration studies for both compounds.  When comparing the two NMR 
titration studies for cholesterol and coprostanol, it is evident that while both compounds 
bind in the same general vicinity, there are select residues that interact differently with 
each compound (figure 4.6).  Paramount in these minute discrepancies between 
compounds are the interactions with residues G708 and G709, the two glycine residues 
crucial for maintaining a flexible, curved TMD.  DEER EPR results showed that when 
G708 was mutated to a leucine, the TMD saw a marked decrease in flexibility, however, 
when G709 was mutated to leucine, no change in flexibility was seen (figure 2.10C).  
When examining the NMR titrations, the results show that cholesterol preferentially 
interacts with G708 and G709, while coprostanol interacts almost exclusively with G709.  
Based on these slightly different interactions, we hypothesize that cholesterol locks the 
TMD of APP in a more rigid conformation by interacting with G708 and G709, while 
coprostanol permits a more flexible TMD with preferential interactions with G709.  The 
increased rigidity induced by the cholesterol/G708/G709 interaction leads to better 
packing within the more rigid environment of cholesterol rich domains.  This leads to an 
entropically favorable scenario of APP partitioning to cholesterol rich domains (figure 
5.1) and may account for the extreme preference for these domains we witnessed in the 
GUV studies. 
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Figure 5.1.  The effect of cholesterol and coprostanol on APP TMD partitioning.  
(A)  Quantification of NMR chemical shift perturbation in the presence of 
cholesterol or coprostanol for residues G708 (black) or G709 (striped).  When 
binding cholesterol, both G708 and G709 show significant chemical shift.  In the 
presence of coprostanol, only G709 demonstrates chemical shift perturbation.  (B)  
DEER EPR data taken from (26) showing that when mutated to leucine, only the 
G708L mutation induced a change in TMD flexibility compared to the wild type 
protein.  (C)  The model for how cholesterol binding induces rigidity in the TMD of 
APP and promotes partitioning to cholesterol rich domains (orange head groups) 
while coprostanol permits a flexible TMD that promotes partitioning to Ld 
membrane domains (grey head groups). 
 
 
While the curvature and flexibility of the TMD as a whole may play important 
roles in regulating γ-Secretase cleavage and Aβ generation, our HDX data gives a more 
detailed picture as to how local dynamics within the TMD may regulate these processes 
as well.  In collaboration with the Langosch laboratory, we found that in addition to being 
curved and flexible as a whole, the TMD contained three distinct regions of local 
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dynamics.  The three regions were the N-terminus of the TMD (above the hinge region 
at G708/G709), a middle C-terminus region (residues 710-718), and the extreme C-
terminal section (residues 718-723).  The N-terminal region (which contains the 
GxxxGxxxG motif) is highly dynamic in nature.  We speculate the local dynamics of the 
backbone atoms in this region may facilitate the binding of ligands, such as cholesterol, 
or may promote protein/protein interactions using the GxxxGxxxG motif.  In addition, 
high backbone dynamics in this region may not only facilitate the movement of APP 
through the active site of γ-Secretase, but could also play a role in permitting release of 
the Aβ peptide, once a desired peptide length has been reached. 
The fraying of the lower C-terminal region of the TMD may be very important for 
allowing processive cleavage of APP by γ-Secretase.  Given that substrate helix 
unraveling is considered to promote proteolysis, the increased dynamics of this region 
may facilitate local hydration of bonds being prepared for cleavage.  The HDX data 
suggests that dynamics increase downstream of the ε-cleavage site.  This local 
unraveling at the helix C-terminus results from absent H-bonds and side-chain/side-
chain interactions between the respective i and i + 3,4 residues as well as from 
increased solvation.  It is plausible, that this fraying of the substrate helix promotes the 
initial endoproteolytic cuts at the ε-site.  The newly formed C-termini of the resulting C48 
and C49 fragments would then be frayed themselves which would facilitate ζ-cleavages; 
this, in turn, would produce frayed C45 and C46 fragments, etc.  It is unclear if these 
local dynamics regulate the difference between Aβ40/42 production, but the possibility is 
strong (237), and requires further investigation.     
 
APP, Cholesterol, and Redefining the Amyloid Hypothesis 
 Findings from our lab give concrete evidence linking the binding of cholesterol by 
the TMD of APP to AD, by connecting this binding event to partitioning of C99 to 
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cholesterol rich (Lo) membrane domains.  These events led to a model of how 
cholesterol binding by APP may promote the amyloidogenic pathway (figure 5.2). 
  
 
 
Figure 5.2.  A model of how cholesterol binding promotes the amyloidogenic 
cleavage pathway.  When not in complex with cholesterol, APP is preferentially 
cleaved by α-Secretase at the plasma membrane surface.  Binding of cholesterol 
promotes a conformational change in the N-helix of APP, occluding the α-
Secretase cleavage site.  Following this binding event, APP is partitioned to 
cholesterol rich membrane domains, which is followed by cleavage by β- and γ-
Secretase and leads to Aβ generation.  In AD, changes in cholesterol metabolism 
enhance the APP/cholesterol binding event and increase Aβ production. 
 
It is known that cleavage of APP by α-Secretase occurs at the plasma membrane 
surface in Ld membrane domains (1).  It is suggested that this dynamic membrane 
environment exposes the α-Secretase cleavage site (K687) (42).  When examining the 
30 lowest energy structures calculated during structure determination of C99, the results 
show that the N-helix (which includes the α-Secretase cleavage site) is highly dynamic 
when placed in a bicelle environment that mimics Ld membrane domains (see figure 
17B), supporting the notion that increased dynamics of the N-helix promote the non-
amyloidogenic pathway.  Findings from the Kramer lab corroborate this in the reverse 
manner, showing that when placed in model membranes mimicking Lo domains, 
accessibility to the α-Secretase cleavage site is decreased.  Using solid state NMR, they 
showed that when placed in Lo membrane domains (albeit, domains without cholesterol), 
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the α-Secretase cleavage site showed a marked decrease in dynamics.  In addition, 
experiments utilizing the enzyme trypsin showed that the α-Secretase cleavage location 
was not only less dynamic, but also occluded.  This result was obtained as the amino 
acid sequence of C99 contains a trypsin cut site proximal to residue K687 (40).  These 
results suggest that cholesterol binding, and more specifically partitioning to cholesterol 
rich membrane domains, by APP may preferentially promote Aβ production by not only 
promoting the enhanced proximity between APP and β-Secretase in cholesterol rich 
domains, but also by actively preventing α-Secretase cleavage by occluding the 
cleavage site (Figure 5.3). 
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Figure 5.3.  Cholesterol binding mediates selection between the non-
amyloidogenic and amyloidogenic cleavage pathways by altering the α-Secretase 
cleavage site.  Full length APP (green) contains a flexible N-helix that sits on the 
membrane surface.  The dynamic nature of this helix preferentially exposes the α-
Secretase cleavage site, allowing for enhanced α-Secretase (red) cleavage in the 
dynamic, bulk membrane (gray).  Cholesterol binding to APP promotes the 
amyloidogenic cleavage pathway by two mechanisms; the first is to occlude the α-
Secretase cleavage site and the second is to partition APP to cholesterol rich 
domains (pink) by β-Secretase (yellow). 
 
 
Our results shed new light as to how cholesterol binding and membrane 
partitioning by APP may play crucial roles in promoting Aβ generation via the 
amyloidogenic pathway, but further investigation must be done in order to connect the 
events that lead to over stimulation of the amyloidogenic pathway in AD.  Carefully 
studying the vast literature on cholesterol and AD, makes it appear that at first glance 
there are two distinct schools of thought.   The first contends there are increased levels 
of cholesterol in AD.  The second hypothesizes that decreased levels of cholesterol 
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stimulate the overproduction of Aβ.  However, when the mechanisms that drive both the 
increase and decrease of cholesterol in AD are coupled with the mechanisms found in 
our current work on cholesterol binding and membrane partitioning, it may be possible to 
link both increased and decreased cholesterol levels into one, unifying, mechanism that 
promotes Aβ generation in AD. 
Under physiological conditions APP is preferentially cleaved by the non-
amyloidogenic pathway, resulting in low, biologically relevant, levels of Aβ within the 
brain.  This means that APP is preferentially cleaved by α-Secretase, an event that 
occurs at the plasma membrane surface, indicating the majority of APP leaves the TGN, 
is transported to the plasma membrane and is cleaved.  Cleavage at the plasma 
membrane by α-Secretase needs to be a relatively fast event, as the turnover of APP at 
the plasma membrane surface is quite rapid, as very little APP can be detected at the 
cell surface at a given time (1).  This process leaves very little APP to be cleaved by β-
Secretase, an event that is known to occur predominantly in endosomal compartments. 
APP and β-Secretase co-localize in endosomal compartments either following 
endocytosis from the cell membrane in a clathrin dependent manner, or from direct 
transport from the TGN to endosomal compartments (121). 
It is known that many pro-AD risk factors have altered expression levels in AD.  
The protein CYP46 has increased expression (95, 96), while the protein Seladin-1 is 
down regulated (87).  CYP46 is the enzyme that converts cholesterol to 24-
hydroxycholesterol, which is the form of cholesterol able to cross the blood brain barrier 
and exit the brain.  Overexpression of this enzyme in AD would lead to an 
overabundance of 24-hydroxycholesterol, ultimately depleting the levels of cholesterol 
within the brain.  Seladin-1 is the enzyme responsible for converting demosterol to 
cholesterol, the last step in the cholesterol synthesis pathway.  Down regulation of this 
protein would lead to the over accumulation of demosterol, and, as with the 
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overexpression of CYP46, the ultimate decrease in total brain cholesterol levels.  While 
a decrease of ~20% cholesterol is expected during normal aging, a loss of 30% 
cholesterol is connected to neurodegeneration (95), highlighting the delicate balance of 
cholesterol metabolism in AD. 
Work from the Chochina lab demonstrated that there is an asymmetry in the 
distribution of cholesterol between the two faces of the plasma membrane; in young 
neurons approximately 85% of the total cholesterol is found in the cytofacial leaflet, 
where cholesterol rich domains do not form.  As neurons age, there is a marked 
increase in the levels of cholesterol in the exofacial leaflet (up to 35%), leading to 
increased cholesterol rich domain formation at the plasma membrane surface (111).   
When combined with the evidence of altered cholesterol metabolism by either 
CYP46 or Seladin-1, the hypothesis is generated that decreased levels of cholesterol will 
create a “cholesterol sink” at the plasma membrane surface, resulting in 
overcompensation and increased movement of cholesterol to the exofacial leaflet.  This 
increase of cholesterol in the exofacial leaflet will create a higher probability of 
cholesterol binding by APP and partitioning to cholesterol rich domains, with an overall 
increase in Aβ production.  This increase in Aβ due to the imbalance of cholesterol in the 
plasma membrane leaflets leads to local neuronal cell death.  As neurons begin to die, 
this forces the surrounding neurons to uptake the cholesterol being synthesized and 
shuttled by the neighboring astrocytes.   
Additionally, the cholesterol content is increased within these cells as the 
imbalance between exo- and cytofacial leaflets generates more cholesterol uptake and 
synthesis, resulting in increased cholesterol levels not only at the plasma membrane, but 
also in the ER and potentially the TGN.  Feeding into this increase in neuronal 
cholesterol levels is the evidence that the ApoE4 protein (pro-AD risk factor) is 
overexpressed in some forms of AD (222).  While the exact role ApoE4 plays in AD is 
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still being investigated, a known function for this protein is transporting cholesterol from 
neighboring astrocytes to neurons.  An increase in ApoE4 expression (due to the extra 
allele found in some forms of AD (93)) could ultimately lead to an increase in this 
cholesterol transport, thus increasing the levels of cholesterol in neighboring neurons.  
The net increase of cholesterol stimulates an increase in the production of APP, as seen 
by the study from the Octave lab (29).  The combination of increased APP expression 
and increased cholesterol levels, both at the plasma membrane and TGN, initiates a 
vicious cycle of overproduction of Aβ, neuronal death, and increased cholesterol update 
by surrounding cells.  In both cases of decreased and increased cholesterol, there is a 
higher prevalence of cholesterol rich domains present in the membrane.  Thus here is a 
new mechanism uniting how decreased, and eventually increased, levels of cholesterol 
promote the overproduction of the Aβ peptide in AD (figure 5.4).   
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Figure 5.4.  A new model for how both decreased and increased levels of 
cholesterol contribute to Aβ generation in AD.  (A)  The top panel represents APP 
processing under normal conditions.  APP is preferentially trafficked to the 
plasma membrane where it is rapidly processed by α-Secretase.  A small portion 
of APP is processed by the amyloidogenic pathway, by binding cholesterol and 
partitioning to cholesterol rich domains either at the plasma membrane or in the 
TGN.  Partitioning to cholesterol rich (Lo) domains results in Aβ generation in 
endosomal compartments.  (B)  The middle panel represents Aβ generation under 
conditions of decreased cholesterol.  Cholesterol levels are decreased by over 
expression of CYP46 or decreased expression of Seladin-1.  This causes the 
enhanced movement of cholesterol from the cytofacial to the exofacial leaflet, 
creating more cholesterol rich domains at the plasma membrane, which increases 
APP partitioning to Lo domains and increases Aβ production.  In addition, this 
change in cholesterol content induces the cell to uptake more cholesterol, 
creating a larger pool of cholesterol rich domains in the ER and TGN, which 
increases Aβ production.  This increase in Aβ causes abnormal cell death, and as 
neurons begin to die, the neighboring neurons uptake cholesterol being shuttled 
by the surrounding astrocytes.  (C)  This increases the cholesterol content of 
neighboring neurons (bottom panel).  An increase in cholesterol stimulates the 
over expression of APP.  Due to the increase in APP and cholesterol at the plasma 
membrane, this enhances APP partitioning to cholesterol rich domains, and 
ultimately, Aβ production.  This furthers neuronal death, and is propagated 
throughout the brain in AD.  APP unbound to cholesterol is represented by a cyan 
cylinder,  APP bound to cholesterol is red, α-Secretase is colored magenta, and β-
Secretase is colored blue.  Aβ is colored purple.  Cholesterol rich Lo domains are 
colored red.  Stimulated pathways are highlighted with enlarged arrows.  It should 
be noted that endocytosis of APP and β-Secretase can be a separate event, it is 
for simplicity that they are shown being endocytosed in the same vesicle in the 
cartoon.  
 
 
Future Directions 
Investigation of How the Structure of C99 Regulates γ-Secretase Cleavage 
 The results from the 3D structure determination of C99 indicate that the curved 
structure of the TMD may be an ideal shape for proper cleavage by γ-Secretase.  In 
order to validate this theory, the structure of the TMD should be altered via mutagenesis 
to create a straight TMD, to test whether a curved substrate is not only ideal, but 
necessary, for γ-Secretase cleavage.  Changes in TMD structure should be monitored 
by DEER EPR to assess the magnitude of distance change from residues G700 and 
L723 following mutagenesis.  Information gained during these studies would highlight 
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key structural features needed for intramembrane proteolysis, and may yield insight 
regarding means of selection for enzymes that cleave numerous substrates. 
 In addition with the effect of different TMD structures on γ-Secretase cleavage, 
the effect of altered TMD dynamics on γ-Secretase cleavage should also be 
investigated.  Both our DEER EPR and HDX results suggest that the TMD of APP is not 
only curved, but dynamic in nature.  In addition to the curvature being important for γ-
Secretase cleavage, the flexibility of the TMD may also play a pivotal role in not only 
regulating the overall cleavage event, but also in determining which length Aβ peptide is 
generated.  Mutations should be made at residues G708 and G709 to modify TMD 
flexibility.  Changes in flexibility should be monitored by DEER EPR to determine the 
magnitude of the change.  
As well as investigating how changes in TMD structure via designed 
manipulation impact γ-Secretase cleavage, these same concepts could be used to study 
how known mutations in familial AD (FAD) or changes in membrane dynamics influence 
cleavage.  Multiple FAD mutations occur within the TMD of APP, with most occurring 
near the γ-Secretase cleavage region.  The effect of these mutations is still not known, 
and the impact could range from a change as simple as altering the accessibility of γ-
Secretase during cleavage to something as complex as altering the curvature or 
flexibility of the TMD.  We have shown that binding of cholesterol leads to increased 
partitioning of C99 to cholesterol rich membrane domains, domains that have unique 
biophysical properties when compared to the bulk membrane.  Research has shown that 
cholesterol may serve as a co-factor to increase γ-Secretase activity (352).  While 
cholesterol could be having an impact on γ-Secretase itself, the compound could also be 
inducing changes in the flexibility of the TMD of C99 or having an impact on the 
accessibility of the γ-Secretase cleavage locations.   Investigating how these changes in 
 185 
 
the TMD of C99 impact γ-Secretase cleavage, might provide a window into decreasing 
the production of Aβ during AD. 
 In order to determine changes in both structure and flexibility an in vitro γ-
Secretase assay should be developed, similar to those used by the Wolfe lab (371).  
These assays work by purifying intact γ-Secretase complexes from cell membranes 
(they utilize Chinese hamster ovary (CHO) cells, but other cell lines can be investigated) 
utilizing a relatively mild detergent such as CHAPSO.  Using a mild detergent is key as 
to not disrupt the integrity and function of the γ-Secretase complex.  C99 should be 
expressed and purified from E. Coli as described (28) into a CHAPSO containing 
solution.  Cleavage of C99 by γ-Secretase should be conducted by mixing the two 
solutions together and monitoring the production of the AICD via western blot analysis.  
In addition, differences in Aβ40 versus Aβ42 levels could be detected utilizing both 
western blot analysis or sandwich ELISA assays.   
 By determining the impact that changes in curvature and flexibility have on 
proper γ-Secretase cleavage of the TMD of APP, we can gain a better understanding of 
how to specifically manipulate this event to ultimately prevent Aβ production.  If changes 
in curvature or flexibility (via mutagenesis or different membrane environments) reduce 
or inhibit γ-Secretase cleavage, compounds could be investigated or designed that 
mimic these changes.  This type of information would be paramount in investigating 
means that prevent cleavage of APP by γ-Secretase, but still permit cleavage of Notch 
and other substrates to reduce toxicity.     
 
Impact of Cholesterol Binding and Membrane Fluidity on APP Cleavage 
 Our results demonstrate that C99 can specifically bind cholesterol in the 
DHPC/DMPC bicelle model membrane system.  Additionally, we have shown that this 
binding event partitions C99 to cholesterol rich membrane domains, where it is 
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hypothesized that full length APP is cleaved by the amyloidogenic pathway to generate 
the Aβ peptide.  While our findings are for the APP cleavage product C99, we 
hypothesize that the results would be consistent for full length APP, as both proteins 
contain the same TMD regions that could potentially interact with cholesterol.  These 
results indicate that the binding event between APP and cholesterol may be a key step 
in promoting the etiology of AD.   
 In order to gain a more in depth understanding of how cholesterol binding 
actually promotes amyloidogenesis, we must determine the 3D structure of C99 in 
complex with cholesterol.  Determining the 3D structure of this complex by NMR, will 
further the research from the Kramer lab (40), which indicates that following partitioning 
to Lo like membrane domains, the α-Secretase cleavage site becomes occluded.  3D 
structure determination of the C99/cholesterol complex with NMR will not only show if 
the N-helix (which contains the α-Secretase cleavage site) has an altered structure 
following cholesterol binding, but we will also help achieve a better understanding of the 
dynamics of this region following the interaction with cholesterol.  Our initial structural 
studies show that the N-helix is highly dynamic when in a cholesterol free/Ld like 
membrane domain. Moving forward, the observation of any changes upon cholesterol 
binding will illuminate possible structural means of regulating the non-amyloidogenic and 
amyloidogenic cleavage pathways. 
 In addition to providing critical insight regarding mechanisms of promoting Aβ 
generation, the determination of the 3D structure of the C99/cholesterol complex will 
introduce a strong foundation for developing potent therapeutics to potentially abrogate 
Aβ production in vivo.  Initial results from our lab indicate that the partitioning of C99 to 
cholesterol rich membrane domains is a pharmacological target, as the addition of the Ld 
favoring compound coprostanol was able to actively remove C99 from Lo membrane 
domains.  By determining the 3D structure of the C99/cholesterol complex, key 
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interactions between the protein and the lipid will be identified, allowing for the 
development of compounds that mimic these interactions more tightly.  This information 
can be coupled with features of sterols that prefer the Ld phase (like coprostanol), to 
potentially develop a therapeutic agent that will bind APP more tightly than cholesterol 
and also prevent its partitioning to Lo domains.  This novel approach to preventing Aβ 
generation has the potential to be very effective, as it would be a means to specifically 
block the amyloidogenic processing of only APP, while simultaneously not interrupting 
cholesterol rich domain formation in cells, which could potentially harm the function of 
other vital proteins. 
While our results on membrane partitioning are very encouraging to show that 
C99 partitions to cholesterol rich domains in vivo, it is recognized that this is a difficult 
phenomenon to recapitulate in cells, as Lo domains have yet to be imaged in real time.  
While not the ideal solution of monitoring the partitioning of APP in vivo, a new method 
has been developed that is more physiological than the GUV studies utilized in our work.  
These experiments are in the form of plasma membrane derived vesicles (GPMVs) (232, 
372).  The end results of GPMV studies appear very similar to GUV experiments, 
however, the vesicles being imaged are derived from cellular membranes as opposed to 
being synthetically generated by electroformation.  The fact that these vesicles are 
derived from cells (such as Chinese hamster ovary (CHO), human embryonic kidney 
(HEK), or COS-7) allows for a better membrane mimetic to study membrane protein 
partitioning as these membranes contain a larger milieu of native lipids as well as 
potentially containing a variety of membrane proteins.  This means they more efficiently 
replicate the crowded cell membrane environment.  In addition, GPMV experiments will 
allow us to monitor the membrane partitioning of full length APP (with an N-terminal CFP 
tag), hopefully validating the hypothesis that full length APP partitions to Lo domains in 
native cell membranes.  In order to monitor full length APP partitioning, exogenous 
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overexpression of APP is required, giving the opportunity to add in the specific 
cholesterol binding mutations (E693A and G704A as cholesterol deficient binding and 
G696A as no effect on cholesterol binding) to monitor whether the interaction between 
APP and cholesterol is the ultimate driving force behind APP partitioning, or if other 
factors, such as Lo associated adaptor proteins like AP-4 and flotillin, are needed for 
APP partitioning.   
 One final area of research that should be pursued in the vein of cholesterol and 
amyloidogenesis is the observed co-localization between APP/C99 and β-Secretase in 
GUV and GPMV membrane mimetics.  Previous studies have been down showing that 
APP and β-Secretase can co-localize in cells by using such methods as detergent 
resistant membrane preparation (33), FRET (121), and antibody cross-linking (122).  
Examining the interaction between C99 and β-Secretase in GUVs and GPMVs would 
reveal that this interaction does in fact occur within cholesterol rich membrane domains, 
findings that are only speculative to date.  In addition, by utilizing the C99 mutants that 
cannot bind cholesterol, it can be determined if this reduces the co-localization between 
C99 and β-Secretase.  Finally, by using a raftophobic compound such as coprostanol, it 
would be possible to investigate if one could pharmacologically reduce the co-
localization between C99 and β-Secretase in cholesterol rich membrane domains. 
 
Projection of Future Work on C99 and AD 
 The studies presented in this dissertation have highlighted key structural and 
functional aspects of C99 and how they regulate and promote amyloidogenesis.  These 
findings have established a strong predicate for furthering our understanding of how the 
structure of the TMD of APP regulates AD as well as how cholesterol is a key 
component in regulating β-Secretase cleavage.  To expand on these findings, potential 
future experiments in the realm of cellular biology could be of great significance. 
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 Published work and potential future experiments will show that the curved nature 
of the TMD of APP is vital for not only proper cleavage by γ-Secretase, but we 
hypothesize may also be a key feature in determining γ-Secretase substrate specificity.  
Once results establish how changes in flexibility and curvature, either by mutations or 
changes in membrane properties, influence the ability of γ-Secretase to cleave C99, 
ensuing experiments should investigate how these changes influence the ratio between 
Aβ40 and Aβ42 production.  Initial studies should be performed using in vitro γ-
Secretase assays as described above, and should they prove successful transfection of 
full length APP and any mutant forms into cells containing γ-Secretase should be the 
undertaken in the next stage of experiments.  Results from cellular studies would verify 
that key changes in the structure of the TMD would result in phenotypic changes in Aβ 
production seen in AD.  One could envision that key FAD mutations may influence the 
structure or flexibility of the TMD and preferentially produce Aβ42.  A better 
understanding of the mechanism of γ-Secretase cleavage, specifically by observing how 
changes in APP TMD structure influence cleavage and Aβ production, might lead to the 
development of novel therapeutics to more tightly regulate any changes in TMD 
structure or flexibility. 
 In conjunction with determining how structural features of the TMD of APP 
regulate γ-Secretase cleavage in a more cellular setting, it is important to pursue how 
the cholesterol binding properties of APP translate to changes in Aβ production in cells.  
While our findings have shown that C99 can partition to cholesterol rich membrane 
domains (results hopefully validated using GMPVs and full length APP), future work 
showing that altering this partitioning, either via mutagenesis or partitioning altering 
compounds, reduces Aβ production is paramount.  Elucidating how the disruption of this 
membrane partitioning decreases Aβ production, will not only definitively show that 
membrane partitioning is vital to Aβ production in AD, but will also show that this event is 
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a previously unexplored, viable therapeutic target for treating, and potentially preventing, 
AD onset. 
  
Concluding Remarks 
The initial structural and function studies on C99 and their impact on the 
understanding of how AD progresses have been established in our reports.  These 
findings highlight how 3D structure determination can play a vital role in gaining a better 
picture of how a protein functions. Additionally, our results have shown definitive 
evidence that C99 can specifically bind cholesterol, and that this binding event is directly 
responsible for partitioning C99 into cholesterol rich membrane domains.  Both findings 
highlight the important need for further studies exploring the relationship between 
cholesterol and AD, as intricacies of this relationship may hold critical keys into 
unlocking potential therapeutics to treat and prevent AD onset.  By furthering the initial 
studies that explore how the structure of the TMD of APP plays a role in γ-Secretase 
cleavage and how the interaction with cholesterol and the membrane partitioning to 
cholesterol rich domains influence Aβ production, we may begin to gain a better 
understanding of how these mechanisms influence the etiology of AD.  
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